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Abstract
The emergence and spread of antibiotic resistance hampers effective treatment of bacterial
infections. This is particularly the case for infections involving a biofilm component, as
the activity of existing antibacterial drugs against these surface-attached communities is
limited. The work presented in this thesis sought to identify and characterise compounds
with antibacterial and antibiofilm activity against the important pathogen, Staphylococcus
aureus.
Antistaphylococcal activity was assessed for 16 antioxidants that are used in cosmetics,
traditional medicines or as food additives, and which have been reported previously
to have some antibacterial activity. Initial experiments with tert-butylhydroquinone
(TBHQ) showed that activity that had previously been ascribed to the antioxidant,
was a consequence of its conversion to tert-butylbenzoquinone (TBBQ) under culture
conditions. TBBQ displayed innate bactericidal activity against S. aureus that was
effected through perturbation of the bacterial membrane. The other antioxidants also
inhibited staphylococcal growth through perturbation of the cytoplasmic membrane, and
compounds that displayed selective action against bacterial membranes were identified.
Of the agents with bacterial specificity, TBBQ, celastrol and nordihydroguaiaretic acid
(NDGA) also eradicated staphylococcal biofilms; a rare property amongst antibacterial
agents. Although these antioxidants exhibited a similar membrane-damaging mode of
action, their mechanisms of antibiofilm activity differed. TBBQ eradicated preformed
biofilms through sterilisation of slow-growing and persister cell populations, whilst
celastrol and NDGA caused physical disruption of the biofilm. All three antioxidants
acted synergistically with gentamicin against biofilms, eradicating surface attached
populations at concentrations that did not cause irritation or visible damage to a human
skin equivalent.
vThe potent and selective antibacterial activity, and low resistance potential upon extended
subculture, suggest that these compounds could be used topically in combination with
gentamicin to treat infected wounds.
vi
Contents
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
Contents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
List of figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
List of tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xv
1 Introduction 1
1.1 The burden of bacterial infections . . . . . . . . . . . . . . . . . . . . . 1
1.2 The causes of antibiotic treatment failure . . . . . . . . . . . . . . . . . . 3
1.2.1 The problem of antibiotic resistance . . . . . . . . . . . . . . . . 3
1.2.2 Antibiotic resistance mechanisms . . . . . . . . . . . . . . . . . 4
1.2.3 Impact of bacterial growth state on antibiotic susceptibility . . . . 9
1.2.4 Bacterial biofilms: a recalcitrant mode of growth . . . . . . . . . 10
1.3 A brief history of antibiotic discovery . . . . . . . . . . . . . . . . . . . 15
1.4 Antioxidants and antibacterial activity . . . . . . . . . . . . . . . . . . . 17
1.5 Objectives of this study . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2 Materials and Methods 24
2.1 Bacterial strains, plasmids, and growth conditions . . . . . . . . . . . . . 24
2.2 Chemicals, reagents and antibacterial compounds . . . . . . . . . . . . . 27
2.3 Stability studies with TBHQ and TBBQ . . . . . . . . . . . . . . . . . . 29
2.4 Antibacterial activity testing . . . . . . . . . . . . . . . . . . . . . . . . 29
CONTENTS vii
2.4.1 Standardised susceptibility testing . . . . . . . . . . . . . . . . . 29
2.4.2 Identification of synergism . . . . . . . . . . . . . . . . . . . . . 30
2.4.3 Time-dependent killing studies . . . . . . . . . . . . . . . . . . . 31
2.4.4 Susceptibility of persisters to antimicrobial agents . . . . . . . . . 31
2.4.5 Identification of bacterial lysis . . . . . . . . . . . . . . . . . . . 32
2.5 Doubling time determinations . . . . . . . . . . . . . . . . . . . . . . . . 32
2.6 Antibacterial MOA studies . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.6.1 Quantification of macromolecular biosynthesis . . . . . . . . . . 32
2.6.2 Bacillus subtilis biosensors . . . . . . . . . . . . . . . . . . . . . 33
2.6.3 Assays to detect perturbation of membranes . . . . . . . . . . . . 34
2.6.4 Quantification of ATP pools . . . . . . . . . . . . . . . . . . . . 37
2.6.5 Determining the mechanism of antibiofilm activity . . . . . . . . 37
2.6.6 Identification and characterisation of a transposon insertion
mutant exhibiting hypersusceptibility to TBBQ . . . . . . . . . . 39
2.6.7 Selection of antioxidant resistant mutants . . . . . . . . . . . . . 40
2.7 Effects of antioxidants on human LabSkinTM . . . . . . . . . . . . . . . . 40
2.8 DNA manipulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.8.1 Bacteriophage transduction . . . . . . . . . . . . . . . . . . . . . 41
2.8.2 DNA extraction, PCR and DNA sequence determination . . . . . 42
2.8.3 Molecular cloning . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3 Antibacterial activity of TBHQ and its oxidation product, TBBQ 45
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.2.1 The phenolic antioxidant TBHQ . . . . . . . . . . . . . . . . . . 46
3.2.2 Aims and Objectives . . . . . . . . . . . . . . . . . . . . . . . . 50
3.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.3.1 Stability studies with TBHQ and TBBQ . . . . . . . . . . . . . . 51
CONTENTS viii
3.3.2 Antibacterial activity of TBHQ and TBBQ . . . . . . . . . . . . . 54
3.3.3 Evaluation of bacterial killing and lysis by TBHQ and TBBQ . . . 56
3.3.4 Antibiofilm activity of TBBQ . . . . . . . . . . . . . . . . . . . . 59
3.3.5 Effect of TBBQ on biofilm structure . . . . . . . . . . . . . . . . 61
3.3.6 Effect of TBBQ on slow- and non-growing cells . . . . . . . . . . 63
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4 Investigations into the antibacterial mechanism of action of TBBQ 67
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.2.1 MOA studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.2.2 Toxicity studies . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.2.3 Putative MOA of TBBQ . . . . . . . . . . . . . . . . . . . . . . 70
4.2.4 Aims and Objectives . . . . . . . . . . . . . . . . . . . . . . . . 72
4.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.3.1 Effects of TBBQ on biosynthetic pathways . . . . . . . . . . . . 73
4.3.2 Membrane damaging assays . . . . . . . . . . . . . . . . . . . . 75
4.3.3 Effect of TBBQ on staphylococcal metabolism . . . . . . . . . . 81
4.3.4 Effect of TBBQ on ROS generation . . . . . . . . . . . . . . . . 87
4.3.5 Identification of TBBQ-resistant and hypersusceptible mutants . . 91
4.3.6 Characterisation of TBBQ mutants . . . . . . . . . . . . . . . . . 93
4.3.7 Genotypic characterisation of TBBQ mutants . . . . . . . . . . . 95
4.3.8 Synergistic interaction of TBBQ with antibiotics . . . . . . . . . 100
4.3.9 Effects of TBBQ on a human skin equivalent . . . . . . . . . . . 101
4.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5 Antioxidants target the cell membrane and eradicate biofilms 105
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
CONTENTS ix
5.2.1 The clinical significance of biofilm infections . . . . . . . . . . . 106
5.2.2 Aims and Objectives . . . . . . . . . . . . . . . . . . . . . . . . 107
5.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
5.3.1 Antibacterial properties of phenylic antioxidants . . . . . . . . . . 107
5.3.2 Antibacterial MOA of antioxidants . . . . . . . . . . . . . . . . . 111
5.3.3 Investigating the mechanistic basis for antibiofilm activity of
phenylic antioxidants . . . . . . . . . . . . . . . . . . . . . . . . 115
5.3.4 Synergistic interactions of antioxidants with antibiotics . . . . . . 124
5.3.5 Effects of celastrol and NDGA on human LabSkinTM . . . . . . . 125
5.3.6 Selection of antioxidant resistant strains . . . . . . . . . . . . . . 128
5.3.7 Characterisation of the celastrol resistant strain . . . . . . . . . . 131
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
6 General conclusions and future work 136
6.1 General Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
6.2 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Appendix 142
A Primers used in this study. . . . . . . . . . . . . . . . . . . . . . . . . . . 142
B MICs of TBHQ and TBBQ against a collection of S. aureus clinical isolates.143
C Addresses of companies . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Bibliography 148
xList of figures
1.1 The major sites of antibiotic action, and mechanisms of bacterial resistance 6
1.2 Mechanisms by which biofilms resist antibacterial agents . . . . . . . . . 13
1.3 Timeline of antibiotic discovery . . . . . . . . . . . . . . . . . . . . . . 16
1.4 Chemical structures of phenylic antioxidants . . . . . . . . . . . . . . . . 18
2.1 Experimental setup for biofilm penetration experiments . . . . . . . . . . 38
3.1 Chemical structures of TBHQ and TBBQ, and oxidative conversion of the
former to the latter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2 Stability of TBHQ at 385 µM (64 µg/mL) in PBS . . . . . . . . . . . . . 52
3.3 Stability of TBBQ at 97 µM (16 µg/mL) in PBS . . . . . . . . . . . . . . 53
3.4 The effect of antibacterial agents at 4x MIC on S. aureus SH1000
suspended in PBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.5 TBHQ/TBBQ stability and killing kinetics against S. aureus SH1000
suspended in PBS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.6 Evaluation of killing and lytic action of TBHQ, TBBQ and comparator
agents against S. aureus SH1000 in MHB . . . . . . . . . . . . . . . . . 58
3.7 Effect of antibacterial agents on biofilm structure . . . . . . . . . . . . . 62
3.8 Activity of compounds at 4x MIC against exponential and stationary
phase S. aureus SH1000 suspended in MHB . . . . . . . . . . . . . . . . 63
3.9 Sterilisation of exponential and stationary phase cultures of S. aureus
SH1000 at 256 µg/mL . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
LIST OF FIGURES xi
3.10 Activity of antibacterial agents against ciprofloxacin- or ampicillin-
induced persisters of S. aureus SH1000 . . . . . . . . . . . . . . . . . . . 65
4.1 Effects of TBBQ and pathway specific inducers on B. subtilis pathway
specific biosensors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.2 Effects of TBBQ and comparator agents on major macromolecular
biosynthesis pathways in S. aureus . . . . . . . . . . . . . . . . . . . . . 75
4.3 Effect of TBBQ and comparator agents at 4x MIC on staphylococcal
membrane potential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.4 Release of intracellular ions following exposure of S. aureus SH1000 to
TBBQ and comparator agents at 4x MIC . . . . . . . . . . . . . . . . . . 79
4.5 Cellular ATP levels following exposure to TBBQ and comparator agents
at 4x MIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.6 Effects of respiratory uncouplers on activity of TBBQ against S. aureus
SH1000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.7 Antibacterial activity of compounds at 4x MIC against small colony variants 84
4.8 Time-kill studies with staphylococci exposed to 8x MIC TBBQ in MHB
supplemented with menadione . . . . . . . . . . . . . . . . . . . . . . . 86
4.9 Time-kill experiments with S. aureus SH1000 and ROS protection
deficient mutants exposed to TBBQ and comparator agents at 4x MIC
in MHB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.10 Time-kill studies with S. aureus SH1000 exposed to TBBQ at 4x MIC in
MHB supplemented with ROS scavengers at 8 mg/mL . . . . . . . . . . 91
4.11 ATP hydrolysis following exposure to TBBQ at 4x MIC in HEPES and
glucose buffer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.12 Schematic of the insertion site of the transposon in CAJ192 C9 . . . . . . 97
4.13 Hematoxylin and eosin stained sections of LabSkinTM exposed to
compounds for 24 hours . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
LIST OF FIGURES xii
5.1 Bactericidal activity of antioxidants against S. aureus SH1000. . . . . . . 110
5.2 Effect of antibacterial agents on S. aureus SH1000 potassium leakage and
membrane potential (4x MIC for 3 hours) . . . . . . . . . . . . . . . . . 113
5.3 Effect of antioxidants and comparator agents at 4x MIC on mammalian
membrane integrity measured by leakage of haemoglobin from erythrocytes114
5.4 Susceptibility of exponential phase, stationary phase or biofilm-
resuspended S. aureus SH1000 cells to celastrol or 8-hydroxyquinoline . . 116
5.5 Viability of S. aureus SH1000 slow-growing and persister cells following
exposure to compounds for 24 hours. . . . . . . . . . . . . . . . . . . . . 118
5.6 Effects of antioxidants at 4x MIC on total ATP levels in S. aureus . . . . . 119
5.7 Quantification of matrix material and adherent cells following exposure
of biofilms to compounds at 256 µg/mL for 24 hours . . . . . . . . . . . 121
5.8 Cell viability and quantification of adherent material following exposure
of biofilms to compounds at 256 µg/mL for 1 hour . . . . . . . . . . . . . 123
5.9 Hematoxylin and eosin stained sections of LabSkinTM exposed to
compounds for 24 hours . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
5.10 Selection of daptomycin and celastrol resistant mutants . . . . . . . . . . 129
xiii
List of tables
1.1 Antibacterial activity and MOA of antioxidants . . . . . . . . . . . . . . 19
2.1 Bacterial strains used in this study . . . . . . . . . . . . . . . . . . . . . 25
2.2 Antimicrobial agents and their solvents used in this study . . . . . . . . . 28
3.1 Reported inhibitory effects of TBHQ against S. aureus strains . . . . . . . 50
3.2 Antibiofilm activity of antibacterial agents against S. aureus SH1000
biofilms grown on the Calgary Biofilm Device . . . . . . . . . . . . . . . 60
3.3 Antibiofilm activity of TBBQ against prolific biofilm-forming strains . . . 60
4.1 Effect of TBBQ and comparator agents at 4x MIC on S. aureus SH1000
membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4.2 Effect of TBBQ on staphylococcal liposomes . . . . . . . . . . . . . . . 80
4.3 Effect of TBBQ and comparator agents at 4x MIC on erythrocytes . . . . 81
4.4 MIC determinations of TBBQ and comparator agents against S. aureus
SH1000 and ROS protection defective mutants . . . . . . . . . . . . . . . 88
4.5 MICs of established antibiotics against TBBQ mutants B7 and CAJ192 C9 95
4.6 Synergism of TBBQ with established antibiotics against planktonic and
biofilm cultures of S. aureus SH1000 . . . . . . . . . . . . . . . . . . . . 101
5.1 MICs, biofilm MICs (bMICs) and minimum biofilm eradication
concentrations (MBECs) of antioxidants against staphylococci . . . . . . 109
5.2 The BacLightTM assay to determine effects of compounds at 4x MIC on
S. aureus SH1000 membrane integrity . . . . . . . . . . . . . . . . . . . 112
LIST OF TABLES xiv
5.3 Synergism of antioxidants with established antibiotics against planktonic
cultures of S. aureus SH1000 . . . . . . . . . . . . . . . . . . . . . . . . 124
5.4 Synergism of antioxidants with established antibiotics against S. aureus
SH1000 biofilms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.5 Susceptibility of the celastrol resistant strain, C3, to antibacterial agents . 130
5.6 Alterations in the genome of the celastrol resistant strain, C3, identified
through WGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
xv
Abbreviations
ATP - adenosine triphosphate
BHA - Brain Heart Infusion agar
BLAST - basic local alignment search tool
BSAC - British Society for Antimicrobial Chemotherapy
C - Celcius
CA-MRSA - community-acquired meticillin-resistant Staphylococcus aureus
CBD - Calgary biofilm device
CCCP - carbonyl cyanide m-chlorophenyl hydrazone
cDNA - complementary deoxyribonucleic acid
CFU - colony forming unit
CLSI - Clinical and Laboratory Standards Institute
CTAB - cetyltrimethylammonium bromide
D-ala - D-alanine
DCCD - dicyclohexylcarbodiimide
D-lac - D-lactate
DMSO - dimethylsulphoxide
DNA - deoxyribonucleic acid
FIC - fractional inhibitory concentration
HA-MRSA - hospital-acquired meticillin-resistant Staphylococcus aureus
HEPES - 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
MBC - minimum bactericidal concentration
xvi
MBEC - minimum biofilm eradication concentration
ME - mosaic ends
MF - major facilitator
MHA - Mueller-Hinton agar
MHB - Mueller-Hinton broth
MIC - minimum inhibitory concentration
MIC90 - minimum inhibitory concentration required to inhibit the growth of 90% of
isolates tested
MMS - macromolecular synthesis
Mn-SOD - manganese superoxide dismutase
MOA - mechanism of action
mRNA - messenger ribonucleic acid
MRSA - meticillin-resistant Staphylococcus aureus
MSCRAMMs - microbial surface components recognising adhesive matrix molecules
MSSA - meticillin-sensitive Staphylococcus aureus
NAD+ - Nicotinamide adenine dinucleotide
NADH - reduced nicotinamide adenine dinucleotide
ndc - no-drug control
NDGA - nordihydroguaiaretic acid
OD - optical density
PBP - penicillin binding protein
PBS - phosphate-buffered saline
PCR - polymerase chain reaction
pH - potential hydrogen
xvii
PIA - polysaccharide intercellular adhesin
PMBN - polymyxin B nonapeptide
PNAG - poly-N-acetyl glucosamine
rRNA - ribosomal ribonucleic acid
RNA - ribonucleic acid
ROS - reactive oxygen species
rpm - revolutions per minute
SCV - small colony variant
SDS - sodium dodecyl sulphate
SOD - superoxide dismutase
TAE - Tris-acetate-EDTA
TBBQ - tert-butylbenzoquinone
TBHQ - tert-butylhydroquinone
TCA - trichloroacetic acid
TE - Tris-EDTA
Tn - transposon
tRNA - transfer ribonucleic acid
VISA - vancomycin-intermediate Staphylococcus aureus
v/v - volume per volume
WGS - whole genome sequencing
WHO - World Health Organization
w/v - weight per volume
1Chapter 1
Introduction
1.1 The burden of bacterial infections
Infectious diseases cause approximately 25% of deaths worldwide (Taylor et al., 2001),
and in 2011, accounted for the loss of ∼6.8 million lives (WHO, 2013). In the USA
alone, communicable diseases cost $120 billion annually (NIAID, 2013). Approximately
1400 species of infectious organisms contribute to morbidity and mortality, including
approximately 500 bacterial species (Taylor et al., 2001). Amongst the bacteria that
contribute to this loss of life are Mycobacterium tuberculosis, Neisseria meningitidis, and
Vibrio cholerae. Of the bacterial pathogens, M. tuberculosis is the organism that leads
to the greatest loss of life, and caused approximately 1.4 million deaths in 2011 alone
(WHO, 2013). M. tuberculosis, N. meningitidis, and V. cholerae are community-acquired
organisms, primarily contributing to loss of life in developing countries. However, in the
industrialised world these organisms contribute less to the burden of infection, and instead
hospital-acquired infections, caused by bacteria such as the Gram-positive staphylococci,
are a major problem (WHO, 2013; Lindsay & Holden, 2004). Staphylococci are human
skin commensals, with Staphylococcus aureus being recovered from the anterior nares of
about 25% of the population (Kluytmans et al., 1997; Lindsay et al., 2012). However,
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under certain conditions, e.g. following surgical procedures or in the immunosuppressed,
these organisms are also capable of causing infections (Klein et al., 2007). In 2005,
S. aureus was estimated to cause around half a million hospitalisations in the USA, costing
$9.5 billion to treat and causing ∼11,400 deaths (Klein et al., 2007; Noskin et al., 2005).
S. aureus is the most common cause of hospital-acquired infections (Lindsay & Holden,
2004), and conditions caused by this organism include skin and soft tissue infections,
impetigo, infective endocarditis, septicaemia, pneumonia and toxic shock syndrome
(David & Daum, 2010; Noble, 1998). The coagulase-negative organism Staphylococcus
epidermidis causes fewer severe infections in healthy hosts than S. aureus, but frequently
infects individuals with an indwelling medical device, or who are immunocompromised
(McCann et al., 2008).
Treatment of bacterial infections is heavily dependent upon antibiotics, one of the most
successful classes of chemotherapeutic agent to have been developed (Davies & Davies,
2010; Wright, 2007). However, there are problems with the antibiotics currently deployed
clinically, which drives the need to develop new antibacterial agents. As will be discussed
in this chapter and thesis, difficulties in treating bacterial infections result from the
presence of antibiotic-resistant bacteria, cells in different growth states, and bacteria
growing as biofilms. A major aspect of this study will be assessing antioxidants and their
utility as antibacterial and antibiofilm agents. Therefore, information pertaining to the
use of antioxidants as novel antibacterial agents will be reviewed. This chapter will focus
on research carried out with S. aureus, since the aim of this investigation was to identify
agents with useful antistaphylococcal activity. It should also be noted that whilst the strict
historical definition of ‘antibiotic’ refers to natural products with antibacterial properties
(Clardy et al., 2009), the terms ‘antibiotic’ and ‘antibacterial agent’ are frequently used
interchangeably in scientific literature and also throughout this thesis.
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1.2 The causes of antibiotic treatment failure
1.2.1 The problem of antibiotic resistance
Although antibiotics are often successful in treating bacterial infections, there are
situations in which antibiotics fail (Corey, 2009). Drug-resistant bacteria are a significant
contributing factor to treatment failure, elevated care costs and mortality rates (Gandhi
et al., 2010). The prevalence of bacteria that are able to resist the effects of commonly
prescribed antibiotics has increased over the last decade (EARS-Net, 2013), necessitating
the development of agents to which bacteria are not yet resistant. However, bacterial
resistance is not a new phenomenon; resistance to penicillin was identified in S. aureus
within a year of its introduction to clinical use (Barber & Rozwadowska-Dowzenko,
1948). Subsequently novel antibiotics were discovered including aminoglycosides and
tetracyclines, but as was the case with penicillin, resistance was identified soon thereafter
(within 2 years of their FDA approval) (Bush, 2004). In recent years, antibiotic resistance
has become more widespread due to multiple factors, including increased antibiotic
consumption, veterinary practice, and improper use of antibiotics (Coates et al., 2011;
Davies, 2006). This has created a situation in which first-line antibiotics are no longer
effective against some bacteria and too few new compounds are being approved in order
to replace antibiotics that can no longer be used in a clinical setting (Coates et al., 2011).
These circumstances have prompted the World Health Organization to declare antibiotic
resistance ‘one of the three greatest threats to human health’ and signals ‘an end to modern
medicine as we know it’ (WHO, 2013).
The rise of multidrug resistant meticillin resistant S. aureus (MRSA) has been well
documented in the media, and recent research estimates that MRSA accounts for up to
54% of clinical S. aureus isolates and is found in up to 24% of hospital patients (Dulon
et al., 2011). Indeed, MRSA is the most frequently isolated organism in nosocomial
settings (Wang & Barrett, 2007). However, in the UK, reductions in the number of
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infections caused by MRSA since 2006 has been attributed to introduction of successful
infection control measures, such as improved hand hygiene and patient screening and
decolonisation (Edgeworth, 2011). In addition to β-lactam resistance, MRSA strains
often also carry genes that confer resistance to other antibiotics including macrolides,
aminoglycosides, and tetracyclines (Lindsay & Holden, 2004). Concerns regarding
MRSA were initially centered around its presence in the healthcare setting (HA-MRSA).
However, more recently community acquired-MRSA (CA-MRSA) has been shown to
cause infections in healthy individuals and may have more severe outcomes (David &
Daum, 2010). CA-MRSA often contains pore-forming toxins encoded by the Panton-
Valentine Leukocidin genes, and generally causes skin and soft tissue infections (Baba
et al., 2002; David & Daum, 2010). There is high genetic diversity within MRSA,
and different strains predominate in different countries (Lindsay, 2010). MRSA is not
necessarily more pathogenic than meticillin sensitive S. aureus, but it does cause more
deaths, longer hospitalisation and increased care costs due to initial treatment failure
(Cosgrove, 2006). Where β-lactams can be prescribed, due to infections caused by
susceptible S. aureus, these antibiotics are the frontline treatment. However, if the
infection is caused by MRSA, vancomycin or daptomycin are the recommended treatment
options for patients with bacteraemia or infective endocarditis (Liu et al., 2011).
1.2.2 Antibiotic resistance mechanisms
Bacteria are genetically plastic and can evolve to become resistant to one or a number
of antibacterial agents. Classical inherited resistance to antibiotics may arise through
endogenous (mutational) or exogenous means (by horizontal gene transmission) (Silver,
2011). In staphylococci, resistance may result from acquisition of mobile genetic
elements through transformation, conjugation, or transduction (Lindsay, 2010). Indeed,
mobile genetic elements account for 15-20% of the staphylococcal genome, with
staphylococcal cassette chromosome mec (SCCmec) and plasmids generally carrying
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resistance genes (Lindsay et al., 2012).
Resistance to antibiotics can result through a number of means (Figure 1.1) (Wright,
2010). Bacteria may evade the effects of antibiotics by down regulating porin production,
increasing expression of efflux pumps or through acquisition of mutations that increase
pump efficiency (Webber & Piddock, 2003; Piddock, 2006). Efflux pumps may transport
a specific substrate or a range of substrates (Webber & Piddock, 2003), and the genome
of S. aureus suggests that the organism may be capable of producing ∼17 multidrug-
resistance efflux pumps (Kaatz et al., 2003). These are subdivided into groups based upon
their structure, and in staphylococci, the majority are members of the major facilitator
(MF) superfamily, which traverse the membrane. Their substrates include macrolides,
tetracyclines, and fluoroquinolones along with biocides and dyes (Kaatz et al., 2003).
Although overexpression of efflux pumps rarely causes high-level resistance to clinically
relevant antibiotics, it may augment development of antibiotic target site mutations
(Webber & Piddock, 2003).
Resistance to tetracycline has been well characterised and occurs via both efflux and
target protection in staphylococci. Tetracycline perturbs bacterial protein synthesis by
preventing binding of aminoacyl-tRNA in the peptidyltransferase centre of the 30S
ribosomal subunit, and in the process inhibits bacterial growth (Chopra & Roberts, 2001).
Bacteria may carry plasmid-located tet(K) and tet(L) that code for specific pumps, which
efflux tetracycline from the cell in exchange for a proton. Alternatively, resistance is due
to ribosomal protection proteins, which are coded for by resistance determinants such as
tet(M) and tet(O). When translated these proteins bind to the ribosome and allosterically
prompt release of tetracycline from the ribosome (Schmitz et al., 2001; Roberts, 2005).
Other resistance mechanisms involve modification of the antibacterial target. In the
case of vancomycin, the antibiotic target is the pentapeptide linker of peptidoglycan
(Courvalin, 2006). S. aureus contains the bacteria-specific polymer, peptidoglycan,
which is composed of repeated units of N-acetyl glucosamine-N-actyl muramic acid
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Figure 1.1: The major sites of antibiotic action, and mechanisms of bacterial resistance. Image adapted from Wright
(2010).
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that are cross-linked by pentapeptides (Silhavy et al., 2010). The precursor of
peptidoglycan crosses the cell membrane and is attached to the cell wall polysaccharide
via transglycosylation. Cross linking of the pentapeptide with other cell wall peptides
occurs by enzyme-assisted transpeptidation (Courvalin, 2006). The glycopeptide
vancomycin inhibits growth by binding to the D-Ala-D-Ala termini of the pentapeptide,
stericially hindering transglycosylation (Courvalin, 2006). The consequent disruption to
the peptidoglycan structure results in weakening of the cell wall and cell lysis (Tomasz,
1979). In S. aureus VanA-type resistance is mediated through a dehydrogenase (VanH)
that reduces pyruvate, forming D-Lac, and a ligase (VanA), which forms a bond between
D-Ala and D-Lac. This results in conversion of pentapeptide termini from D-ala-D-Ala
to D-Ala-D-Lac in the pentapeptide linkers. Additionally, a D,D-dipeptidase (VanX)
hydrolyses existing D-Ala-D-Ala, and a D,D-carboxypeptidase (VanY) removes the
terminal D-Ala that will be replaced by D-Lac via VanA. This modifies the vancomycin
binding pocket, and allows pentapeptides to undergo transglycosylation (Courvalin,
2006). The presence of enterococcal derived vanA affords the carrier high level resistance
to vancomycin, but has been identified in only a small number of S. aureus strains
(Courvalin, 2006), and infections caused by vancomycin-resistant S. aureus remain rare to
date (Melo-Cristino et al., 2013). Vancomycin resistant S. aureus also avoid bactericidal
effects of the antibiotic via thickening of the peptidoglycan layer, titrating out the effects
of vancomycin (Cui et al., 2003).
Similarly, rifampicin- and quinolone-resistant strains evade the inhibitory effects of these
drugs by target modification. Rifampicin is an RNA synthesis inhibitor that binds to the
β subunit of the transcriptional catalyst RNA polymerase, blocking elongation of RNA
(Chopra, 2007). Mutations in rpoB (coding for the RNA polymerase β subunit), provide
rifampicin resistant strains with a means to evade antibiotic effects (O’Neill et al., 2000).
The binding of quinolones to DNA gyrase and topoisomerase IV (responsible for DNA
supercoiling and separation of chromosomes) causes conformational changes that inhibit
progression of the replication fork and stall DNA replication, leading to chromosome
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fragmentation and cell death (Blondeau, 2004; Collin et al., 2011). Resistance to
quinolones is conferred by mutations in grlA/gyrA and grlB/gyrB (coding for subunits
of topoisomerase IV/DNA gyrase) (Collin et al., 2011; Blondeau, 2004). These genetic
alterations reduce drug affinity for the primary target, and may act in concert with efflux
mechanisms in quinolone resistant staphylococci (Collin et al., 2011; Blondeau, 2004;
Piddock, 2006).
S. aureus are resistant to antibiotics, such as meticillin, due to target bypass. β-lactams
inhibit peptidoglycan synthesis by covalently binding to the active site of transpeptidases,
also known as penicillin-binding proteins (PBPs), which inhibits cell wall cross linking.
The product of mecA, located within the mobile genetic element SCCmec, is an alternative
penicillin-binding protein (PBP2a) that displays reduced affinity for β-lactams (Lindsay,
2010; Alekshun & Levy, 2007).
Finally, antibiotics may be enzymatically inactivated by hydrolysis, group transfer
or redox reactions (Wright, 2005). A classic example of resistance caused by
enzymatic modification is bacterial production of β-lactamase, an enzyme that cleaves the
β-lactam ring of penicillins, rendering them inactive. More than 1000 β-lactamases have
been discovered (Bush & Fisher, 2011), and can be grouped into four classes. Types
A, C and D are serine β-lactamases and B contains zinc metallo enzymes (Rubtsova
et al., 2010). Similarly, aminoglycoside resistance primarily occurs in staphylococci
through the presence of aminoglycoside modifying enzymes (Schmitz et al., 1999).
These antibiotics exert their effect upon the 30S subunit of the bacterial ribosome by
inhibiting translocation of tRNA from the A-site to the P-site, and there is evidence
to suggest that aminoglycosides also cause membrane damage and incorporation of
mistranslated proteins into lipid bilayers (Kotra et al., 2000; Davis, 1987). The most
common aminoglycoside modifying enzymes have acetyltransferase, adenylyltransferase
and phosphotransferase activity, and alter aminglycosides at amino or hydroxyl groups,
inducing loss of ribosome-binding and protein synthesis inhibition (Schmitz et al., 1999).
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1.2.3 Impact of bacterial growth state on antibiotic susceptibility
Antibiotic resistance contributes to difficulties in treating bacterial infections, but bacteria
displaying altered growth states also appear to affect the outcome of antibiotic treatment.
Hard-to-treat infections include those where small colony variants (SCVs) are present
(Proctor et al., 2006). SCVs form small, non-pigmented, non-haemolytic colonies and
display unique gene expression patterns. They commonly have altered toxin production,
adhesion and respiratory pathways and are linked to chronic infection (Proctor et al.,
2006). Staphylococcal SCVs are either defective in thymidine biosynthesis, or have a
malfunctioning electron transport chain and altered membrane potential as a consequence
of defective menadione or haemin biosynthesis (Proctor et al., 2006). SCVs have been
implicated in persistent osteomyelitis, sinusitis, arthritis, and device-related bloodstream
infections (Seifert et al., 2003; Proctor et al., 2006). It has been suggested that the
generation of SCVs is a normal aspect of the pathogenesis of infection, and contributes
to aminoglycoside treatment failure. Aminglycoside uptake is dependent upon the
cytoplasmic membrane potential, which is reduced in SCVs with a defective electron
transport chain, rendering the antibiotic unable to access intracellular targets (Proctor
et al., 2006).
Tolerant bacteria (exhibiting a bacteriostatic response to antibacterial challenge that
is bactericidal for the majority of the population) can contribute to difficulties in
eradicating bacterial infections, and like SCVs, have a mutation/mutations that cause
the phenotype (Proctor et al., 2006; Griffiths & O’Neill, 2012). In tolerant bacteria
these genetic alterations cause a shift from a bactericidal to a bacteriostatic response to
antibiotics (Griffiths & O’Neill, 2012). Tolerance is defined as a minimum bactericidal
concentration: minimum inhibitory concentration (MBC:MIC) ratio ≥32 (Bizzini et al.,
2007), where MBC is a 99.9% kill (3 log10 CFU/mL reduction in viable cells after 24
hours) (Bizzini et al., 2009). This response has been identified in staphylococci and
streptococci and is associated with exposure to β-lactams and glycopeptides (Griffiths
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& O’Neill, 2012). The genetic basis of tolerance in several S. aureus strains is due to
mutations in GdpP, a putative signaling protein (Griffiths & O’Neill, 2012). Tolerant cells
are clinically relevant, with β-lactam tolerant S. aureus infections requiring long treatment
regimens, frequently causing treatment failure and patient relapses (Rajashekaraiah et al.,
1980).
Bacteria may also become refractory to antibiotics due to non-inherited resistance
mechanisms (Levin & Rozen, 2006). This is achieved by drug indifference, where the
whole bacterial population is resistant to killing due to metabolic inactivity, or due to
the presence of persisters; a sub-population of cells that are killed by antibiotics at a
slower rate. Persistence (also known as phenotypic tolerance) is a pre-existing property
of bacteria in which metabolic inactivity is transitory, and persisters are not genetically
different from other cells within the population (Levin & Rozen, 2006). Persisters
tolerate the presence of antibiotics due to down regulation of cellular processes that are
targeted by the majority of antibacterial agents (Keren et al., 2004). Antibiotics that target
biosynthetic pathways are less effective against cells that are not actively growing, as there
are fewer active targets that can be corrupted (Keren et al., 2004). Therefore, compounds
that are under development as antibacterial agents would ideally display activity against
these resilient populations of cells, in addition to avoiding existing antibiotic resistance
mechanisms.
1.2.4 Bacterial biofilms: a recalcitrant mode of growth
Arguably biofilms and the infections that are associated with this mode of growth pose
the greatest challenge to therapy and biofilms include some of the types of antibiotic
insusceptible cells discussed in the previous section. Bacterial biofilms are found
throughout nature, existing in thermal springs, corroding pipes, and are even found on
the international space station (Weidler et al., 2007; Juhna et al., 2007; Kim et al.,
2013). In a clinical setting, biofilms are implicated in the development of infections
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such as dental caries, endocarditis, sinusitis, cystic fibrosis pneumonia and infections
of indwelling medical devices (Fux et al., 2005; Del Pozo & Patel, 2007; Brady et al.,
2008; Bendouah et al., 2006). In staphylococci, environmental stimuli may initiate
the conversion from a planktonic mode of growth to biofilm formation; for example,
under iron-limited conditions and in the presence of ethanol (Johnson et al., 2005;
Lim et al., 2004). Staphylococcal cells adhere to surfaces with the assistance of ∼20
different proteins known as MSCRAMMs (microbial surface components recognising
adhesive matrix molecules) (Walsh et al., 2008). These include fibronectin binding
proteins A and B, which are attached to peptidoglycan in the S. aureus cell wall (Greene
et al., 1995). Attached cells generate extracellular matrix that contains: proteins;
teichoic acid; extracellular DNA; and polysaccharide intercellular adhesin (PIA), which
is primarily made of poly-N-acetyl glucosamine (PNAG) (Izano et al., 2008; Mack et al.,
1996). Maturation of staphylococcal biofilms is dependent upon PIA generated via the
intercellular adhesion (ica) operon (Heilmann et al., 1996), and is aided by a number of
surface proteins, such as accumulation-associated protein (S. epidermidis) and biofilm-
associated protein (S. aureus) (Hussain et al., 1997; Cucarella et al., 2001).
Regulation of biofilm-associated genes is primarily through transcriptional regulators
including the transcriptional repressor IcaR, staphylococcal accessory regulator (sarA),
accessory gene regulator (agr), and the alternative sigma factor (SigB) (Beenken et al.,
2003; Boles & Horswill, 2008; Beenken et al., 2004; Rachid et al., 2000; Nicholas
et al., 1999). The ica operon contains the negative regulator IcaR and biosynthetic genes
icaADBC. Repression of IcaR transcription enhances icaADBC expression, leading to
PIA production and generation of biofilms (Jefferson et al., 2003). However, biofilm
formation is multifactorial and may occur in an ica-independent fashion; for example
S. aureus UAMS-1 has mutations in the ica operon but is still able to form biofilms
(Beenken et al., 2004). The sigB operon is also involved in biofilm regulation, enhancing
production of cell surface proteins that aid initial biofilm formation (Rachid et al., 2000;
Nicholas et al., 1999). Likewise, the global regulator sarA is necessary for biofilm
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formation (Beenken et al., 2003), whilst agr plays a crucial role in biofilm dispersal
(Boles & Horswill, 2008). Therefore, the regulation of biofilm-associated genes involves
a complex network, the subtleties of which are not yet fully understood.
Following the attachment of cells to a surface, formation of cell-cell bridges, and release
of extracellular matrix (Lindsay & Von Holy, 2006), the biofilm increases in structural
complexity. Mature forms contain mushroom-like structures and water channels to allow
water and oxygen to penetrate the biofilm, and diffusion of waste products (Massol-Deya
et al., 1995). The extracellular matrix protects bacteria within the biofilm from the host’s
immune system (Hall-Stoodley et al., 2004), and some bacteria are dispersed from the
mature biofilm as planktonic cells that can colonise new surfaces (Kaplan, 2010).
The cells contained within the biofilm experience a range of environments and
consequently display stratified anabolic activity. Those near the surface of the biofilm
have sufficient nutrients and oxygen (Rani et al., 2007). However, for those bacteria
deep within the biofilm, low availability of metabolites and oxygen, and the buildup
of waste products creates conditions inhibitory to growth. Under these circumstances
bacteria may exhibit a beneficial survival strategy: cessation of active growth. Thus,
biofilms contain bacteria in a range of metabolic states: growing aerobically; growing
anaerobically/fermentatively; non-growing and dead cells (Rani et al., 2007; Mah &
O’Toole, 2001).
Bacteria contained within biofilms are 10-1000x less susceptible to antibiotic action than
planktonic counterparts (Mah & O’Toole, 2001), and biofilm recalcitrance to antibiotic
action is a consequence of multiple mechanisms (Figure 1.2). Antibiotics that are used
clinically were selected for development on the basis of their activity against planktonic
cells, without consideration for antibiofilm activity. As such, agents that are capable
of eradicating biofilms may display different characteristics to established antibiotics.
For example, antibiofilm agents may need to retain activity against tolerant bacteria,
which are present in biofilms and contribute to antibiotic insusceptibility (Nguyen et al.,
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2011). Tolerance in biofilms is generated by nutrient starvation that causes physiological
changes following induction of the stringent response (Nguyen et al., 2011). The presence
of dormant or persister cells alongside metabolically active bacteria also contributes to
difficulty in eradicating biofilms. Ciprofloxacin has been shown to kill growing cells at
the edges of P. aeruginosa biofilms and colistin is active against metabolically inactive
cells at the centre, but the compounds cannot eradicate whole biofilms when applied
individually (Høiby et al., 2010). Therefore, monotherapy may simply kill a portion of the
cells, leaving persister cells to repopulate the biofilm upon removal of antibiotic (Lewis,
2006). As such, biofilms may be most successfully treated with synergistic combinations
of antibacterial agents (Høiby et al., 2010).
Figure 1.2: Mechanisms by which biofilms can resist antibacterial agents. The matrix
limits access of some antibiotics to the centre of the biofilm, where tolerant, persister
and dormant cells display reduced drug susceptibility. Bacterial cells display altered gene
expression and produce antibiotic degrading enzymes. Antibiotic resistance arises due to
enhanced mutability of biofilm cells, and can be rapidly disseminated.
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Additionally, biofilms accelerate both the emergence and dissemination of antibiotic
resistance. Staphylococcal biofilms display increased mutability, which enables
development of resistance through spontaneous mutation at an increased rate (Ryder
et al., 2012). Furthermore, dramatic increases in conjugative transfer of plasmids enable
rapid dissemination of plasmid-borne resistance determinants within surface-adhered
populations (Savage et al., 2013).
Bacteria in biofilms alter their gene expression, enhancing production of efflux pumps and
antibiotic modifying enzymes (Høiby et al., 2010). Indeed, upregulation of efflux pumps
and transporters accounts for ∼20% of all the genes upregulated in biofilms (Kvist et al.,
2008). Increased levels of β-lactamases are found near the surface of the biofilm, where
the concentration of antibiotic is highest. This response is mediated via quorum sensing-
regulated mechanisms, in which organisms sense a critical concentration of bacteria
within in a limited space and respond by altering gene expression (Høiby et al., 2010).
For those compounds that are not degraded enzymatically, exclusion from the biofilm
may reduce antibiotic activity. For example, oxacillin, cefotaxime and vancomycin have
retarded penetration through the staphylococcal matrix, whilst ciprofloxacin and amikacin
diffusion is unaffected (Singh et al., 2010).
The continual emergence of antibiotic resistant bacteria, and ability of organisms to avoid
the lethal effects of antibiotics when growing under certain conditions contributes to
the urgent need for discovery of new antibacterial agents. Since a large proportion of
infections involve bacterial biofilms (Davies, 2003), it is particularly important to discover
new antibacterial agents that can eradicate biofilms. Furthermore, to overcome problems
associated with antibiotic resistance, compounds would ideally have a novel MOA, as
resistance to these agents would be less likely to arise through alterations to an existing
resistance mechanism (O’Neill & Chopra, 2004). There are numerous methods that can
be employed to identify novel inhibitors and antibiotic discovery strategies are considered
the following section.
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1.3 A brief history of antibiotic discovery
Antibacterial drug discovery programmes aim to identify compounds with targets that are
essential to the bacteria, have no human homologues, and have low potential to generate
resistance (Silver, 2011). There are a number of approaches that can be taken to achieve
these goals. Historically, the majority of existing antibiotics have been discovered through
empirical screens of fermentation products, and modification of compounds with known
antibacterial activity. Early research into antibiotics include Duschense’s identification of
bactericidal products from fungi in the 1890s (Duckett, 1999), and Fleming’s detection
of penicillin from mould in 1929 (Fleming, 1929; Conly & Johnston, 2005). During the
1930s, sulphonamides were discovered (Conly & Johnston, 2005), and in the following
decades numerous classes of antibiotics were identified. This era was termed as the
‘golden age’ of antibiotic discovery, during which time aminoglycosides, tetracyclines,
macrolides, quinolones and cephalosporins were discovered and brought into use (see
Figure 1.3) (Silver, 2011; Conly & Johnston, 2005).
Subsequently, the impetus moved to target based screening in order to avoid rediscovery
of the same compounds from natural product libraries. This approach had limited
success, but yielded some compounds that reached the market, such as trimethoprim and
fosfomycin (Silver, 2011). By the 1970s, antibiotic discovery had slowed significantly.
In recent times, rational/structure-based drug design has increased in popularity, though
as yet no compounds have been successfully developed as antibiotics (O’Neill & Chopra,
2004; Silver, 2011). Additionally, large-scale chemical screens have been carried out
by pharmaceutical companies, but have been fruitless, in part due to inadequate or
unsuitable chemical libraries (Silver, 2011). While compounds with antibacterial activity
are readily discovered, they are rarely suitable for development due to inhibitory activity
in mammalian cells. Difficulties in delivering chemical inhibitors of bacterial targets into
cells and avoiding efflux contribute to low discovery rate. This is a problem particularly
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Figure 1.3: Timeline of antibiotic discovery. Image reproduced from Silver (2011).
for Gram-negative antibacterials, for which the outer membrane is a significant challenge
(Silver, 2011). In the last 40 years, although analogues of existing antibiotics have
been developed, very few novel antibiotic classes have been discovered and successfully
developed for human use. This ‘discovery void’ directly contributes to current difficulties
in treating bacterial infections, as there are reducing numbers of effective antibiotics
(Silver, 2011; Coates et al., 2011).
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1.4 Antioxidants and antibacterial activity
Due to the dearth of successful development of novel antibiotics, investigating
underexploited compounds has become increasingly common (Chopra, 2003).
Antibiotics such as daptomycin and retapamulin, that had previously been discovered
but were not developed for clinical use, have been successfully revisited (Hawkey,
2008; Kirst, 2012). Repurposing of compounds that are already in human use, for
example in healthcare products, may be a rewarding approach to discovery of new
antibacterial agents. Therefore, the present study sought to investigate the antibacterial
properties of antioxidants that were already known to have some antibacterial activity.
This project arose from research carried out at Evocutis (formerly Syntopix), the aim
of which had been to identify antioxidants that could resolve acne due to activity
against Propionibacterium acnes. Several antioxidants displayed potentially useful
activity against Gram-positive bacteria, and patents held by Evocutis cover the use
of tert-butylhydroquinone (TBHQ) and AO 2246 as topical acne treatments (Seville
& Wilkinson, 2008; Jones et al., 2008a). From the screens carried out at Evocutis
(susceptibility testing of propionibacteria and staphylococci to antioxidants in broth), 16
phenylic antioxidants were identified that had antistaphylococcal activity (see Figure 1.4
for chemical structures). A number of these antioxidants are in use as cosmetics additives
or food preservatives (Seville & Wilkinson, 2008; Merrifield & Yang, 1965; Fung et al.,
1985), whilst others derive from plants that have been used medicinally (thymoquinone
from Nigella sativa (Chaieb et al., 2011), NDGA from Larrea tridentate (Martins
et al., 2013), celastrol from Tripterygium wilfordii (Chen et al., 2011) and bakuchiol
from Psoralea corylifolia (Katsura et al., 2001). These antioxidants have been used in
medicinal applications or are approved for human consumption, suggesting that they do
not have overt eukaryotic toxicity. Table 1.1 contains a list of phenylic antioxidants with
known antibacterial activity and information pertaining to their mechanism of action.
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Figure 1.4: Chemical structures of phenylic antioxidants All structures obtained from PubChem
(http://pubchem.ncbi.nlm.nih.gov/).
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Compound
MIC for a range
Mechanism of action Reference
of bacteria (µg/mL)
Antioxidant 2246 0.98-31.25 - Seville & Wilkinson (2008)
Bakuchiol 1-32
In Streptococcus mutans bakuchiol causes Reddy et al. (2010)
membrane damage Katsura et al. (2001)
Benzoyl peroxide 64-512 - Eady et al. (1994)
Carnosic acid 2-30
In S. aureus carnosic acid increases membrane Moreno et al. (2006)
permeability and affects efflux Horiuchi et al. (2007)
Celastrol 0.3-1.3 - Moujir et al. (1990), Ankli et al. (2000)
Dihydroxychalcone 0.1-100
In S. aureus dihydroxychalcone may damage Zampini et al. (2005)
the cell envelope or affect efflux Tran et al. (2012)
8-hydroxyquinoline 0.9-15.6
In B. subtilis 8-hydroxyquinoline inhibits C¸olak et al. (2009)
DNA synthesis Mariner et al. (2011)
Idebenone 1.6-100
In Helicobacter pylori idebenone inhibits
Inatsu et al. (2006)
respiration and decreases intracellular ATP
Table 1.1: Antibacterial activity and MOA of antioxidants .
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Compound
MIC for a range
Mechanism of action Reference
of bacteria (µg/mL)
Lauryl gallate 6.25-100
In P. aeruginosa and S. aureus lauryl gallate disrupts the
Kubo et al. (2003)membrane, inhibits the respiratory chain and causes ROS
generation. ROS are not the sole cause of death
Menadione 2-3.2
In S. aureus ROS generation contributes to Inatsu et al. (2006), Chaudhuri et al. (2010)
antibacterial activity, but is not the sole cause of death Schlievert et al. (2013)
NDGA 125-500 - Martins et al. (2013)
TBHQ 0.5-31
In E. coli TBHQ may induce ROS production Raccach & Henningsen (1982)
that could damage DNA or membranes Jones et al. (2008a), (Malone et al., 2008)
Thymohydroquinone 4-125 - Toama et al. (1974)
Thymoquinone 8-512
In P. aeruginosa and S. aureus thymoquinone increases Chaieb et al. (2011)
membrane permeability or affects efflux Kouidhi et al. (2011)
Totarol 0.4-3.2
In B. subtilis and S. aureus totarol increases membrane Kubo et al. (1992)
permeability through membrane depolarisation and Nicholas et al. (1999)
inhibits the respiratory chain Foss et al. (2013)
Vitamin K5
64-1024 - Miranda et al. (2011)
hydrochoride
Table 1.1 (continued): Antibacterial activity and MOA of antioxidants.
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Little or nothing is known about the antibacterial MOA of approximately half of the
antioxidants under investigation here (Table 1.1). For the remaining compounds, studies
suggest that antioxidants either induce membrane damage (Katsura et al., 2001; Horiuchi
et al., 2007; Tran et al., 2012; Kubo et al., 2003; Kouidhi et al., 2011; Foss et al., 2013),
or kill bacteria through generation of reactive oxygen species (ROS) (Kubo et al., 2003;
Malone et al., 2008; Schlievert et al., 2013). Aerobic respiration causes the continual
production of ROS through the electron transport chain (Cabiscol et al., 2000). In
bacteria oxidation of respiratory chain components transfers electrons to O2, generating
superoxide. This reactive species is converted to hydrogen peroxide, which undergoes the
Fenton reaction, involving cycling of transition metals such as Fe2+, eventually forming
hydroxyl radicals, water and Fe3+ (Cabiscol et al., 2000; Farr & Kogoma, 1991).
Excess production of ROS can exert deleterious effects on bacteria by interacting with
cell components and may contribute to antioxidant MOA (Farr & Kogoma, 1991; Kubo
et al., 2003; Malone et al., 2008; Schlievert et al., 2013). DNA can be damaged by
hydroxyl radicals at either the sugar or base by extraction of a hydrogen atom from the
deoxyribose ring. This leads to its collapse and creation of single- and double-strand
breakage (Farr & Kogoma, 1991). Protein function can be lost due to superoxide or
hydrogen peroxide induced structural modifications, including peptide fragmentation and
side chain alterations (Cabiscol et al., 2000). Iron-sulphur cluster-containing enzymes
are particularly susceptible to oxidative damage leading to enzyme inactivation and
degradation (Farr & Kogoma, 1991). Hydroxyl radicals can also damage polyunsaturated
fatty acids in membranes and cause lipid peroxidation. This disrupts membrane function
by reducing fluidity, due to shortening of fatty acid chains, and disturbance of membrane
bound proteins (Farr & Kogoma, 1991).
A number of the antioxidants are reported to damage the bacterial membrane, which
is a property that is often associated with antibiofilm activity (Hurdle et al., 2011).
Additionally, the antioxidants thymoquinone, benzoyl peroxide and bakuchiol were found
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to inhibit growth of bacterial biofilms, although eradication of preformed surface-attached
communities has not been documented to date (Chaieb et al., 2011; Coenye et al., 2007;
Reddy et al., 2010). Therefore, there are indications that these antioxidants are suitable
for investigation as antibacterial agents, and the possibility of antioxidants displaying
antibiofilm activity is of particular interest.
1.5 Objectives of this study
Due to the increasing prevalence of multidrug-resistant bacteria and the critical lack of
novel antibiotics in development, this study aimed to identify potential candidates for
antistaphylococcal treatments. In order to avoid some of the pitfalls of recent attempts to
identify new antibacterial agents (Silver, 2011), studies were carried out with compounds
that were already known to have whole-cell antibacterial activity. Studies focused on
inhibitors of S. aureus, a nosocomial and community-acquired pathogen of major clinical
significance (Livermore, 2009). A number of antioxidants were screened for activity
against both planktonic and biofilm cultures, and synergistic interactions of compounds
with existing antibiotics were assessed. If compounds had detectable inhibitory activity
against biofilms, the basis of this rare property was investigated by studying effects on
components of the biofilm.
Characterisation of the MOA of antibacterial agents is a critical aspect of novel drug
development (O’Neill & Chopra, 2004). Therefore, the killing kinetics and MOA of
promising antioxidants were determined. MOA experiments were used to identify the
effects of compounds on common antibacterial targets: the synthesis of macromolecules
and the bacterial membrane. The development of resistance to agents was investigated
in vitro in order to provide information about the likelihood of appearance of high-
level resistance in the clinic. Following identification of resistant mutants, the genetic
basis of altered susceptibility was studied via genome sequence determination and the
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contribution of any identified mutations was confirmed through complementation studies.
This provided further information regarding the cellular target of the compound. Finally,
compounds with useful antibacterial activity were assessed for bacterial specificity and
effects on eukaryotic cells. It is hoped that this approach has identified a lead/several lead
compounds that could be developed as antibacterial products.
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Materials and Methods
2.1 Bacterial strains, plasmids, and growth conditions
Laboratory strains of bacteria used in this study are listed in Table 2.1. Clinical
S. aureus isolates used for susceptibility testing were part of a culture collection belonging
to the Antimicrobial Research Centre, University of Leeds. Plasmid pEPSA5 was used
in complementation studies (Forsyth et al., 2002). Staphylococci and Pseudomonas
aeruginosa were propagated in Mueller-Hinton broth (MHB) at 37◦C with aeration and
on Mueller-Hinton agar (MHA) (Oxoid). Strains of E. coli and B. subtilis were grown
in Luria-Bertani broth at 37◦C with aeration and on Luria-Bertani agar (Oxoid). For
studies with daptomycin and valinomycin, culture media were supplemented with calcium
(50 µg/mL, in the form of CaCl2) and potassium chloride (0.1 M), respectively.
For biofilm penetration experiments using cellulose-ester membrane filter discs
(Millipore), biofilms were grown on Brain Heart Infusion agar (BHA) (Oxoid),
and staphylococcal biofilms in microtitre plates were grown in Tryptic Soy
Broth (TSB) (Oxoid). Small colony variants were generated by transduction of
hemB::ermB and menD::ermC from S. aureus 8325-4 (Bates et al., 2003) into
S. aureus SH1000 using phage φ11 (Section 2.8.1) (Foster, 1998).
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Strain Comments References/Source
Staphylococcus aureus
SH1000
Standard laboratory strain Horsburgh et al. (2002),
(S. aureus 8325-4 with functional rsbU) O’Neill (2010)
ATCC 23723 Antibiotic susceptibility testing strain BSAC (1991)
ATCC 29213 Antibiotic susceptibility testing strain BSAC (1991)
UAMS-1 Prolific biofilm-forming strain Gillaspy et al. (1995)
KC043 SH1000 with defective ahpC/katA Cosgrove et al. (2007)
MHK11AM SH1000 with defective sodA/sodM Karavolos et al. (2003)
SH1000 hemB::ermB Small colony variant This study
SH1000 menD::ermC Small colony variant This study
RN4220 Restriction deficient derivative of S. aureus
8325-4
Fairweather et al. (1983)
CAJ192 C9 Part of the University of Leeds Tn library This study
B7 - This study
C3 - This study
Staphylococcus epidermidis
RP62A Prolific biofilm-forming strain (ATCC 35984) Ryder et al. (2012)
Table 2.1: Bacterial strains used in this study.
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Strain Comments References/Source
Bacillus subtilis
1S34 (pS77) DNA synthesis biosensor Urban et al. (2007)
1S34 (pS63) RNA synthesis biosensor Urban et al. (2007)
1S34 (pS72) Protein synthesis biosensor Urban et al. (2007)
1S34 (pS107) Cell wall synthesis biosensor Urban et al. (2007)
1S34 (pNS14) Fatty acid synthesis biosensor Fischer et al. (2004)
Escherichia coli
1411 K-12 strain O’Neill et al. (2002)
SM1411 1411 with defective acrAB O’Neill et al. (2002)
AB734 K-12 strain Shapiro & Baneyx (2002)
ES100 AB734 with defective tolC Shapiro & Baneyx (2002)
DH5α Standard cloning strain Invitrogen
Pseudomonas aeruginosa
PAO1 Standard laboratory strain Stover et al. (2000)
Table 2.1 (continued): Bacterial strains used in this study.
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2.2 Chemicals, reagents and antibacterial compounds
Antibiotics and chemicals were from Sigma-Aldrich unless otherwise stated. Ampicillin
was purchased from Fisher Scientific, cefotaxime from MP Biomedicals, ciprofloxacin
from Bayer, carbonyl cyanide m-chlorophenylhydrazone (CCCP) from Millipore,
daptomycin from Cubist Pharmaceuticals, dicyclohexylcarbodiimide (DCCD) from Alfa
Aesar, flucloxacillin from CP Pharmaceuticals, linezolid from Pfizer, meropenem from
AstraZeneca, moxifloxacin from Bayer, SEP155342 from Sunovion Pharmaceuticals,
triclosan from LG Life sciences, vancomycin from Duchefa Biochemie, D-luciferin from
Melford, ethanol and nuclease-free water from Fisher Scientific, and the radiolabeled
chemicals [methyl-3H]thymidine (70-95 Ci/mmol), [5,6-3H]uridine (31-56 Ci/mmol),
and L-[G-3H]glutamine (20-50 Ci/mmol) from GE Healthcare. XF-73 and XF-70 were
gifts from Destiny Pharma and antioxidants were gifts from Evocutis. SYPRO R© Ruby,
3,3’-dipropylthiadicarbocyanine iodide (DiSC3(5)), the Live/Dead BacLightTM kit, ATP
Determination Kit and SYBR safe gel stain were from Invitrogen. The PCR nucleotide
mix was from Promega and phospholipids were from Avanti Polar Lipids. Antimicrobial
agents and their solvents are described in Table 2.2.
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Compound Solvent Compound Solvent
Ampicillin Water Linezolid Water
AO2246 DMSO Menadione DMSO
Bakuchiol DMSO Meropenem Water
Benzoyl peroxide Ethanol Moxifloxacin Water
Carnosic acid Ethanol Mupirocin 50% (v/v) ethanol
CCCP DMSO NDGA Ethanol
Cefotaxime Water Nisin 20 mM HCL
Celastrol DMSO Norfloxacin Water
Chloramphenicol 50% (v/v) ethanol Oxacillin Water
Chlorhexidine DMSO Rifampicin DMSO
Ciprofloxacin 20 mM HCL SDS Water
Clofazamine 50% (v/v) ethanol SEP155342 DMSO
CTAB Water Spectinomycin Water
Daptomycin Water TBBQ Ethanol
DCCD Ethanol TBHQ Ethanol
Dihydroxychalcone DMSO Tetracycline Water
Erythromycin 50% (v/v) ethanol Thymohydroquinone DMSO
Flucloxacillin Water Thymoquinone Ethanol
Fosfomycin Water Totarol DMSO
Fusidic acid 50% (v/v) ethanol Triclosan Ethanol
Gentamicin Water Valinomycin DMSO
8-hydroxyquinoline Ethanol Vancomycin Water
Idebenone Ethanol Vitamin K5 Ethanol
Kanamycin Water XF-70 Water
Lauryl gallate Ethanol XF-73 Water
Table 2.2: Antimicrobial agents and their solvents used in this study. CCCP: carbonyl
cyanide m-chlorophenyl hydrazone; CTAB: cetyltrimethylammonium bromide; DCCD:
dicyclohexylcarbodiimide; NDGA: nordihydroguaiaretic acid; SDS: sodium dodecyl
sulphate; Vitamin K5: Vitamin K5 hydrochloride.
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2.3 Stability studies with TBHQ and TBBQ
Extinction coefficients for TBHQ (2945.1 M−1cm−1) and TBBQ (16274.3 M−1cm−1)
were determined at their absorbance maxima (290nm and 252nm, respectively) (Li et al.,
2002) using known concentrations of both compounds in PBS. Stability studies were
performed at 37◦C with shaking using starting concentrations of TBHQ and TBBQ for
which absorbance readings could be taken without requiring dilution of the solution
(absorbance values of<0.8); for TBHQ, the concentration used was 385 µM (64 µg/mL),
and for TBBQ, 97 µM (16 µg/mL). The Beer-Lambert law was used to calculate the
concentrations of TBHQ and TBBQ present in solution over time (Cammack et al., 2006).
The stability of TBHQ/TBBQ was measured in PBS (pH 6, 6.5 or 7) under aerobic and
anaerobic conditions, and following addition of ascorbic acid up to 512 µg/mL.
2.4 Antibacterial activity testing
2.4.1 Standardised susceptibility testing
MICs were determined in broth by exposing bacteria to serial dilutions of antibacterial
agents in MHB according to Clinical and Laboratory Standards Institute (CLSI)
broth microdilution guidelines (Cockerill et al., 2012). Minimum Bactericidal
Concentrations (MBCs) were determined by enumerating bacteria surviving challenge
with concentrations of antibacterial agents above the MIC; bacterial colonies were
counted after incubation at 37◦C for 18-24 hours on MHA, and the MBC defined as the
minimum concentration of antibacterial agent that caused 99.9% kill (Barry et al., 1999).
Biofilm MICs (bMICs) and Minimum Biofilm Eradication Concentrations (MBECs) were
determined using S. aureus SH1000 biofilms grown using the Calgary Biofilm Device
(CBD), which supports ∼107 CFU/peg (Nunc, Roskilde, Denmark) (Ceri et al., 1999;
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Miller et al., 2005). Biofilms were washed twice in saline before being exposed to
antibacterial agents in MHB at 37◦C for 24 hours. The bMICs were determined as
the lowest concentration of compound that inhibited planktonic growth of bacteria shed
from the biofilm. The CBD pegs were washed twice in saline and transferred to drug-
free MHB. Following incubation at 37◦C for 24 hours, the MBEC was determined as
the lowest concentration of compound that effectively sterilised the biofilm, allowing no
further planktonic growth. Susceptibility testing was conducted on a minimum of three
independent occasions to ensure reproducibility.
2.4.2 Identification of synergism
Synergistic interactions of antioxidants with antibiotics were evaluated for planktonic
cultures and biofilms grown on the CBD using the checkerboard method (Pillai et al.,
2005). In planktonic synergism experiments, compound concentrations ranged from
2x MIC to 1/32x MIC. In biofilm synergism experiments, antioxidant concentration
ranged from 2x MBEC to 1/32x MBEC and antibiotic concentrations ≤256 µg/mL. The
fractional inhibitory concentration (FIC) index was calculated as follows:
FIC index =
(
lowest concentration A
MIC A
)
+
(
lowest concentration B
MIC B
)
.
An FIC value ≤0.5 represents a synergistic interaction, a value of 1 is an additive
interaction and ≥2 is an antagonistic interaction.
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2.4.3 Time-dependent killing studies
Time-kill assays were performed using a method adapted from Oliva et al. (2003). Briefly,
bacteria were cultured to early exponential phase (OD600 of 0.2) in MHB and challenged
with antibacterial agents at 4x MIC. In some instances, bacteria were cultured to early
exponential phase, washed and resuspended in PBS or 5 mM HEPES buffer (pH 7.2)
supplemented with 5 mM glucose pre-warmed to 37◦C, before exposure to antibacterial
agents. Bacterial viability was monitored by dilution in PBS and plating cultures onto
MHA, and enumerating colonies after incubation at 37◦C for 18-24 hours.
Time-kill experiments were also performed with bacterial cells in non-growing states.
Overnight cultures of SH1000 were harvested by centrifugation and cells were
resuspended in the supernatant media to an OD600 of 0.2 before exposure to antibacterial
agents. SH1000 biofilm cells were liberated from 48-hour-old biofilms grown on cellulose
discs by incubation in cellulase (1 mg/ml in 0.05 M citrate buffer pH 5.0) (Ryder et al.,
2012), before being washed and resuspended to OD600 of 0.2 in HEPES and glucose
buffer.
2.4.4 Susceptibility of persisters to antimicrobial agents
Persister cells were generated by growing SH1000 to early exponential phase, then
exposing the cells to ampicillin or ciprofloxacin at 10x MIC for 24 hours at 37◦C. Cells
were then washed and resuspended to the same volume in MHB, and surviving persisters
were challenged with antioxidants at 10x MIC (Wiuff et al., 2005; Wu et al., 2012).
Bacterial viability was monitored following exposure to antioxidants by plating cultures
onto MHA, and enumerating colonies after incubation for 18-24 hours at 37◦C.
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2.4.5 Identification of bacterial lysis
To detect bacterial lysis following challenge with antibacterial agents at 4x MIC or
256 µg/mL, the culture turbidity of early exponential phase cultures at 37◦C was
monitored by absorbance measurements at 600nm (Oliva et al., 2003).
2.5 Doubling time determinations
Overnight cultures were diluted 1:100 in MHB and incubated at 37◦C with aeration until
reaching an OD600 of ∼0.1. The absorbance at 600nm was measured every 4 minutes
until the culture reached an OD600 of ∼0.2. Log10 OD values were plotted against
time (minutes) and a line of best fit was calculated. Doubling times were determined
as follows:
Doubling time (minutes) = log10(2)
gradient of line of best fit .
2.6 Antibacterial MOA studies
2.6.1 Quantification of macromolecular biosynthesis
Antibacterial agents commonly exert their activity through inhibition of macromolecular
biosynthesis pathways (O’Neill & Chopra, 2004). Therefore, the effect of TBBQ
on biosynthesis of DNA, RNA and protein was monitored in early exponential phase
cultures of S. aureus SH1000 (OD600 of 0.2) by following the incorporation of the
radiolabeled precursors [methyl-3H]thymidine, [5,6-3H]uridine and L-[G-3H]glutamine
into macromolecules (Wilson et al., 1995; Ooi et al., 2009). Cultures were grown
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to early exponential phase (OD600 0.2) in MHB, then radiolabels were added to
1 µCi/mL. Cultures were incubated with precursors for 10 minutes at 37◦C with aeration
prior to addition of compounds at 4x MIC. Ciprofloxacin was used as the positive
control for DNA synthesis inhibition experiments, rifampicin for RNA, and tetracycline
for protein. Samples were taken before adding compounds to cultures and were
sampled again following a 10 minute incubation. Samples (500 µL) were processed
by dilution in 5 mL of ice cold 10% TCA, and maintaining on ice for 30 minutes
to precipitate macromolecules. For RNA experiments, MF 100 glass microfiber filters
(Fisher Scientific) were washed with 2.5 mL of 10 mM unlabelled uridine before samples
were filtered using a vacuum pump. Samples on filters were washed twice with 5 mL
10% TCA and 5% acetic acid before being transferred to 5 mL Emulsifier-SafeTM
scintillation cocktail (PerkinElmer) in scintillation counter vials (Greiner Bio-One) for
quantification using a Packard Tri-Carb 2100TR liquid scintillation analyser (Packard
Bioscience).
2.6.2 Bacillus subtilis biosensors
The action of TBBQ was also investigated using a suite of pathway-specific biosensor
strains of B. subtilis that have previously been described for use in MOA studies (Mariner
et al., 2011; Urban et al., 2007). Bacteria were grown to an OD600 of 0.2, and were
then exposed to a range of concentrations of TBBQ or control antibiotic above and below
the MIC (0.005 - 20 µg/mL TBBQ). Samples (100 µL) of culture containing compounds
were incubated at 37◦C with aeration for 1 hour (cell wall biosensor), 1.5 hours (RNA
biosensor) and 3 hours (protein, DNA and fatty acid biosensors). Subsequently, 60 µL of
0.8 mM luciferin in 0.1M citrate buffer (pH 5) was added to cultures and luminescence
measured in white luminescence microtitre plates (Greiner Bio-One) using a FLUOstar
Omega plate reader (BMG, LABTECH). Luminescence was compared with a drug-free
control, and induction was identified as a >2 fold increase in relative luminescence.
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2.6.3 Assays to detect perturbation of membranes
2.6.3.1 The BacLightTM assay
The effect of antibacterial compounds on the integrity of the staphylococcal membrane
was assessed using the BacLightTM assay (Ooi et al., 2009; Hilliard et al., 1999).
S. aureus SH1000 was grown to OD600 0.5-0.6. Volumes of cultures were washed in
sterile deionised water and resuspended to twice the volume. Cells were incubated with
5% SDS or test compounds at 4x MIC for 10 minutes at room temperature with aeration,
and then were washed and resuspended in water. Samples (500 µL) were diluted in a
further 1.5 mL of water and mixed with 6 µL of BacLightTM reagent. Samples were
incubated in the dark for 15 minutes and fluorescence measured at an excitation of 485 nm
and emission of 530 nm or 645 nm using a PerkinElmer LS 45 luminescence spectrometer.
The ratio of green:red fluorescence was determined and percentage membrane integrity
was calculated with respect to the SDS positive control. Compounds were considered
membrane damaging if they caused >30% loss of membrane integrity.
2.6.3.2 Measurement of cytoplasmic membrane potential
Membrane potential and leakage of intracellular ions from cells resuspended in HEPES
and glucose buffer was determined following exposure to antibacterial agents over a
3-hour period at 4x MIC (Hobbs et al., 2008). Cultures of S. aureus SH1000 were grown
to exponential phase (OD600 0.2), washed twice and resuspended in HEPES and glucose
buffer. For membrane potential measurements, cells were incubated with 0.1 M KCl and
2 µM DiSC3(5) for 30 minute at 37◦C to allow uptake of dye. Subsequently, cultures
were exposed to compounds at 4x MIC and samples removed at appropriate time points.
Cells were pelleted and 1 mL of supernatant was mixed with 1 mL DMSO. The pellet
was lysed in DMSO for 10 minutes, and was then added to an equal volume of HEPES
and glucose buffer. Extracellular and intracellular fluorescence was measured on a LS 45
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luminescence spectrometer (PerkinElmer) at an excitation of 622 nm and an emission of
670 nm. Membrane potential was calculated using the Nernst equation (Silverman et al.,
2001),
∆ψ = −
RT
F
ln
(
DiSC3(5) inside
DiSC3(5) outside
)
,
and was expressed as a percentage of the initial value. ∆ψ is the membrane potential in
mV, R is the universal gas constant, T is the absolute temperature and F is the Faraday
constant.
2.6.3.3 Measurement of ionic leakage
For ionic leakage experiments, cells resuspended in HEPES and glucose buffer were
exposed to compounds at 4x MIC at 37◦C with aeration for 3 hours. Samples (5 mL)
were removed at regular intervals, filtered through a sterile 0.2 µm filter and stored at
-20◦C until they could be analysed by flame atomic absorption spectroscopy. The positive
controls for potassium leakage experiments were cells that had been boiled for 10 minutes
prior to filtration. For magnesium leakage experiments, cells were incubated at 37◦C
with 100 µg/mL lysostaphin for 3 hours before filtration. Potassium standards (0.05,
0.1, 0.2, 0.5, 1, 1.5, 2, 2.5 and 3 µg/mL) and magnesium standards (0.01, 0.025, 0.05,
0.075, 0.1, 0.2, and 0.3 µg/mL) were made in HEPES and glucose buffer, and a Perkin
Elmer AAnalyst 100 spectrometer was used to generate standard curves from which ionic
contents of samples were calculated (Ioannou et al., 2007).
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2.6.3.4 Haemolysis assay
The ability of compounds to damage mammalian membranes was examined by measuring
haemolysis of equine erythrocytes (Oliva et al., 2003). Briefly, lithium heparin-treated
whole equine blood (Matrix Biologicals) was centrifuged at 1000 x g for 10 minutes at
4◦C, and the supernatant and buffy coat discarded. The erythrocyte pellet was washed
and resuspended to 5% v/v in 10 mM Tris-HCl buffer containing 0.9% NaCl (pH 7.4)
at 4◦C. Erythrocytes were diluted 25-fold in buffer, and pre-incubated at 37◦C for 15
minutes prior to use. Erythrocytes were exposed to a concentration of antibacterial
agent equivalent to 4x MIC against S. aureus SH1000 for 1 hour at 37◦C. Mixtures
were centrifuged at 3000 x g for 5 minutes, then the extent of haemoglobin leakage was
measured at OD540, and expressed as a percentage of the positive control (5% SDS).
2.6.3.5 Liposome disruption
Disruption of staphylococcal liposomes was measured at 4x MIC following 3 hour
incubation with compounds as previously described (StGelais et al., 2007; Randall
et al., 2013). Briefly, carboxyfluorescein-containing liposomes were generated with a
phospholipid content analogous to the S. aureus cytoplasmic membrane: 40% cardiolipin
(wt/wt) and 60% phosphatidylglycerol (Avanti Polar Lipids). S. aureus liposomes
(50 µM) were exposed to compounds at 4x MIC for 3 hours and leakage of
carboxyfluorescein was measured in a fluorescence microtiter plate (Greiner Bio-One)
at 485 nm using a FLUOstar Omega plate reader. Liposome integrity was calculated as a
percentage of the positive control, treated with 0.5% Triton X-100.
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2.6.4 Quantification of ATP pools
Total concentrations of ATP were monitored in exponential phase cultures of S. aureus
SH1000 using a luciferin-luciferase chemiluminescence assay (O’Neill et al., 2004).
Cultures were grown to OD600 0.2 before being washed twice, resuspended in HEPES
and glucose buffer, and exposed to compounds at 4x MIC. Samples were processed at
regular intervals by pelleting cells and transferring supernatant to an equal volume of
DMSO. Cell pellets were lysed in DMSO for 10 minutes, and an equal volume of HEPES
and glucose buffer was added. Samples (10 µL) of extracellular or intracellular samples
were transferred to white luminescence microtitre plates (Greiner Bio-One) and 90µL
of ATP standard solution, made according to the manufacturer’s instructions, was added
using a repeater pipette immediately before taking luminescence measurements using a
FLUOstar Omega plate reader. Total ATP levels were calculated from intracellular and
extracellular samples. ATP remaining was calculated as a percentage of the starting ATP.
2.6.5 Determining the mechanism of antibiofilm activity
2.6.5.1 Penetration of antibacterial agents through biofilms
To assess the penetration of compounds into staphylococcal biofilms, biofilms were grown
on cellulose discs for 48 hours (Ryder et al., 2012), and were then transferred to BHA
containing antioxidants or vancomycin at 256 µg/mL. A 13 mm cellulose disc was placed
on the biofilm, on top of which was placed a 6 mm antibiotic disc (Oxoid) moistened
with PBS (Figure 2.1). Following incubation at 37◦C for 24 hours, the antibiotic disc was
transferred to a petri dish containing MHA spread with SH1000. Following incubation
at 37◦C for 24 hours, the diameter of zone of inhibition was measured and compared
with a calibration curve generated using discs impregnated with known concentrations of
antibiotics. The concentration of test compound in each disc and percentage penetration
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was calculated with respect to a control assembly containing no biofilm (Anderl et al.,
2000; Singh et al., 2010).
6 mm antibiotic disc
13 mm cellulose disc
48 hour old biofilm
Agar containing compound
Figure 2.1: Experimental setup for biofilm penetration experiments.
2.6.5.2 Quantification of adherent biofilm material
Alterations in biofilm structure following challenge with antibacterial agents were
detected by quantifying matrix material and adhered cells by staining with SYPRO R©
Ruby and SYTO R© 9, respectively (Frank & Patel, 2007). Microtitre plates were pre-
conditioned with 20% normal pooled human plasma (Sera Laboratories International)
in 0.05 M carbonate buffer overnight at 4◦C. Subsequently, SH1000 biofilms were
grown in wells for 24 hours, and exposed to antioxidant at 256 µg/mL in MHB, or
proteinase K (100 µg/mL in 20 mM tris pH7.5 and 100 mM NaCl), for 1 or 24 hours
(Frank & Patel, 2007). Biofilms were washed in water before being stained with SYPRO R©
Ruby containing 0.167 µM SYTO R© 9 for 30 minutes. Following a further wash in water,
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absorbance was measured at an excitation of 480 nm and emission of 620 nm (matrix) and
520 nm (cells) (Frank & Patel, 2007). In parallel experiments, total biofilm viability was
measured following exposure to compounds for 1 hour. Detached cells were collected,
and adherent cells were dispersed by incubation with proteinase K (100 µg/mL) in buffer
for 1 hour. All cells were washed in PBS before being plated onto MHA, and enumeration
of colonies was carried out after incubation for 18-24 hours at 37◦C.
2.6.6 Identification and characterisation of a transposon insertion
mutant exhibiting hypersusceptibility to TBBQ
A near-saturation transposon library containing ∼20500 transposon mutants (Blake &
O’Neill, 2012) was screened for hypersusceptibility to TBBQ. The library was generated
at the University of Leeds by random mutagenesis of S. aureus SH1000 with the Tn
InsTetG+2Cm (Blake & O’Neill, 2012). Samples (0.2 µL) of overnight culture were
transferred to MHA in square petri dishes containing doubling dilutions of TBBQ. Each
square petri dish contained inocula from 6 microtitre plates. The concentration of TBBQ
used to identify hypersusceptibility was determined in a pilot study. Briefly, 6 transposon
library plates were chosen at random and were used to inoculate agar containing doubling
dilutions of TBBQ at or below the MIC. The concentration at which 1-4 strains per
library plate displayed altered susceptibility was selected for the full screen (14 µg/mL).
Putative hypersusceptible transposants were re-screened twice and altered susceptibility
was confirmed by broth MIC according to CLSI methodology (Section 2.4.1). The Tn
insertion site of mutants was identified by direct sequence determination of genomic
DNA using an outward facing promoter, Tnp out2 (Appendix A) (Bertram et al., 2005).
The link between genotype and hypersusceptibility was confirmed by demonstrating that
transduction of the Tn insertion into SH1000 resulted in co-transfer of the phenotype
(Section 2.8.1).
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2.6.7 Selection of antioxidant resistant mutants
Spontaneous mutation frequencies were determined for antioxidants and the control
agent, rifampicin, as described previously (O’Neill et al., 2001). Briefly, S. aureus
overnight cultures were spread on drug-free MHA and MHA containing antimicrobial
compounds at 4x MIC, and were incubated at 37◦C for 48 hours. Mutation frequencies
were expressed as the number of drug resistant mutants as a proportion of the total
population.
For compounds where mutants were not identified from mutation frequency
determinations, attempts were made to select resistant mutants using the extended
spectrum MIC method (Friedman et al., 2006). Cultures of S. aureus SH1000 were
challenged with antibacterial agents using broth MIC methodology (Section 2.4.1) with
the exception that the dilution series had smaller increments between concentrations
(doubling-dilutions from 256, 192 and 160 µg/mL). Following 24 hour incubation at
37◦C, the MIC was recorded and cells from the well containing the highest concentration
of drug that permitted growth were used as the inoculum for the next MIC. The process
was repeated for 40 passages, during which cells were continually exposed to selective
compounds. Putative resistance was confirmed by standard broth MIC methodology.
2.7 Effects of antioxidants on human LabSkinTM
To test whether antioxidants have potential as topical antistaphylococcal agents, the
effect of compounds on a living skin equivalent was assessed. Fully differentiated,
28-day-old LabSkinTM and maintenance medium were provided by Evocutis. At the
start of the experiment, spent LabSkinTM medium was removed and stored at -80◦C
until analysis. Medium was replaced with fresh LabSkinTM maintenance medium and
100 µL of test compound at 10 or 4x MIC in sterile deionised water (0.2% v/v solvent
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load) was spread across the surface of each individual LabSkinTM using an inoculation
loop. The drug-free control was exposed to deionised water and solvent alone, and the
positive control was incubated with 5% SDS. LabSkinTM was incubated at 37◦C, 5% CO2,
>95% relative humidity for 6 hours (Holland et al., 2008), then medium was removed
and stored at -80◦C, and replaced with fresh maintenance medium. LabSkinTM was
incubated for a further 18 hours before medium was sampled again. Tissue was fixed in
10% neutral buffered formalin for 24 hours before being embedded in wax and carrying
out hematoxylin and eosin staining and visual inspection of tissue sections (Holland
et al., 2008). To identify potential skin irritation following application of compounds,
IL-1α ELISA analysis was carried out on sampled medium (Bernhofer et al., 1999;
Rasmussen et al., 2010). Interleukin-1α ELISAs were performed using a Human IL-1
alpha/IL-1F1 Quantikine ELISA Kit (R&D systems) and were performed according to
the manufacture’s instructions. IL-1α was quantified at 450nm using a FLUOstar Optima
plate reader, and compared with the positive control.
2.8 DNA manipulation
2.8.1 Bacteriophage transduction
Overnight cultures of donor strains, containing the gene of interest, were grown in phage
broth (20 g/L Oxoid nutrient broth No. 2). Cultures were diluted 1:100 in phage broth
supplemented with 10 mM calcium chloride. Approximately 105 phage φ11 particles
were added to 300 µL of cells and incubated at room temperature for 30 minutes.
Volumes (10 mL) of molten phage top agar (phage broth and 3.5 g/L oxoid agar No.1)
supplemented with 10 mM calcium chloride was mixed with cells and poured over two
plates containing phage base agar (phage broth and 7 g/L oxoid agar No.1) supplemented
with 10 mM calcium chloride. Plates were incubated at 37◦C in a sealed bag for
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24-48 hours. The phage top agar of plates with the highest dilution that gave confluent
lysis was centrifuged, and the phage-containing supernatant was filtered twice through
0.45 µm filters and was stored at 4◦C (Foster, 1998).
Recipient bacteria were grown overnight in 20mL TSB, then were centrifuged and
resuspended in 1 mL TSB. Samples (500 µL) of recipient cells and 500 µL phage were
incubated in 1 mL LB supplemented with 10 mM calcium chloride at 37◦C statically for
25 minutes, then with agitation (200 rpm) for a further 15 minutes. Cells were washed and
resuspended in 1 mL ice-cold 20 mM sodium citrate before incubation on ice for 2 hours.
Phage-containing recipient cells were spread on TSA supplemented with 0.05% sodium
citrate and selection antibiotic, and were incubated at 37◦C overnight. To ensure loss of
phage, single colonies containing the gene of interest were streaked on TSA containing
sodium citrate and selection antibiotic (Foster, 1998).
2.8.2 DNA extraction, PCR and DNA sequence determination
Genomic DNA was extracted from S. aureus using the PurEluteTM bacterial genomic kit
(EdgeBio). Briefly, 2 mL of S. aureus culture was pelleted and washed in 1 mL TE
buffer. Cells were resuspended in 400 µL of spheroplast buffer supplemented with 100
µg/mL lysostaphin, and were incubated at 37◦C for 1 hour. DNA was purified from
samples according to the manufacturer’s instructions, with the addition of incubation with
proteinase K (100 µg/mL) at 37◦C for 15 minutes prior to addition of Advamax 2 beads.
Plasmid DNA was purified from bacteria using the QIAprep Spin Miniprep Kit (Qiagen)
according to the manufacturer’s instructions. Purified DNA was stored at -20◦C.
Polymerase chain reactions were performed with Phusion R© High-Fidelity DNA
Polymerase (New England Biolabs) according to standard methodology (Sambrook &
Russell, 2001). Oligonucleotide primers were designed using OLIGO 6.0 software
(Molecular Biology Insights Inc.), and manufactured by Eurofins MWG Operon. PCR
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conditions were based upon the manufacturer’s recommendations (Appendix A).
PCR products were visualised by gel electrophoresis (Sambrook & Russell, 2001).
Agarose gels contained SYBR safe gel stain (1:10000) in 0.8% agarose (w/v) in Tris-
acetate-EDTA (TAE) buffer (40 mM Tris acetate, 1 mM EDTA). Hyperladder I and II
(Bioline Reagents) were used alongside DNA samples to determine the molecular weight
of PCR products. A potential difference of 90 V was applied across gels for 30-40
minutes. PCR products were purified using the QIAquick PCR Purification Kit (Qiagen)
according to the manufacturer’s instructions, and were stored at -20◦C.
The sequence of PCR products was determined by Beckman Coulter Genomics, and direct
genomic sequence determination for locating transposon insertion sites was carried out
by Microsynth AG. DNA sequence determination data were analysed using Sequencher
software, version 4.9 (Gene Codes Corporation). Whole genome sequencing and analysis
of resistant mutants was carried out by Leeds Institute of Molecular Medicine, University
of Leeds.
2.8.3 Molecular cloning
The vector pEPSA5 (Forsyth et al., 2002) and DNA fragments for ligation were
modified using restriction enzymes purchased from New England Biolabs. Ligations
were performed using the Quick LigationTM Kit (New England Biolabs), and both
restriction digests and ligation reactions were carried out according to the manufacturer’s
instructions.
Chemically competent E. coli DH5α cells were prepared according to the Inoue method
(Sambrook & Russell, 2001). E. coli were transformed by incubating 100 µL of
competent cells and 10 µL of ligation reaction on ice for 1 hour. Cells were mixed with
1 mL of SOC media (New England Biolabs) and incubated at 37◦C with aeration for
1 hour before spreading onto LBA containing selection antibiotic.
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Electrocompetent S. aureus cells were generated using a method modified from Schenk &
Laddaga (1992). A 25 mL culture was grown to OD600 0.6 in TSB with 2.5% yeast extract.
Cells were harvested by centrifugation and were washed 3 times in dH2O, before a final
wash in 10% glycerol. Cells were incubated in 10% glycerol for 15 minutes, pelleted, and
resuspended to 800 µL in 10% glycerol and stored at -80◦C (Schenk & Laddaga, 1992).
Cells (60 µL) were transformed with 2 µL of vector in a GenePulser 0.1 cm electrode
gap cuvette at 2.3 kV, 100 Ω, 25 µF in a GenePulser XCell Electroporation System (Bio-
Rad). Transformed cells were resuspended in 390 µL TSB+YE immediately. Cells were
incubated at 37◦C with aeration for 1 hour before spreading onto TSA containing selection
antibiotic (Schenk & Laddaga, 1992).
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Chapter 3
Antibacterial activity of
tert-butylhydroquinone (TBHQ) and its
oxidation product,
tert-butylbenzoquinone (TBBQ)
The work contained within this chapter has been published in part in Ooi et al. (2013).
N. Ooi, I. Chopra, A. Eady, J. Cove, R. Bojar and A. J. O’Neill (2013) Antibacterial
activity and mode of action of tert-butylhydroquinone (TBHQ) and its oxidation product,
tert-butylbenzoquinone (TBBQ). Journal of Antimicrobial Chemotherapy, 68 (6): 1297-
1304.
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3.1 Abstract
The antioxidant TBHQ is a food additive reported to have antibacterial activity, and may
therefore have application in the healthcare setting. Work reported in this chapter was
undertaken to characterise the antimicrobial activity of TBHQ and its oxidation product,
TBBQ. TBHQ underwent oxidation in buffer to form TBBQ in a pH- and oxygen-
dependent manner. When oxidation was prevented, TBHQ lacked useful antibacterial
activity. In time-kill experiments TBHQ (4x MIC) induced reductions in bacterial
viability only after 2 hours, which coincided with the commencement of TBBQ formation.
These experiments indicate that TBBQ is responsible for the activity previously
attributed to TBHQ. Susceptibility testing was performed against a number of medically
relevant organisms. TBBQ was most effective against Gram-positive bacteria, and
displayed activity against both planktonic (MIC 8 µg/mL) and biofilm cultures (MBEC
64 µg/mL) of S. aureus SH1000. TBBQ was rapidly and extensively bactericidal, causing
>4-log10 reduction in cell viability within 6 hours at 4x MIC, but was non-lytic. TBBQ
retained cidal activity against slow-growing cells, sterilising stationary phase and persister
cultures following 24 hour incubation with the compound. The antioxidant did not
induce dispersal of staphylococcal biofilms. Therefore, the ability of TBBQ to eradicate
preformed biofilms is due to activity against slow- and non-growing cells contained within
the biofilm.
3.2 Introduction
3.2.1 The phenolic antioxidant TBHQ
Within the last 25 years, the rate of discovery of antibiotics from novel classes has
declined dramatically (Silver, 2011). Therefore, revisiting existing chemicals with known
Chapter 3. Antibacterial activity of TBHQ and its oxidation product, TBBQ 47
antibacterial activities may be a rewarding approach to drug discovery. The lipophilic
antioxidant tert-butylhydroquinone (TBHQ) is a sterically-hindered hydroquinone with a
phenol ring at its core (Figure 3.1a). TBHQ was approved for use in the USA as a food
preservative in 1972 (Fung et al., 1985; Przybylski et al., 1998; Raccach & Henningsen,
1982), and has been shown to possess antibacterial activity (Fung et al., 1985). TBHQ
has predominantly been employed for the stabilisation and preservation of fats/foods with
high fat content owing to its radical-scavenging activity (Fung et al., 1985; Kashanian &
Dolatabadi, 2009).
An important consideration when seeking to characterise the biological properties of
antioxidants is their stability in solution, as they can undergo oxidation to form other
chemical species. Since the biological properties of an antioxidant and its breakdown
products may differ, care must therefore be taken to relate observed properties to the
chemical species present. As TBHQ has most often been used as an additive for vegetable
oils (Kashanian & Dolatabadi, 2009), previous studies have examined its stability at
temperatures reached in the frying process. At such temperatures (175◦C-185◦C) TBHQ
is oxidised primarily to tert-butylbenzoquinone (TBBQ) (Figure 3.1a), although smaller
quantities of a number of other compounds have been detected, including dimerised
TBHQ (Kim & Pratt, 1990; Hamama & Nawar, 1991) and free radical species that
decompose to alternate oxidation products (Hamama & Nawar, 1991). The degradation
of TBHQ to TBBQ at high temperatures is summarised in Figure 3.1b. TBBQ that has
formed as a consequence of TBHQ degradation may then be reduced back to TBHQ,
generating a redox cycling system in the presence of a source of reducing equivalents
(Kim & Pratt, 1990).
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(a)
(b)
Figure 3.1: Chemical structures of TBHQ and TBBQ, and oxidative conversion of
the former to the latter. Panel (a): The chemical structure of tert-butylhydroquinone
(TBHQ) and tert-butylbenzoquinone (TBBQ). Panel (b): A schematic for the transition
metal assisted oxidation of TBHQ to TBBQ with the associated production of superoxide,
hydrogen peroxide and hydroxyl radicals (Li et al., 2002).
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TBHQ has a relatively broad spectrum of antimicrobial activity that encompasses
bacterial species responsible for human disease, including E. coli, S. aureus, Klebsiella
pneumoniae, P. aeruginosa, Streptococcus mutans, Streptococcus agalactiae and
Pediococcus pentosaceus (Raccach & Henningsen, 1982; Fung et al., 1985; Kupp et al.,
1985; Ogunrinola et al., 1996; Davidson et al., 1981; Rico-Munoz & Davidson, 1984;
Chew et al., 1985). Fung et al. exposed 8 Gram-positive and 16 Gram-negative species to
TBHQ (Fung et al., 1985), and found that Gram-positive organisms were generally more
susceptible to the antibacterial effects of TBHQ, but sensitivity varied by species. In agar
susceptibility testing TBHQ inhibited approximately 90% of the species at a concentration
of 500 ppm (∼500 µg/mL) (Fung et al., 1985; Davidson et al., 1981).
Studies with S. aureus highlight the necessity for standardised methodology for TBHQ
susceptibility testing; different studies have reported varying inhibitory concentrations, in
part due to different starting inocula. Until the methodology has been standardised using
a specified inoculum the efficacy of TBHQ cannot be assessed properly. However, it is
clear that TBHQ is active against strains of S. aureus (Table 3.1).
In view of its history of safe use in foods and its antibacterial activity, TBHQ has been
under consideration for use in healthcare products by Evocutis (Fitzgerald et al., 2008).
Therefore, work reported in this chapter was undertaken to characterise the antibacterial
activity of TBHQ.
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S. aureus
strain
Response TBHQ
concentration
Cells/mL Reference
z-88 No inhibition 50 µg/mL 1.2x103 Raccach & Henningsen
(1982)
A100 >2log10 reduction
in viability
100 ppm 107 Rico-Munoz & Davidson
(1984)
100 Bacteriostatic 30 µg/mL 3x103 Raccach & Henningsen
(1982)
- Bacteriostatic 25 ppm 2.4x105 Davidson et al. (1981)
Newbould
305
Bactericidal 250 ppm 104 Chew et al. (1985)
100 Bactericidal 100 µg/mL 3x103 Raccach & Henningsen
(1982)
Table 3.1: Reported inhibitory effects of TBHQ against S. aureus strains.
3.2.2 Aims and Objectives
Work described in this chapter aims to determine the stability of TBHQ and TBBQ
in solution at temperatures relevant to the study of their antimicrobial activity. The
relationship between compound stability and antibacterial activity will be investigated,
and killing kinetics determined. The spectrum of activity of the compounds will be
assessed, with a particular emphasis on their antistaphylococcal and antibiofilm activity.
Compound effects on the structure of S. aureus biofilms, and activity against slow-
growing or persister cells that are located within biofilms will be investigated.
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3.3 Results and discussion
3.3.1 Stability studies with TBHQ and TBBQ
Although degradation of TBHQ has been observed at high temperatures (∼180◦C),
stability has not been examined at temperatures relevant to the study of its antibacterial
activity. TBHQ maintained in PBS at 37◦C was found to be unstable, degrading
in a pH- and oxygen-dependent manner (Figure 3.2a, 3.2b). At neutral pH, this
degradation proceeded rapidly, with only ∼50% of the starting concentration remaining
after 6 hours (Figure 3.2a). Concentrations of TBHQ decreased and TBBQ increased
concurrently, indicating that TBHQ was primarily being oxidised to form TBBQ. The rate
of degradation of TBHQ was slower at more acidic pH (Figure 3.2a), and degradation
did not occur under anaerobic conditions (Figure 3.2b). Addition of the antioxidant
ascorbic acid, which has previously been shown to inhibit decomposition of TBHQ at
100 µg/mL (Tsuji et al., 2005), was able to inhibit the degradation of TBHQ at pH 7 in a
concentration-dependent manner (Figure 3.2c).
Since TBHQ undergoes rapid oxidation to TBBQ in aqueous solutions, experiments were
performed to assess whether this oxidation product is stable in solution. Under aerobic
conditions at 37◦C, TBBQ was found to degrade only slowly and in a pH-independent
manner, with 90% of TBBQ remaining after 6 hours (Figure 3.3a). However, and in
contrast with TBHQ, TBBQ was unstable under anaerobic conditions and its degradation
could not be prevented by concentrations of ≤512 µg/mL of ascorbic acid (Figure 3.3b
and 3.3c). The reduction in TBBQ concentration was not accompanied by an increase in
TBHQ, indicating that TBBQ must be undergoing conversion to an alternative product.
Since addition of ascorbic acid to this product prompted regeneration of TBHQ (Figure
3.3c), the TBBQ breakdown product is likely to be the intermediary semiquinone anion
radical (Figure 3.1b).
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Figure 3.2: Stability of TBHQ at 385 µM (64 µg/mL) in PBS. Panel (a): aerobic
stability; Panel (b): anaerobic stability; Panel (c): stability following a 24 hour incubation
in the presence of ascorbic acid. Concentration of compound in PBS is plotted against the
y-axis (mean of at least three independent replicates; error bars show standard deviations).
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Figure 3.3: Stability of TBBQ at 97 µM (16 µg/mL) in PBS. Panel (a): aerobic stability;
Panel (b): anaerobic stability; Panel (c): stability following a 24 hour incubation in the
presence of ascorbic acid. Concentration of compound in PBS is plotted against the y-axis
(mean of at least three independent replicates; error bars show standard deviations).
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3.3.2 Antibacterial activity of TBHQ and TBBQ
TBHQ and TBBQ MICs and MBCs were determined against the S. aureus laboratory
strain SH1000, and two commonly used S. aureus susceptibility testing strains (ATCC
23723 and ATCC 29213). TBHQ exhibited an MIC and MBC of 8 µg/mL and
8-16 µg/mL against all three strains. TBBQ had comparable activity, exhibiting an MIC
and MBC of 4-8 µg/mL and 8-16 µg/mL. The MIC90 of TBHQ and TBBQ against 70
clinical S. aureus isolates (which included meticillin-resistant [MRSA] and vancomycin-
intermediate [VISA] strains) was 16 µg/mL, with MICs of TBHQ and TBBQ ranging
from 8-32 µg/mL and 4-16 µg/mL respectively (Appendix B).
Studies on the stability of TBHQ implied that this agent would undergo extensive
conversion during the course of a 24 hour MIC determination (Figure 3.2a), with potential
impact on its antibacterial activity. Therefore, the possibility of stabilising TBHQ in
solution was investigated. Since both the absence of oxygen and addition of ascorbic
acid inhibited degradation of TBHQ (Figure 3.2b and 3.2c), MICs were determined
anaerobically and following the addition of ascorbic acid to the culture media. Under
anaerobic conditions there was an 8-fold increase in TBHQ MIC against S. aureus
SH1000, from 8 µg/mL to 64 µg/mL. TBHQ MICs also increased dramatically in the
presence of ascorbic acid, reaching 512 µg/mL (64-fold increase) upon addition of
ascorbic acid at 1024 µg/mL. Therefore, TBHQ lost useful antibacterial activity when
spontaneous oxidation of TBHQ to TBBQ was prevented. In contrast, TBBQ retained
activity in the absence of oxygen, with only a 2-fold increase in TBBQ MIC observed,
and the addition of 1024 µg/mL of ascorbic acid caused an 8-fold increase in MIC. This
suggests that the antibacterial effect associated with TBHQ results either from the process
of conversion of TBHQ to TBBQ (e.g. through the production of reactive intermediates),
or is intrinsic to TBBQ. Since TBHQ and TBBQ are equally effective at inhibiting
bacterial growth (MIC of 8 µg/mL against SH1000 in both cases), the antibacterial activity
of TBHQ cannot be attributed to an intermediate species arising from conversion of
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TBHQ to TBBQ, and must be a property of TBBQ.
The antibacterial activity of a solution containing the breakdown product of TBBQ was
also assessed against S. aureus SH1000, and displayed an MIC of 128 µg/mL. However,
this activity was attributed to the TBBQ remaining in the solution; approximately 10% of
the starting TBBQ remained, a concentration of TBBQ that would provide this level of
antibacterial activity. Thus, the final breakdown product of TBBQ appears to have little
or no antibacterial activity.
Previous studies have suggested that TBHQ has activity against a number of Gram-
positive and Gram-negative species (Fung et al., 1985; Raccach & Henningsen, 1982;
Kupp et al., 1985; Ogunrinola et al., 1996). To investigate the spectrum of activity
of TBBQ, MICs were carried out against a number of bacterial species. TBHQ and
TBBQ displayed limited activity against Gram-negative species as reported previously
(Fung et al., 1985) (E. coli 1411 MIC of 512 µg/mL and P. aeruginosa PAO1 MIC of
>512 µg/mL).
To explore the reason for the poor activity of this compound against Gram-negative
bacteria, susceptibility testing was performed with TBHQ and TBBQ against E. coli in the
presence of an outer membrane permeabilising agent (polymyxin B nonapeptide [PMBN],
at a concentration of 4 µg/mL), and against efflux pump-deficient strains (Shapiro &
Baneyx, 2002; O’Neill et al., 2002). AcrAB is the major transporter in E. coli, and
presence of a functional pump reduces susceptibility to multiple antibacterial agents
(Okusu et al., 1996). The antibacterial activity of TBHQ and TBBQ increased against
E. coli strains lacking AcrAB or TolC (256 and 128 µg/mL against strains SM1411
and ES100, respectively), and reached a level of activity comparable with that observed
against S. aureus (16 µg/mL) in the presence of PMBN (MICs of 32 µg/mL and 16 µg/mL
against SM1411 and ES100, respectively). The results suggest that the limited activity
of the compounds against E. coli is the result both of limited ingress across the outer
membrane, and as a consequence of active efflux from the cell by AcrAB-TolC.
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3.3.3 Evaluation of bacterial killing and lysis by TBHQ and TBBQ
In order to characterise the antibacterial activity of TBHQ and TBBQ further, the
killing kinetics of these compounds were assessed alongside established antibiotics.
Daptomycin caused a reduction in cell viability of approximately 3 log10 cfu/mL after
6 hours in PBS, while tetracycline caused only bacteriostasis (Figure 3.4). TBHQ had
no effect on bacterial viability for the first 2 hours of the experiment, but killing was
observed thereafter (Figure 3.4). The initiation of bacterial killing coincided with the
commencement of conversion of TBHQ to TBBQ (Figure 3.5a), and the extent of kill
increased with rising TBBQ concentration, ultimately leading to a 4 log10 reduction in cell
number after 6 hours (Figure 3.5a). Thus, time-kill studies provided further support for the
concept that TBBQ is responsible for the antibacterial activity of TBHQ. TBBQ showed
no initial lag in killing activity and was rapidly and extensively bactericidal, causing a >5
log10 reduction in cell numbers within 3 hours, and effectively sterilised the culture within
6 hours. Over this period TBBQ degradation was minimal (Figure 3.5b), indicating that
the process of conversion of TBBQ, or a breakdown product of TBBQ, are not responsible
for the lethal effect.
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Figure 3.4: The effect of antibacterial agents at 4x MIC on S. aureus SH1000
suspended in PBS. ndc: no drug control (mean of at least three independent replicates;
error bars show standard deviations).
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Figure 3.5: TBHQ/TBBQ stability and killing kinetics against S. aureus SH1000
suspended in PBS. Panel (a): TBHQ; Panel (b): TBBQ. Percentage of the starting
concentration of compound that remains or percentage that is converted is plotted against
the left y-axis (mean of at least three independent replicates; error bars show standard
errors). Viable count is plotted against the right y-axis (mean of at least three independent
replicates; error bars show standard deviations).
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In nutrient-rich culture medium (MHB), TBHQ and TBBQ displayed reduced activity
against S. aureus SH1000 compared with that seen in PBS. Nonetheless, TBBQ retained
bactericidal activity in MHB, causing >4 log10 reduction in viable cell numbers within 6
hours (Figure 3.6a). At TBHQ or TBBQ concentrations of up to 256 µg/mL, there was
little or no reduction in culture turbidity over a 24 hour period (Figure 3.6b), indicating
that bacterial killing by TBBQ occurred without concomitant cell lysis. The absence
of cell lysis is a beneficial property, as there is reduced risk of releasing immunogenic
bacterial molecules into the host’s bloodstream (Nau & Eiffert, 2002).
(a)
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
Time (Hours)
lo
g
1
0
C
F
U
/m
L
ndc
Daptomycin
Tetracycline
TBHQ
TBBQ
(b)
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Time (Hours)
A
b
so
rb
a
n
ce
O
D
6
0
0
n
m
ndc
TBHQ
TBBQ
SEP155342
Figure 3.6: Evaluation of killing and lytic action of TBHQ, TBBQ and comparator
agents against S. aureus SH1000 in MHB. Panel (a): killing kinetics of compounds at
4x MIC; Panel (b): absorbance at 600 nm of cultures exposed to TBHQ and TBBQ at 256
µg/mL, or the positive control agent SEP155342 at 4x MIC (8 µg/mL) (Oliva et al., 2003)
(mean of at least three independent replicates; error bars show standard deviations).
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3.3.4 Antibiofilm activity of TBBQ
Upon demonstrating that TBBQ is responsible for the activity of TBHQ, which itself
has little antibacterial activity, experiments were performed to examine whether TBBQ
had antibiofilm activity. Pre-formed staphylococcal biofilms were exposed to TBBQ,
which inhibited both the shedding of cells from the biofilm (bMIC of 64 µg/mL) and
achieved complete eradication of biofilms (MBEC of 64 µg/mL). This property was not
shared with the other tested antibacterial agents (Table 3.2). TBBQ also had the ability
to eradicate biofilms generated by other staphylococci, including prolific biofilm-forming
strains (Ryder et al., 2012) (Table 3.3).
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Antibacterial agent MIC (µg/mL) bMIC (µg/mL) MBEC (µg/mL)
Cefotaxime 0.5 4 >256
Chlorhexidine 1 1 >256
Ciprofloxacin 2 4 >256
CTAB 2 2 >256
Daptomycin 1 2 >256
Erythromycin 0.5 0.5 >256
Fosfomycin 16 8 >256
Flucloxacillin 0.125 4 >256
Fusidic acid 0.25 0.5 >256
Gentamicin 0.5 1 >256
Meropenem 0.5 0.5 >256
Mupirocin 0.125 0.25 >256
Nisin 2 >16 >16
Oxacillin 1 1 >256
Rifampicin 0.008 0.02 >256
SDS 256 256 >256
TBBQ 8 64 64
Tetracycline 1 0.5 >256
Vancomycin 1 2 >256
Table 3.2: Antibiofilm activity of antibacterial agents against S. aureus SH1000
biofilms grown on the Calgary Biofilm Device.
Strain MIC (µg/mL) bMIC (µg/mL) MBEC (µg/mL)
S. aureus SH1000 8 64 64
S. aureus UAMS-1 8 16 16
S. epidermidis RP62A 4 32 64
Table 3.3: Antibiofilm activity of TBBQ against prolific biofilm-forming strains.
Chapter 3. Antibacterial activity of TBHQ and its oxidation product, TBBQ 61
3.3.5 Effect of TBBQ on biofilm structure
Given that the ability to eradicate biofilms is rare property amongst antibacterial agents,
experiments were carried out to determine how TBBQ exerts its antibiofilm effect.
The effect of TBBQ on biofilm structural components (adhered matrix and cells) was
investigated in staphylococcal biofilms maintained in MHB. Matrix material and biofilm-
encapsulated cells were stained with the fluorescent dyes SYPROr Ruby and SYTOr 9
and quantified. Proteinase K-disrupted biofilms, causing dissociation of all cells and the
majority of the extracellular matrix. At concentrations above the MBEC, TBBQ did not
cause a significant reduction in the quantity of adhered matrix material or cells (Figure
3.7a and 3.7b), indicating that TBBQ does not induce dissociation of biofilms that are
actively growing.
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Figure 3.7: Effect of antibacterial agents on biofilm structure. Biofilms were exposed
to proteinase K at 100 µg/mL, or test compounds at 256 µg/mL for 24 hours. Panel (a):
attached matrix; Panel (b): attached cells. The data labeled T0 shows the quantity of
matrix and cells before the addition of compounds. Data are the means of at least three
independent replicates, with error bars showing standard deviation.
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3.3.6 Effect of TBBQ on slow- and non-growing cells
Biofilm-encapsulated cells display physiological heterogeneity, including slow- or no
growth and persistence (Shapiro et al., 2011; Singh et al., 2009). Since TBBQ does
not exert antibiofilm activity through disruption and release of biofilms from surfaces,
the effects of TBBQ on the mixed population of cells contained within biofilms was
investigated (Figure 3.8). Unlike the comparator agent daptomycin, TBBQ retained a
small amount of activity against non-dividing cells at 4x MIC, causing∼1 log10 reduction
in viable cells after 6 hours. Thus, TBBQ has some activity against non-growing cells
even at concentrations that are below those capable of eradicating biofilms.
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Figure 3.8: Activity of compounds at 4x MIC against exponential and stationary
phase S. aureus SH1000 suspended in MHB. Mean of at least three independent
replicates; error bars show standard deviations.
Initial experiments carried out at 4x MIC (32 µg/mL) were not sufficient to display
bactericidal activity against stationary phase cells over 6 hours. However, TBBQ
eradicates S. aureus SH1000 biofilms at 64 µg/mL. Therefore, sterilisation of biofilms
may be a consequence of cidal activity against slow-growing cells at higher concentrations
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and over longer exposure times than were tested. Further experimentation measured
compound activity against exponentially growing and stationary phase cultures incubated
with antibacterial agent at 256 µg/mL for 24 hours. At the tested concentration (4x
MBEC), TBBQ sterilised cultures of both growing and non-growing cells; a property
that was not shared with the comparator agent daptomycin (Figure 3.9).
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Figure 3.9: Sterilisation of exponential and stationary phase cultures of S. aureus
SH1000 at 256 µg/mL. Mean of at least three independent replicates; error bars show
standard deviations.
Biofilms are a reservoir not only for slow-growing cells, but also persisters (Singh et al.,
2009). Therefore, compound activity was tested against persisters that were generated
by pre-exposure of S. aureus to ciprofloxacin or ampicillin at 10x MIC for 24 hours.
TBBQ was the only agent that could completely sterilise a population of persister cells
(Figure 3.10). Hence, TBBQ may inhibit and eradicate pre-existing biofilms by remaining
active against metabolically inactive and persister cells that could otherwise repopulate
the biofilm following removal of antibacterial agent.
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Figure 3.10: Activity of antibacterial agents against ciprofloxacin- or ampicillin-
induced persisters of S. aureus SH1000. Mean of at least three independent replicates;
error bars show standard deviations.
3.4 Conclusions
The antioxidant TBHQ was unstable under bacterial culture conditions, and degraded
forming TBBQ. Halting the conversion of TBHQ to TBBQ (via the addition of ascorbic
acid or incubation under anaerobic conditions) dramatically reduced antibacterial activity,
i.e. TBHQ had little intrinsic antibacterial activity when prevented from undergoing
oxidation. The oxidative product, TBBQ, possessed inherent antibacterial activity
that was then lost upon degradation. TBBQ displayed antibacterial activity against
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a number of bacterial species, but was most active against Gram-positive organisms.
Potent bactericidal activity against S. aureus was not associated with cell lysis up
to the maximum tested concentration (256 µg/mL). The compound also eradicated
staphylococcal biofilms; a rare property in antibacterial agents. It is proposed that TBBQ
sterilises biofilms by retaining activity against slow- and non-growing cells contained
within the biofilm.
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Chapter 4
Investigations into the antibacterial
mechanism of action of TBBQ
The work contained within this chapter has been published in part in Ooi et al. (2013).
N. Ooi, I. Chopra, A. Eady, J. Cove, R. Bojar and A. J. O’Neill (2013) Antibacterial
activity and mode of action of tert-butylhydroquinone (TBHQ) and its oxidation product,
tert-butylbenzoquinone (TBBQ). Journal of Antimicrobial Chemotherapy, 68 (6): 1297-
1304.
4.1 Abstract
MOA studies are an important aspect of preclinical evaluation of antibacterial agents.
Therefore, initial studies attempted to identify whether the bactericidal compound TBBQ
acts through inhibition of pathways commonly targeted by antibiotics. TBBQ did
not display preferential inhibition of any single macromolecular synthetic pathway, but
disrupted the staphylococcal membrane. The antioxidant induced loss of membrane
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potential and leakage of intracellular ions, without causing damage to staphylococcal
liposomes or inducing haemolysis. Additionally, intracellular ATP was hydrolysed and
ROS were generated within cells exposed to TBBQ. Only low level TBBQ resistance
could be selected using the extended spectrum MIC method, and a hypersusceptible
mutant was identified by screening a near-saturation Tn library. Mutations were identified
in the resistant (B7) and hypersusceptible (CAJ192 C9) strains by PCR and the role of
the genes in TBBQ susceptibility was confirmed by complementation. The potential
roles of these alterations are discussed in this chapter, but require further investigation.
B7/CAJ192 C9 did not display cross-resistance/hypersusceptibility to other agents,
suggesting that TBBQ has a novel MOA. Eukaryotic toxicity of the compound was
investigated using a human skin equivalent. Exposure to TBBQ for 24 hours did not
irritate or damage skin. Therefore, TBBQ appears to interact specifically with bacterial
membranes and could potentially be used as a topical treatment. In view of the potent
bactericidal and antibiofilm activity of TBBQ, and absence of development of high-level
resistance or damage to skin, this compound warrants further investigation as a candidate
antistaphylococcal agent.
4.2 Introduction
4.2.1 MOA studies
Characterisation of the MOA of antibacterial agents is an important phase of preclinical
evaluation, as it can guide further development of potentially useful agents (O’Neill &
Chopra, 2004). There are a large number of tools available to investigate MOA, and the
experiments descried in the following section have been successfully used in previous
studies (O’Neill & Chopra, 2004). Initial MOA studies may include measurements of
effects of compounds on macromolecular synthesis (MMS) through incorporation of
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radiolabeled precursors into DNA, RNA and protein (Wilson et al., 1995). Compounds
may also be screened against whole-cell B. subtilis biosensors (Mariner et al., 2011).
Expression profiling was used to identify promoters that are induced following exposure
to inhibitors of known biosynthetic pathways (DNA, RNA, protein, cell-envelope or
fatty acid synthesis). Promoter-luciferase reporter constructs were then used to generate
bacterial biosensors (Urban et al., 2007), which can be employed in high-throughput
screening of inhibitors to identify agents that affect specific pathways.
Compounds that damage the bacterial membrane simultaneously inhibit all MMS
pathways and may not induce any of the biosensors (Ooi et al., 2009). Membrane
perturbation can be confirmed by measuring ingress/egress of fluorescent dyes and
leakage of intracellular components (Ooi et al., 2009). Until relatively recently,
membrane-damaging activity had been considered an undesirable property of a novel
inhibitor, as some compounds may have promiscuous interactions with both prokaryotic
and eukaryotic membranes (Hurdle et al., 2011). Daptomycin is a membrane-damaging
antibiotic that disrupts bacterial cytoplasmic membranes specifically by inserting into the
phospholipid bilayer in the presence of calcium and oligomerises to form a pore through
which intracellular components are lost (Randall et al., 2013; Hobbs et al., 2008). The
successful introduction of daptomycin into clinical practice suggests that selective toxicity
of membrane-damaging agents may be achieved by optimisation of the dosing regimen
(Dvorchik et al., 2003). Therefore, compounds that disrupt the bacterial membrane are
receiving increasing interest, particularly due to the emerging concept that membrane-
active agents may be usefully employed against non-growing and persistent bacterial
populations (Hu et al., 2010; Hurdle et al., 2011).
Agents with novel targets or those that affect essential bacterial components are desirable
as resistance to these agents is less likely to arise by minor alterations to either existing
resistance mechanisms or conserved structures. The development of resistance should
be assessed during preclinical evaluation, as resistant mutants can provide insight into
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the cellular target of the compound (O’Neill & Chopra, 2004). Artificial under- or over-
expression of the inhibitor’s target should cause hypersusceptibility or resistance to the
compound respectively, and can be used to confirm that the gene of interest is indeed the
target of the inhibitor (O’Neill & Chopra, 2004).
4.2.2 Toxicity studies
Upon characterisation of an antibacterial agent’s MOA, the compound should be tested for
selective toxicity. Since the primary concern with membrane-damaging agent agents is
human toxicity, any promising inhibitor that displays this MOA must undergo rigorous
toxicity testing. There is an array of experiments that can be used to investigate
detrimental effects of compounds on eukaryotic cells, including those that measure
leakage of haemoglobin from erythrocytes (Oliva et al., 2003); metabolic activity as an
indicator of cell viability via reduction of dyes (Fotakis & Timbrell, 2006); release of
inflammatory cytokines indicating irritation (Bernhofer et al., 1999); physical damage
to the structure of human skin equivalents (Rasmussen et al., 2010); or in vivo LD50
determinations with test animals (Lorke, 1983). Compounds that are active through a
non-specific MOA are likely to display host toxicity in vivo, and may not be taken further
in antibacterial drug discovery programmes (Silver, 2011).
4.2.3 Putative MOA of TBBQ
The rapid bactericidal and antibiofilm activity of TBBQ against staphylococci suggest
that the compound has potential to be used clinically as an antibacterial agent. The
MOA of TBBQ has not been determined, however attempts have been made to assess
the impact that the precursor TBHQ has on bacteria (Malone et al., 2008). In Chapter 3
it was shown that TBHQ is rapidly converted to TBBQ and that the antibacterial activity
attributed to TBHQ is due to TBBQ. Therefore, previous MOA studies of TBHQ may in
Chapter 4. Investigations into the antibacterial mechanism of action of TBBQ 71
fact have described the MOA of TBBQ. TBHQ was reported to induce single- and double-
strand breakage of supercoiled double stranded plasmid DNA at concentration≥ 0.1 mM
(∼16 µg/mL) (Okubo et al., 1997). DNA damage was enhanced in the presence of
transition metals, and the addition of ROS scavengers or metal chelators inhibited DNA
cleavage. This suggests that TBHQ may undergo metal-assisted redox reactions causing
lesions in DNA (Okubo et al., 1997; Li et al., 2002).
The contribution of ROS generation to antibiotic MOA was investigated by Kohanski
et al. (2007), who suggested that bactericidal but not bacteriostatic antibiotics induce
lethal generation of ROS. It was proposed that fluoroquinolones, β-lactams and
aminoglycosides lead to hyperactivation of the electron transport chain, increasing NADH
consumption and inducing superoxide generation. This reactive species destabilises
iron-sulphur cluster-containing enzymes, causing leaching of iron. Subsequently, iron-
assisted Fenton reactions generate hydroxyl radicals, which contribute to cell death
through damage to bacterial macromolecules (Kohanski et al., 2007). Numerous research
papers investigating this hypothesis have appeared in the literature, some in support of
Kohanski’s theory (Wang & Zhao, 2009) and some in opposition (Ricci et al., 2012).
Although the subject has divided the research community (Wright et al., 2013), two
recent papers provide compelling evidence that refute the hypothesis (Liu & Imlay,
2013; Keren et al., 2013). The following observations were of particular significance:
bactericidal antibiotics caused an equivalent loss of cell viability anaerobically as
aerobically; antibiotics did not induce significant increases in hydrogen peroxide levels;
strains lacking hydrogen peroxide detoxification enzymes were not more sensitive to
all bactericidal antibiotics; and DNA repair mutant strains did not display increased
susceptibility to kanamycin or ampicillin, (Liu & Imlay, 2013; Keren et al., 2013).
Therefore, under certain conditions some bacteria may generate ROS following exposure
to some bactericidal antibiotics, but the extent to which this contributes to cell death is
debatable.
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Investigations into the contribution of ROS in antibiotic MOA highlight the importance of
identifying the primary lethal interaction as opposed to the response of stressed or dying
cells. Whilst TBHQ may be capable of inducing ROS production that damages DNA,
these studies serve as a reminder that attempts should be made to distinguish between
primary and secondary effects following antibacterial challenge. Furthermore, TBHQ-
induced ROS damage to DNA has not been measured in whole-cell assays with bacteria.
Experiments carried out on cellular components in vitro must be confirmed under culture
conditions, as identified effects may not contribute to MOA in living organisms.
No further research has been carried out into the MOA of TBHQ. However the
antibacterial activity of another antioxidant that is related to TBBQ has been studied. The
food preservative 3-tert-butyl-4-hydroxyanisole (BHA) interacts with E. coli membrane
phospholipids, and solubilises membrane proteins, affecting the molecular organisation
of membranes (Okubo et al., 1997; Simonetti et al., 2002). TBBQ, like structurally
related BHA, could affect bacterial membranes. Furthermore, compounds that are rapidly
bactericidal displaying activity against bacterial biofilms may be expected to be active
through disruption of the cytoplasmic membrane (Ooi et al., 2009, 2010; Hurdle et al.,
2011).
4.2.4 Aims and Objectives
Work described in this chapter was intended to determine the mechanism by which TBBQ
exerts it antibacterial activity, and to identify any detrimental effects of the compound
on eukaryotic cells. To assess the potential for the compound to be used clinically,
synergistic interactions with existing antibiotics and the rate of resistance development
will be assessed. A staphylococcal transposon library will be screened with the intention
of isolating mutants that are hypersusceptible to TBBQ, and these strains, along with
TBBQ-resistant mutants, will be characterised in order to provide further information
about the cellular target of TBBQ.
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4.3 Results and discussion
4.3.1 Effects of TBBQ on biosynthetic pathways
As part of the preclinical evaluation of TBBQ, the MOA of the compound was
investigated at the cellular level. Antibacterial agents commonly exert their activity
through inhibition of macromolecular biosynthesis pathways (O’Neill & Chopra, 2004).
Therefore, preliminary experiments examined the effects of TBBQ on bacteria using a
suite of B. subtilis biosensors responsive to inhibition of specific biosynthetic pathways
(Mariner et al., 2011; Urban et al., 2007). The DNA, RNA, protein, cell wall and fatty
acid biosynthesis biosensors were induced in response to the positive control agents
ciprofloxacin, rifampicin, tetracycline, vancomycin, and triclosan respectively. Positive
controls caused a maximum increase in luminescence of 80.5-, 12.3-, 5.2-, 2.6- and 8.6-
fold respectively in comparison with the drug-free control. No induction was observed
with any of the biosensors for TBBQ in the concentration range 0.005 - 20 µg/mL (Figure
4.1). Therefore, exposure to TBBQ does not induce promoters that are responsive to these
pathways in B. subtilis.
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Figure 4.1: Effects of TBBQ and pathway specific inducers on B. subtilis pathway
specific biosensors. Panel (a): DNA biosensor (yorB promoter-luciferase reporter fusion
strain); Panel (b): RNA biosensor (yvgS promoter-luciferase reporter fusion strain); Panel
(c): protein biosensor (yheI promoter-luciferase reporter fusion strain); Panel (d): cell
wall biosensor (ypuA promoter-luciferase reporter fusion strain); Panel (e): fatty acid
biosensor (fabHB promoter-luciferase reporter fusion strain). Horizontal line indicates
2-fold increase in relative luminescence. Mean of at least three independent replicates;
error bars show standard errors.
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To investigate whether TBBQ inhibits synthesis of specific macromolecular biosynthetic
pathways in staphylococci, incorporation of radiolabeled precursors into macromolecules
was compared with known inhibitors of DNA, RNA and protein synthesis (ciprofloxacin,
rifampicin and tetracycline respectively). At 4x MIC TBBQ inhibited all three
macromolecular synthetic pathways within 10 minutes, with no evidence for preferential
inhibition of a single biosynthetic process (Figure 4.2).
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Figure 4.2: Effects of TBBQ and comparator agents on major macromolecular
biosynthesis pathways in S. aureus. Percentage incorporation of 3H thymidine, uridine
and glutamine into SH1000 DNA, RNA and protein respectively (mean of at least three
independent replicates; error bars show standard errors).
4.3.2 Membrane damaging assays
Rapid bactericidal activity, failure to induce pathway-specific biosensors, and non-specific
inhibition of macromolecular synthesis are features common to antibacterial agents that
act on bacteria by compromising the integrity of the cytoplasmic membrane and/or
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inhibiting energy metabolism (Ooi et al., 2009; Shapiro & Baneyx, 2002; O’Neill &
Chopra, 2004). Therefore, the BacLightTM assay was used to examine whether TBBQ acts
on staphylococcal membranes. This method involves exposing bacteria to antimicrobial
agents before staining with two fluorescent nucleic acid dyes: SYTO R© 9 and propidium
iodide. The bacterial cell membrane is permeable to SYTO R© 9, which can stain all
cells, but propidium iodide only stains cells with a compromised membrane. Membrane
damage allows increased propidium iodide staining and reduces SYTO R© 9. Therefore,
the ratio of the dyes is a direct measure of compound-induced membrane damage
(Hilliard et al., 1999). A number of antibiotics and known membrane-damaging agents
(nisin, CTAB and valinomycin) were used as comparator agents. Nisin is a lantibiotic
that generates pores in the membrane, which dissipates the proton motive force and
promotes leakage of cellular components (McAuliffe et al., 2001). Similarly, the biocide
CTAB forms micelles that interact with the lipid component of membranes causing
depolarisation and lysis (Simo˜es et al., 2005; Vieira & Carmona-Ribeiro, 2006). The
MOA of valinomycin is distinct from the other agents, acting as an ionophore that
stimulates passive permeabilisation of the membrane to potassium ions (Bhattacharyya
et al., 1971).
S. aureus cells exposed to ampicillin, rifampicin, vancomycin, tetracycline, and
daptomycin for 10 minutes retained between 90 and 100% membrane integrity, while
TBBQ and the known membrane disruptors nisin, CTAB and valinomycin reduced
membrane integrity over the same time period (Table 4.1).
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Antimicrobial compound % membrane integrity (± SE)
None 100 ± 0
Ampicillin 99.9 ± 0.1
CTAB 0.5 ± 0.3
Daptomycin 94.7 ± 5.3
Nisin 4.6 ± 1.5
Rifampicin 94.7 ± 5.3
5% SDS 0 ± 0
TBBQ 66.1 ± 4.3
Tetracycline 90.9 ± 9.1
Valinomycin 27.4 ± 3.8
Vancomycin 100 ± 0
Table 4.1: Effect of TBBQ and comparator agents at 4x MIC on S. aureus SH1000
membranes. Results are the means of at least three independent determinations, SE -
standard error.
Experiments with the fluorescent dye DiSC3(5) are a more sensitive measure of membrane
perturbation. DiSC3(5) accumulates in polarised cells and is released following loss of
membrane potential (Wu & Hancock, 1999). TBBQ, like other membrane disrupting
agents, caused rapid dissipation of membrane potential in staphylococcal cells suspended
in HEPES and glucose buffer (Figure 4.3). Within 5 minutes ∼70% membrane potential
was lost, an effect comparable with that of the known membrane-damaging agent, nisin.
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Figure 4.3: Effect of TBBQ and comparator agents at 4x MIC on staphylococcal
membrane potential. Mean of at least three independent replicates; error bars show
standard errors.
In order to determine whether membrane perturbation following exposure to TBBQ
was extensive enough to allow leakage of intracellular ions, release of potassium and
magnesium was measured. TBBQ induced leakage of potassium from cells exposed
to compound at 4x MIC in HEPES and glucose buffer, but did not cause release of
magnesium (Figure 4.4). Therefore, the interaction of TBBQ with the membrane could
either specifically promote active potassium export, or enhance passive diffusion of K+
through potassium specific transporters. Since loss of membrane potential precedes
gradual efflux of potassium ions, it is likely that membrane depolarisation triggers K+
export in an attempt to recover membrane potential (Shapiro, 2000). Therefore, in contrast
with other membrane-damaging agents, such as daptomycin (Hobbs et al., 2008), TBBQ
may have relatively subtle effects on the membrane and not simply form pores allowing
non-specific diffusion of intracellular components.
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Figure 4.4: Release of intracellular ions following exposure of S. aureus SH1000
to TBBQ and comparator agents at 4x MIC. Panel (a): potassium leakage; Panel
(b): magnesium leakage (mean of at least three independent replicates; error bars show
standard errors).
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To establish whether TBBQ interacts with the phospholipid bilayer or other components
of the membrane, staphylococcal liposomes were exposed to compounds at 4x MIC
for 3 hours (Table 4.2). TBBQ did not cause leakage of dye contained within
liposomes, suggesting that the compound does not directly disrupt the staphylococcal
lipid bilayer. Since TBBQ does not cause bacterial lysis, generalised leakage of
intracellular components or destructure liposomes, the interaction with the membrane is
not surfactant-like. Instead, damage may be through disruption of components embedded
within the lipid bilayer, such as the proteins of the electron transport chain.
Compound Liposome integrity± SE
ndc 100 ± 0
CTAB 98.0 ± 0.0
Daptomycin 23.5 ± 1.2
Nisin 111.5 ± 4.3
TBBQ 92.0 ± 0.5
Tetracycline 87.9 ± 1.6
Vancomycin 100.6 ± 0.4
Table 4.2: Effect of TBBQ on staphylococcal liposomes. Experiments were carried out
by C. Randall, University of Leeds (mean of at least three independent replicates; SE -
standard errors).
Since antibacterial compounds that compromise the bacterial membrane may show
comparable effects on mammalian membranes, it is important to establish the bacterial
selectivity of agents with this MOA (Payne et al., 2007). Therefore, TBBQ was tested for
its ability to cause haemolysis of mammalian erythrocytes. Agents that do not damage
membranes caused <5% loss in erythrocyte integrity, whilst the known membrane
disruptors nisin, valinomycin and CTAB induced haemolysis (Table 4.3). TBBQ had
little effect on erythrocyte integrity (Table 4.3), which indicates that the interaction with
cell membranes is bacteria-specific.
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Antimicrobial compound % Erythrocyte Integrity (± SE)
ndc 100 ± 0
Ampicillin 97.7 ± 1.1
CTAB 0 ± 0
Daptomycin 97.9 ± 0.7
Nisin 54.9 ± 4.6
5 % SDS 0 ± 0
TBBQ 93.5 ± 2.0
Tetracycline 99.2 ± 0.4
Valinomycin 49.1 ± 3.4
Vancomycin 96.3 ± 3.7
Table 4.3: Effect of TBBQ and comparator agents at 4x MIC on erythrocytes. Results
are the means of at least three independent determinations, SE - standard error.
4.3.3 Effect of TBBQ on staphylococcal metabolism
Rapid bactericidal activity and cessation of macromolecular synthesis may be induced
by altered energy metabolism in addition to membrane disruption. Since TBBQ does
not appear to disrupt the phospholipid bilayer of staphylococci, the interaction with
the membrane may be through disruption of other components, such as membrane-
embedded proteins that comprise the electron transport chain. Measurement of ATP
leakage from cells is a standard gauge of membrane disruption (Hobbs et al., 2008; Ooi
et al., 2009). However, experimentation revealed that TBBQ did not cause leakage of
ATP, measured by decreases in intracellular and concurrent increases in extracellular ATP
levels. Instead, total ATP levels were depleted in cells exposed to TBBQ, indicating that
the compound induced hydrolysis of intracellular ATP stores (Figure 4.5). The ability of
TBBQ to diminish ATP levels was unusual, as this property was not observed with other
antibacterial agents.
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Figure 4.5: Cellular ATP levels following exposure to TBBQ and comparator agents
at 4x MIC. Values were calculated as a percentage of an untreated control. Mean of at
least three independent replicates; error bars show standard errors.
The effect of supplementation with the ATP synthase/ATPase inhibitor DCCD and
uncoupling agent CCCP on TBBQ activity was tested (Figure 4.6). This experiment
aimed to identify whether active ATP generation and/or ATP hydrolysis is required for
TBBQ to effect antibacterial activity. Neither of the agents reduced TBBQ activity,
suggesting that the primary MOA is not a consequence of disruption to ATP/ADP cycling.
Since the addition of respiratory inhibitors does not abolish TBBQ activity, it can be
assumed that an active electron transport chain coupled with an active ATP synthase is not
required for bactericidal activity. Thus, ATP depletion is likely to be a secondary effect of
TBBQ’s interaction with its target, and may be due to upregulation of ATPase activity
in an attempt to recover membrane potential (Figure 4.6). Since energy production
genes are involved in persister formation (Mah & O’Toole, 2001), ATP depletion may
contribute to TBBQ’s ability to sterilise cultures. Fewer persisters are formed from
populations of mutants with reduced energy production, suggesting that maintenance of
ATP pools is implicated in persister formation (Mah & O’Toole, 2001). Hydrolysis of
ATP following exposure to TBBQ may impede the generation of persisters and contribute
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to the compound’s ability to sterilise bacterial cultures.
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Figure 4.6: Effects of respiratory uncouplers on activity of TBBQ against S. aureus
SH1000. Cells were exposed to TBBQ in HEPES and glucose buffer at 4x MIC
supplemented with 0.25x MIC DCCD or CCCP (mean of at least three independent
replicates; error bars show standard deviations).
Although TBBQ does not inhibit phospholipid-bound ATP synthase/ATPase, it may
affect other components of metabolic pathways. Small colony variants (SCVs) are
slow-growing cells that arise spontaneously in staphylococcal populations (Singh et al.,
2009). SCVs have reduced membrane potential, restricted energy metabolism, and are
less susceptible to antibiotics (Von Eiff et al., 2006). To investigate whether TBBQ is
active against bacteria with a defective electron transport chain, time-kill experiments
were carried out in MHB with SH1000 hemB::ermB and SH1000 menD::ermC. SCVs
were resistant to the activity of the aminoglycoside gentamicin (Figure 4.7b), as has been
described previously (Von Eiff et al., 2006). TBBQ retained some activity against SH1000
hemB::ermB, but was not active against the menD knockout, which has a more restricted
energy metabolism (Figure 4.7c) (Von Eiff et al., 2006).
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Figure 4.7: Antibacterial activity of compounds at 4x MIC against small colony
variants. Panel (a): drug-free control; Panel (b): gentamicin; Panel (c): TBBQ. Mean of
at least three independent replicates; error bars show standard deviations.
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The limited activity of TBBQ against SCVs, may be due to their altered membrane
potential (∆ψ). SH1000 had a ∆ψ of -72.9 ± 2.0 mV, and exhibited a 4.5 log10
reduction in CFU/mL following exposure to TBBQ for 6 hours (Figure 4.7c). The ∆ψ
of SH1000 menD::ermC was ∼15% of that of SH1000 (-12.4 ± 4.7 mV), and TBBQ
induced little cell death in time-kill experiments with the strain (Figure 4.7c). SH1000
hemB::ermB had an intermediate effect on membrane potential (∆ψ = -26.3 ± 5.7) and
TBBQ antibacterial activity, displaying ∼1.5 log10 reduction in CFU/mL over 6 hours.
Since TBBQ retained activity against stationary phase and persister cells (Figure 3.9 and
Figure 3.10), reduced activity against SCVs cannot be attributed to inability to kill slow-
growing cells. Therefore, TBBQ activity may be dependent upon the ability to depolarise
the membrane and/or disrupt components of normal metabolic pathways that are bypassed
in SCVs.
Menadione is a precursor of menaquinone, an element of the staphylococcal electron
transport chain that is required for normal growth of staphylococci (Goldenbaum et al.,
1975; Von Eiff et al., 2006). Since TBBQ has reduced activity against the menadione-
deficient SH1000 menD::ermC, the compound may inhibit the normal function of this
precursor or a downstream product. In order to test this hypothesis, SH1000 menD::ermC
cultures were exposed to TBBQ supplemented with menadione at 1/4x MIC (4 µg/mL).
TBBQ has little activity against SH1000 menD::ermC at 4x MIC (see Figure 4.7c).
Therefore, to identify alterations in killing activity, TBBQ concentration was increased
to 8x MIC.
The addition of menadione to cultures of SH1000 menD::ermC caused resumption of
active growth, with cultures showing increases in viable cell numbers over 6 hours (Figure
4.8a). This suggests that menadione can penetrate cells and be used as a precursor for
menaquinone. Since active growth was resumed in SH1000 menD::ermC supplemented
with menadione, susceptibility to TBBQ was expected to be restored. However,
menadione abrogated the bactericidal activity of TBBQ against SH1000 menD::ermC
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(Figure 4.8a). This suggests that TBBQ does not target menadione or a downstream
product. As menadione could not suppress TBBQ activity against SH1000 (Figure 4.8b),
the supplement cannot simply degrade TBBQ leading to reduced activity against SH1000
menD::ermC. Therefore, exogenous menadione may interfere with binding of TBBQ to
a target that has altered expression in SH1000 menD::ermC due to its restricted energy
metabolism.
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Figure 4.8: Time-kill studies with staphylococci exposed to 8x MIC TBBQ in MHB
supplemented with menadione. Menadione (men) was added at 4 µg/mL (1/4x MIC).
Panel (a): menadione deficient SH1000 menD::ermC; Panel (b): SH1000 (mean of at
least three independent replicates; error bars show standard deviations).
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4.3.4 Effect of TBBQ on ROS generation
It has been suggested that antibiotics stimulate the formation of hydroxyl radicals, which
contribute to cell death through damage to bacterial macromolecules and membranes
(Kohanski et al., 2007). TBBQ is capable of participating in redox reactions and
is therefore likely to produce ROS (Okubo et al., 1997) Therefore, the effect of the
antioxidant on ROS protection defective mutants was investigated to examine whether
ROS generation could contribute to its MOA. In S. aureus, sodA codes for the major
Mn-SOD that dismutates endogenous superoxide, and sodM, is produced in response to
extracellular superoxide (Karavolos et al., 2003). Hydrogen peroxide induces expression
of catalase encoded by katA, and alkyl hydroperoxide reductase coded by ahpC, which
are responsible for degrading this ROS (Clements & Foster, 1999). The MICs of
TBBQ, antibiotics and membrane-damaging agents were determined against SH1000, the
superoxide dismutase double knockout (MHK11AM), and the catalase and peroxidase
knockout (KC043) (Table 4.4). A number of compounds appeared to inhibit growth of
MHK11AM and KC034 at lower concentrations than SH1000. Since this was not the
case for all compounds the strains are not simply unfit, and the differences in MICs may
be due to differences in ROS generation by different agents.
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S. aureus MIC (µg/mL)
Antibacterial agent SH1000 MHK11AM KC043
Ampicillin 0.5 0.125 0.25
Chloramphenicol 4 4 4
Ciprofloxacin 4 1 1
Clofazamine 4 0.5 0.5
Daptomycin 2 2 1
Fosfomycin 16 8 8
Fusidic acid 0.125 0.0625 0.0625
Gentamicin 0.125 0.125 0.125
Kanamycin 2 1 1
Linezolid 4 2 2
Norfloxacin 8 4 4
Rifampicin 0.016 0.016 0.016
Spectinomycin 64 32 32
Vancomycin 2 2 2
CCCP 2 1 2
Chlorhexidine 1 1 1
CTAB 2 2 2
Nisin 8 8 8
SDS 256 256 256
TBBQ 8 2 4
Triclosan 0.25 0.25 0.125
Valinomycin 2 1 1
Table 4.4: MIC determinations of TBBQ and comparator agents against S. aureus
SH1000 and ROS protection defective mutants. MHK11AM is superoxide dismutase
deficient and KC043 is catalase and peroxidase deficient. Values in green denote
hypersusceptibilty to compounds relative to SH1000.
Chapter 4. Investigations into the antibacterial mechanism of action of TBBQ 89
MHK11AM and KC043 were exposed to TBBQ and comparator antibiotics to identify
whether ROS generation is a significant contributing factor to cell death. Bacteria
were exposed to compounds at 4x MIC of SH1000 in order to identify differences in
susceptibility of the strains. TBBQ exhibited enhanced activity against the strain lacking
superoxide dismutase (MHK11AM) (Figure 4.9b), suggesting that the MOA of TBBQ
could involve generation of electron transport chain-derived superoxide. In MHK11AM
TBBQ is likely to induce production of superoxide and subsequent formation of hydroxyl
radicals that damage DNA, lipid and protein, leading to cell death Wang & Zhao (2009);
Kohanski et al. (2010). This is not necessarily the case in SH1000 which has a functioning
ROS defense mechanism; however, this experiment serves to confirm that TBBQ has the
ability to induce oxidative stress. Similarly, Schlievert et al. (2013) concluded that ROS
generation may contribute to the MOA of the antioxidant menadione, but that production
of ROS was not the sole mechanism by which bacteria were killed. It is perhaps not
surprising that antioxidants disrupt the bacterial metabolism since the compounds are
capable of redox cycling (Kim & Pratt, 1990).
In contrast with TBBQ, bacteria lacking the ability to eradicate superoxide and hydrogen
peroxide were less susceptible to ciprofloxacin (Figure 4.9c), an antibiotic that inhibits
DNA synthesis in actively growing cells (Ng et al., 1996). Since these strains are more
susceptible to ROS damage of DNA and are likely to be undergoing DNA repair (Gaupp
et al., 2012), the potency of ciprofloxacin may be reduced as DNA synthesis rates are
diminished. The difference in susceptibility of strains challenged with ampicillin was
minor, and by 24 hours there was no difference between the strains (Figure 4.9d). In
support of a number of studies (Ricci et al., 2012; Liu & Imlay, 2013; Keren et al., 2013)
that dispute the claims initially proposed by Kohanski et al. (2007), this study found
that strains unable to detoxify ROS were no more susceptible to bactericidal antibiotics.
Whilst ROS may have been generated upon exposure to antibiotics, their production
is most likely a secondary effect following antibiotic stress, and ROS are unlikely to
contribute to cell death in S. aureus.
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Figure 4.9: Time-kill experiments with S. aureus SH1000 and ROS protection
deficient mutants exposed to TBBQ and comparator agents at 4x MIC in MHB.
MHK11AM is superoxide dismutase deficient and KC043 is catalase and peroxidase
deficient. Panel (a): drug-free control; Panel (b): TBBQ; Panel (c): ciprofloxacin; Panel
(d): ampicillin (mean of at least three independent replicates; error bars show standard
deviations).
To investigate the contribution of ROS generation to the MOA of TBBQ further, time-
kill experiments were carried out with SH1000 exposed to TBBQ supplemented with
superoxide and hydroxyl radical scavengers. The scavengers tiron and thiourea displayed
MICs of >32.8 and 32.8 mg/mL, respectively. Therefore, cultures were exposed to
TBBQ at 4x MIC in MHB supplemented with sub-inhibitory concentrations of scavengers
(8 mg/mL) (Figure 4.10). Neither tiron nor thiourea significantly reduced the bactericidal
activity of TBBQ, suggesting that although TBBQ may enhance ROS production, innate
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protection mechanisms in S. aureus are sufficient to overcome oxidative stress.
0 1 2 3 4 5 6
0
1
2
3
4
5
6
7
8
9
10
TBBQ
ndc
Tiron
Thiourea
TBBQ + tiron
TBBQ + thiourea
Time (Hours)
lo
g
1
0
C
F
U
/m
L
Figure 4.10: Time-kill studies with S. aureus SH1000 exposed to TBBQ at 4x MIC
in MHB supplemented with ROS scavengers at 8 mg/mL. Mean of at least three
independent replicates; error bars show standard deviations.
4.3.5 Identification of TBBQ-resistant and hypersusceptible mutants
4.3.5.1 Isolation of a TBBQ-resistant strain
Bacteria exposed to topical antibacterial agents may be exposed to a steep concentration
gradient and experience a strong selection pressure to develop resistance to the compound
(Hermsen et al., 2012). As such, the ideal topical antibacterial would be both strongly
bactericidal and would not readily select resistance. The membrane-perturbing MOA of
TBBQ may be advantageous in this regard, as there is evidence to suggest that bacteria do
not readily acquire resistance to membrane-active agents (Ooi et al., 2009; Hurdle et al.,
2011). Attempts were made to isolate mutants resistant to TBBQ using standard mutation
frequency determination methodology (Ryder et al., 2012). However, no TBBQ-resistant
mutants were identified (mutation frequency <5.0 x 10−9), suggesting that TBBQ may
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not have a single target site and that resistance to TBBQ may not arise readily (O’Neill
& Chopra, 2004). Therefore attempts were made to select mutants using an extended
concentration range over prolonged periods. The extended spectrum MIC method was
employed with daptomycin as a positive control (Friedman et al., 2006). Following 40
passages the most resistant strain selected with daptomycin had an MIC of 32 µg/mL:
a 16-fold increase in daptomycin MIC. Following 40 passages the most resistant strain
selected with TBBQ had an MIC of 32 µg/mL: a 4-fold increase in TBBQ MIC (strain
B7). This level of resistance was identified following 20 passages, but no further increase
in resistance was observed. Reduced susceptibility to TBBQ was not lost over 4 drug-free
passages, suggesting that stable resistance can arise, but only low level resistance was
observed. TBBQ may disrupt the staphylococcal membrane in such a way that the effects
of the compound may only be overcome by gross alterations in the architecture of the
membrane, which is likely to perturb a number of essential cellular processes. Therefore,
only mutants with relatively minor modifications may be viable, explaining why only low
level TBBQ resistance develops.
Experiments were carried out to assess whether resistant mutants that arise under TBBQ
selection would be more or less likely to survive in a clinical setting. Resistant mutant
fitness was assessed by comparing the doubling time of the parental strain, SH1000
(doubling time of 31.3± 2.4 minutes) to that of B7 (doubling time of 64.1± 2.4). B7 was
growth attenuated, suggesting that TBBQ-resistant mutants may have reduced survival or
ability to cause disease.
4.3.5.2 Identification of a TBBQ hypersusceptible strain
A near-saturation SH1000 transposon library generated and maintained at the University
of Leeds was screened for TBBQ hypersusceptibility. The library comprises ∼20500
mutants containing the transposon InsTetG+2CM (Blake & O’Neill, 2012; Bertram et al.,
2005). The transposon carries a strong outward facing promoter, thus Tn mutants
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can display either overexpression or knock-down of gene expression depending upon
the location and orientation of transposon insertion. Mutants in which the transposon
is inserted with the promoter in the sense direction upstream of the gene display
overexpression. Downstream antisense insertion of the promoter leads to the formation
of antisense mRNA or collision of transcription forks, causing knock-down of gene
expression. Transcription of antisense mRNA that displays reverse complementarity is
hypothesised to form of antisense-gene mRNA duplexes that sterically hinder translation
or are targeted for degradation by the cell. This may reduce the quantity of mRNA
available for translation and concentration of target protein (O’Neill & Chopra, 2004).
Approximately 12500 mutants were screened and one strain, CAJ192 C9, displayed
hypersusceptibility to TBBQ, with an MIC of 2 µg/mL: a 4-fold reduction in MIC.
4.3.6 Characterisation of TBBQ mutants
Extensive ATP consumption was identified in SH1000 exposed to TBBQ (Figure 4.5). To
confirm that this effect is linked to susceptibility to TBBQ, the rate and extent of ATP
hydrolysis was compared for mutant strains following exposure to TBBQ. Both mutants
displayed a similar doubling time, suggesting that they have similar metabolic activity;
as such their ATP consumption would be expected to be similar. However, the TBBQ-
resistant strain consumed less ATP following exposure to TBBQ than the parental strain,
and the hypersusceptible strain displayed enhanced ATP hydrolysis (Figure 4.11). This
confirms that the interaction of TBBQ with staphylococci leads to ATP depletion.
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Figure 4.11: ATP hydrolysis following exposure to TBBQ at 4x MIC in HEPES and
glucose buffer. Values were calculated as a percentage of an untreated control. Mean of
at least three independent replicates; error bars show standard errors.
Cross-susceptibility/resistance studies were also carried out with the hypersusceptible
and resistant mutants challenged with a number of antibiotics and membrane-damaging
agents (Table 4.5). Decreased/increased MIC for all other antimicrobial agents against
CAJ192 C9/B7 would suggest that the strains have altered susceptibility to TBBQ due
a general decrease/increase in fitness. Alternatively, changes in susceptibility to specific
antibacterial agents could identify a shared drug target. Susceptibility of CAJ192 C9 was
not altered for any of the antibacterial agents tested. B7 displayed enhanced susceptibility
to ciprofloxacin (for discussion see Section 4.3.7), but did not show enhanced resistance
to any other agent, suggesting that TBBQ may target a novel component of the bacterial
membrane.
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MIC (µg/mL)
Compound SH1000 B7 192 C9
Ampicillin 0.5 0.5 0.5
Chlorhexidine 2 2 1
Ciprofloxacin 2 0.5 2
Clofazamine 4 4 2
CTAB 2 2 2
Daptomycin 1 1 1
Erythromycin 0.5 0.5 0.5
Gentamicin 0.5 0.5 0.25
H2O2 16 8 8
Nisin 2 2 2
TBBQ 8 32 2
Tetracycline 1 1 1
Valinomycin 2 2 2
Vancomycin 1 1 2
XF-73 1 1 1
XF-70 1 1 1
Table 4.5: MICs of established antibiotics against TBBQ mutants B7 and CAJ192
C9. Values in green and red denote hypersusceptibilty and resistance to compounds
relative to SH1000.
4.3.7 Genotypic characterisation of TBBQ mutants
To investigate the genetic basis of altered susceptibility to TBBQ in mutants, the site at
which the transposon inserted in the genome of CAJ192 C9 was determined, and whole
genome sequence determination (WGS) of B7 was carried out to identify mutations. The
location of transposon insertion was identified by direct sequence determination using
genomic DNA from CAJ192 C9 and the primer Tn out2. The DNA sequence generated
was checked for homology with the S. aureus 8325 genome using the BLAST algorithm
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available on the National Centre for Biotechnology Information website. Homology with
a particular region indicated the approximate insertion site of the transposon, and PCR
amplification and sequence determination of that region identified the precise location
and confirmed the orientation of transposon insertion. The transposon in CAJ192 C9 was
located in the intergenic region directly downstream of SAOUHSC 01723 (coding for a
homologue of a recD/traA type DNA helicase or exodeoxyribonuclease) in the antisense
orientation (Figure 4.12). This might cause knock-down of expression of genes contained
within the operon (containing SAOUHSC 01723 and SAOUHSC 01724). To confirm that
alterations in susceptibility to TBBQ are directly attributable to insertion of the transposon
at this location, the region was transduced into a clean host (SH1000) using phage
φ11. Transduction of the transposon insertion site resulted in co-transfer of the TBBQ-
hypersusceptible phenotype. Thus, this suggests that disruption of this operon specifically
induces hypersusceptibility to TBBQ. The role of the SAOUHSC 01723-containing
operon in TBBQ hypersusceptibilty was confirmed by complementation. The operon
of interest was amplified from SH1000 by PCR using primers 01723op XmaI Fwd and
01723op XbaI Rev (Appendix A) and introduced to CAJ192 C9, in trans, using the
xylose-inducible vector pEPSA5. In the presence of xylose, MIC determinations revealed
that complemented CAJ192 C9 displayed wild-type susceptibility to TBBQ (TBBQ MIC
of 8 µg/mL).
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Figure 4.12: Schematic of the insertion site of the transposon in CAJ192 C9.
Straight black arrows show the direction of gene expression and the curved arrow
shows the direction of expression from the outward-facing promoter of the transposon.
SAOUHSC 01722 is an alanyl-tRNA synthetase, SAOUHSC 01723 is a putative DNA
helicase/exonuclease, and ME represents mosaic ends of the transposon.
Both transduction and complementation suggest that knock-down of expression of the
DNA helicase/exonuclease encoded by SAOUHSC 01723 enhances TBBQ susceptibility.
It is hypothesised that CAJ192 C9 produces fewer molecules of DNA helicase and may
have reduced unwinding and repair of double-stranded DNA. This could enable TBBQ-
induced ROS damage to DNA to accumulate and cause oxidative stress, which could act
in concert with lethal membrane-damaging activity of TBBQ. In SH1000 ROS damage
may play only a minor role in the MOA due to a functional ROS defense mechanism and
DNA repair response.
WGS of B7 identified putative mutations in SAOUHSC 00341, SAOUHSC 01866,
SAOUHSC 02663 and SAOUHSC 02990. PCR amplification and sequence
determination of these genes confirmed that the resistant strain contained a single amino
acid substitution (W33X) in SAOUHSC 01866. This gene codes for a hypothetical
protein with homology to staphylococcal aminoglycoside phosphotransferases, and
choline/ethanolamine kinases. Sequence determination of SAOUHSC 01866 in TBBQ
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mutants recovered in parallel selections that showed modest increases in TBBQ MIC
(2-fold increase) did not share this mutation. To confirm that the single nucleotide
polymorphism confers TBBQ resistance, B7 was complemented with SAOUHSC 01866
from SH1000. This resulted in a 2-fold reduction in TBBQ MIC (16 µg/mL), and suggests
that the product of SAOUHSC 01866 does indeed contribute to TBBQ resistance.
The function of SAOUHSC 01866 is not yet known, but it shares homology with a
number of other genes, including a staphylococcal aminoglycoside phosphotransferase.
S. aureus are resistant to aminoglycosides through expression of O-phosphotransferases
and N-acetyltransferases, which modify the drug, resulting in poor binding to
the ribosome and reduced aminoglycoside activity (Mingeot-Leclercq et al., 1999).
However, aminoglycoside susceptibility is not altered in B7 (Table 4.5), therefore
SAOUHSC 01866 is unlikely to act as an aminoglycoside modifying enzyme.
SAOUHSC 01866 may instead function as a choline or ethanolamine kinase, with which
the gene has homology. Since mutation in SAOUHSC 01866 enhances resistance to
TBBQ, this suggests that a product of one of these enzymes may be targeted by TBBQ.
In S. aureus choline is an osmoprotectant that is oxidised to glycine betaine allowing
the bacterium to resist osmotic pressure (Graham & Wilkinson, 1992). Phosphorylation
of choline by functional SAOUHSC 01866 could reduce intracellular choline pools
rendering bacteria susceptible to stressful environmental conditions. Therefore, mutations
in choline kinase may ensure maintenance of intracellular choline levels, enabling B7
to survive in increased concentrations of TBBQ. This type of response is seen in
daptomycin-resistant strains which upregulate gylcine betaine production to overcome
antibiotic-induced stress (Song et al., 2013). However, many of the comparator agents are
expected to induce stress responses, and since there is no cross-resistance it is unlikely
that B7 is resistant to TBBQ due to enhanced ability to survive under stressful conditions.
Alternatively, resistance to TBBQ could be a consequence of altered membrane lipid
composition. Ethanolamine is a precursor for the phospholipid phosphatidylethanolamine
which is present in small quantities in the staphylococcal cytoplasmic membrane (Short
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& White, 1970, 1971). TBBQ may interact with this phospholipid in the membrane
of SH1000, but mutation of the ethanolamine altering enzyme of B7 could generate a
membrane devoid of phosphatidylethanolamine. Since B7 has only a 4-fold reduction in
TBBQ susceptibility, it is unlikely that phosphatidylethanolamine is the primary target
causing membrane disruption. However, the absence of a functional lipid may either
reduce TBBQ membrane binding efficacy, or cause alterations in membrane structure
rendering bacteria less susceptible to stresses generated by TBBQ. Indeed, alterations
in membrane structure have been identified in daptomycin-resistant strains, leading
to increased membrane fluidity, altered surface charge, and reduced susceptibility to
antibiotic induced membrane depolarisation (Jones et al., 2008b). Therefore, further
experimentation could be carried out to confirm this hypothesis, and is discussed in
Section 6.2.
Hypersusceptibilty of B7 to ciprofloxacin was identified in cross-resistance studies
(Table 4.5). Altered susceptibility could be due to enhanced access of ciprofloxacin
to the bacterial chromosome through alterations in phospholipid bilayer composition
and membrane structure/fluidity. However, hypersusceptibility may not be directly
attributable to the mutation in SAOUHSC 01866, but could be a consequence of
phenotypic alterations due to transcriptional modifications. Since the topoisomerase-
ciprofloxacin-DNA complex behaves as a poison creating lesions in DNA, resistance
to the antibiotic is conferred by reduced expression of DNA gyrase (Ince & Hooper,
2003). Therefore, the reverse may be true if DNA gyrase is overexpressed. In CAJ192
C9, reduced DNA helicase activity and DNA repair may render strains more susceptible
to TBBQ. Conversely, B7 could alter gene expression, inducing upregulation of DNA
synthesis and repair enzymes to counteract the effects of TBBQ. As a consequence, more
DNA gyrase may be available for inhibition by ciprofloxacin in B7, causing increased
susceptibility to the antibiotic.
The putative DNA-repair attenuated CAJ192 C9 displayed only a 4-fold reduction in
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TBBQ MIC. This indicates that the increase in susceptibility to TBBQ due to unrepaired
DNA damage is relatively minor, and damage to DNA is unlikely contribute significantly
to the antioxidant’s MOA. Bacteria may evade the effects of TBBQ through subtle
alterations in the structure of the cytoplasmic membrane, as has been suggested in
B7. This indicates that TBBQ is active through interactions with the staphylococcal
membrane. Thus, sequence determination of hypersusceptible and resistant strains
provides further support for the conclusions drawn from experiments with ROS protection
knockouts and membrane damaging assays regarding TBBQ MOA.
4.3.8 Synergistic interaction of TBBQ with antibiotics
It has been suggested that compounds which compromise the integrity of the bacterial
membrane could be used in combination with existing antibiotics, particularly when
treating infections cause by biofilms (Hurdle et al., 2011). Application of permeabilising
agents, such as colistin administered with imipenem against a P. aeruginosa sepsis model,
has had some success and the use of colistin combination therapy has been re-introduced
in the clinic (Cirioni et al., 2007; Bassetti et al., 2008). Since TBBQ reduces bacterial
membrane integrity, attempts were made to identify synergistic interactions with other
antibacterial agents. Synergism of TBBQ with antibiotics (ciprofloxacin, erythromycin,
gentamicin, oxacillin and tetracycline) was not observed with planktonic cultures (FIC
≥ 0.69). However, TBBQ acted synergistically in combination with gentamicin, an
antibiotic that cannot eradicate biofilms≤256 µg/mL, against biofilms of SH1000 grown
using the Calgary Biofilm Device (FIC ≤ 0.28) (Table 4.6). The combination of 1 µg/mL
gentamicin with 16 µg/mL TBBQ could eradicate staphylococcal biofilms. Therefore,
TBBQ could potentially be used with gentamicin to eradicate staphylococcal biofilms
without application of high concentrations of either compound. Combination therapy
may be employed most usefully against biofilms at the skin surface, such as those formed
in burn wounds and in the nares, which are currently treated with the use of topical agents
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like mupirocin (Coates et al., 2009).
Compounds Planktonic FIC index Biofilm eradication FIC index
TBBQ + ciprofloxacin 0.69 >0.5
TBBQ + erythromycin 0.75 >0.5
TBBQ + gentamicin 1.02 ≤0.28
TBBQ + oxacillin 1.00 >0.5
TBBQ + tetracycline 0.88 >0.5
Table 4.6: Synergism of TBBQ with established antibiotics against planktonic and
biofilm cultures of S. aureus SH1000. FIC index≤ 0.5 is a synergistic interaction, equal
to 1 is an additive interaction and ≥ 2 is an antagonistic interaction.
4.3.9 Effects of TBBQ on a human skin equivalent
For a compound to be developed as a topical antibiofilm agent, it should be able to be
applied to the skin without causing damage or irritation. Keratinocytes release primary
cytokines, such as IL-1α, in response to the presence of irritants. This induces an
inflammation response and the extent of IL-1α release is relative to the degree of skin
irritation (Bernhofer et al., 1999). To determine whether TBBQ has detrimental effects
on the skin at concentrations above those required to kill bacteria, a living skin equivalent
(LabSkinTM) was exposed to TBBQ for 24 hours. At 10x MIC TBBQ did not irritate
LabSkinTM , causing no detectable increase in IL-1α release. The topical agent mupirocin,
which is used clinically for nasal decolonisation, was also non-irritant (Liu et al., 2011).
Hematoxylin and eosin staining of tissue sections confirmed that 24 hour exposure to the
irritant SDS (5%) was severely damaging to skin, causing shedding of the top layers of
skin (stratum corneum and epidermis) and causing injury to the dermis below (Figure
4.13c). Conversely mupirocin and TBBQ (10x MIC) had no visible detrimental effects
on skin (Figure 4.13d and 4.13e). Therefore, TBBQ does not physically damage or irritate
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fully differentiated skin at higher concentrations than is required to sterilise bacterial
cultures. These suggest that TBBQ does not have toxic effects on skin cells and has
the potential to be used as a topical agent.
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Figure 4.13: Hematoxylin and eosin stained sections of LabSkinTM exposed to
compounds for 24 hours. Panel (a): drug-free control; Panel (b): ethanol (0.2% v/v);
Panel (c): 5% SDS; Panel (d): mupirocin 10x MIC; Panel (e): 10x MIC TBBQ. H&E
staining and imaging carried out by J Bradley, Evocutis.
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4.4 Conclusions
TBBQ exerts its antibacterial MOA by causing selective disruption of the staphylococcal
cytoplasmic membrane. Since the antioxidant did not disrupt staphylococcal liposomes,
dissipation of membrane potential and associated membrane disruption are unlikely to
be dependent upon binding to specific lipids in the bilayer. Downstream effects of
membrane perturbation include loss of intracellular potassium ions, extensive hydrolysis
of cellular ATP and probable generation of ROS that are detoxified by innate ROS
protection mechanisms. That TBBQ acts to compromise the integrity of the bacterial
membrane may explain why this compound has the ability to eradicate staphylococcal
biofilms; potent antibiofilm activity is a property that is often associated with membrane-
perturbing agents (Hurdle et al., 2011; O’Neill, 2011). S. aureus does not readily develop
resistance to TBBQ, and strains displaying reduced susceptibility suffer fitness costs as
measured by reduced growth rate. Since TBBQ potentiates the activity of gentamicin
against staphylococcal biofilms, combination therapy could be employed to reduce the
dose and thus toxic effects of gentamicin treatment. Furthermore, TBBQ appears to be
non-toxic to erythrocytes or a human living skin equivalent. Therefore, at concentrations
that could be used to eradicate biofilms on the skin surface, membrane effects are bacteria-
specific, and the inability of S. aureus to develop high level resistance would allow topical
treatment of infections for prolonged periods.
105
Chapter 5
Antioxidants that target the cell
membrane can eradicate staphylococcal
biofilms
5.1 Abstract
Biofilms are involved in ∼80% of bacterial infections in humans, and are refractory to
the action of most antibacterial agents in clinical use. In the search for novel antibiofilm
agents, a selection of antioxidants was assessed for biofilm-eradicating activity. The 15
antioxidants tested all displayed antibacterial activity against planktonic staphylococcal
cultures, and seven also eradicated staphylococcal biofilms. Biofilm-eradicating
antioxidants were all bactericidal and caused membrane perturbation. Eradication of
preformed biofilms following exposure to antioxidants involved dissociation of both cells
and matrix, which occurred before reductions in bacterial viability were detected. This
suggests that antioxidants degrade the matrix and induce release of biofilm cells; the
latter are then subject to the membrane damaging effects of the compounds. The two
most promising agents in respect of antibacterial potency and selective toxicity towards
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bacterial over mammalian membranes (celastrol and NDGA) did not damage LabSkinTM
following topical application. These compounds acted synergistically with gentamicin
against both planktonic and biofilm cultures. Whilst NDGA-resistant mutants could
not be recovered, a strain was isolated that displayed reduced susceptibility to celastrol.
The strain displayed increased mutability and had altered susceptibility to a number of
antibacterial agents. Continuous selection over several days was required to generate
the strain, which displays a celastrol MIC of 8 µg/mL; 4-fold lower than the minimum
biofilm eradication concentration. Therefore, both NDGA and celastrol could potentially
be useful in antibiofilm strategies.
5.2 Introduction
5.2.1 The clinical significance of biofilm infections
Biofilms are found in approximately 80% of bacterial infections in humans (Davies,
2003). S. aureus and S. epidermidis are biofilm-forming organisms implicated in
numerous nosocomial infections, with staphylococcal biofilms being prevalent in chronic
wounds and the most common cause of infections involving indwelling medical devices
(Hall-Stoodley et al., 2004; James et al., 2008; Otto, 2008). Chronic wounds include
pressure ulcers and ulcers on the feet of people with diabetes, which frequently necessitate
limb amputation following treatment failure (James et al., 2008). The presence of biofilms
in burn wounds and ulcers can contribute to persistent inflammation (Wolcott et al., 2010),
and the rate of wound healing is believed to be reduced at sites colonised with S. aureus
(James et al., 2008). Currently, the most effective wound care routine involves regular
debridement and treatment with systemic antibiotics, in addition to topically-applied
antibacterial agents (Wolcott et al., 2010). Therefore, to address the current difficulties
in treating chronic wounds, it is important to discover novel antistaphylococcal agents
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that possess antibiofilm activity in addition to activity against planktonic cells. Previous
research has indicated that phenylic antioxidants may display the ability to eradicate
biofilms, which is rare amongst antibacterial agents (Section 1.4).
5.2.2 Aims and Objectives
Work described in this chapter aims to characterise the antibacterial activity of a number
of phenylic antioxidants, with an emphasis on assessing their activity against biofilms,
and elucidating their antibacterial MOA/the mechanism by which they eradicate biofilms.
Synergistic interactions with existing antibiotics will be identified, and a living skin
equivalent will be exposed to agents that display selective toxicity and antibiofilm activity
in order to assess tolerability. Finally, resistant mutant generation and subsequent
sequence determination will be used to investigate the cellular target of promising
compounds.
5.3 Results and discussion
5.3.1 Antibacterial properties of phenylic antioxidants
Although it has been reported previously that all of the antioxidants examined in this
study display some antibacterial activity (Toama et al., 1974; Moujir et al., 1990; Eady
et al., 1994; Nicholas et al., 1999; Kubo et al., 2002; Zampini et al., 2005; Inatsu et al.,
2006; Moreno et al., 2006; Seville & Wilkinson, 2008; C¸olak et al., 2009; Chaudhuri
et al., 2010; Reddy et al., 2010; Chaieb et al., 2011; Miranda et al., 2011; Martins
et al., 2013), most of them have not been evaluated using standardised procedures
for susceptibility testing. Using CLSI methodology for susceptibility testing, the 15
antioxidants exhibited MICs ranging from 0.25-128 µg/mL against planktonic cultures of
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S. aureus and S. epidermidis (Table 5.1). Approximately half of these compounds (seven
of 15) also demonstrated complete eradication of established staphylococcal biofilms at
concentrations ≤256 µg/mL. By contrast, none of the established antibacterial agents
tested were able to eradicate SH1000 biofilms at ≤256 µg/mL (or, in the case of nisin, at
the maximum achievable concentration of 16 µg/ mL) (Table 3.2).
The ability of compounds to eradicate biofilms is suggestive of bactericidal activity. To
assess this, antioxidant-mediated killing of SH1000 in planktonic culture was examined
by viable counting. Since the antioxidants TBHQ and TBBQ were found to degrade
(Section 3.3.1), it was reasoned that other antioxidants may also degrade over 24 hours.
Therefore, bacterial viability was assessed 6 and 24 hours post antioxidant exposure to
identify compounds that may initially be bactericidal, but that subsequently allow grow-
back. Some antioxidants, such as idebenone, were bacteriostatic, whilst others, such as
NDGA, were bactericidal at 4x MIC (Figure 5.1a). At the MBEC, benzoyl peroxide,
carnosic acid, celastrol and NDGA essentially sterilised planktonic cultures (viable cells
≤0.8 log10 CFU/mL) (Figure 5.1b), whilst AO 2246, bakuchiol and totarol killed bacteria
initially, but allowed grow-back over a 24 hour period (Figure 5.1c). Therefore, none of
the agents with antibiofilm activity (compounds with an SH1000 MBEC of≤256 µg/mL)
displayed bacteriostatic properties.
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Antioxidant MIC (µg/mL) bMIC (µg/mL) MBEC (µg/mL)
SH1000 UAMS-1 RP62A SH1000 UAMS-1 RP62A SH1000 UAMS-1 RP62A
AO 2246 4 4 4 16 4 4 16 16 128
Bakuchiol 4 4 4 8 4 4 16 8 8
Benzoyl peroxide 64 32 32 256 32 64 256 32 64
Carnosic acid 32 32 8 64 32 32 128 64 64
Celastrol 1 0.5 0.25 1 0.25 0.25 32 4 4
Dihydroxychalcone 128 128 128 64 64 64 >256 >256 >256
8-hydroxyquinoline 4 2 1 4 1 1 >256 32 >256
Idebenone 64 64 32 64 16 >256 >256 256 >256
Lauryl gallate 64 64 16 32 8 16 >256 256 >256
Menadione 16 8 8 32 8 32 >256 128 256
Nordihydroguaiaretic acid 64 64 64 64 16 32 128 16 256
Thymohydroquinone 16 8 16 32 4 64 >256 16 64
Thymoquinone 16 8 8 32 2 8 >256 4 32
Totarol 4 2 2 4 2 4 16 8 16
Vitamin K5 hydrochloride 32 16 16 32 8 16 >256 64 128
Table 5.1: MICs, biofilm MICs (bMICs) and minimum biofilm eradication concentrations (MBECs) of antioxidants
against staphylococci.
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Figure 5.1: Bactericidal activity of antioxidants against S. aureus SH1000. Panel
(a): bacterial viability following exposure to antioxidants at 4x MIC for 6 or 24 hours;
Panel (b): bacterial viability following exposure to biofilm-eradicating antioxidants at the
MBEC for 6 or 24 hours; Panel (c): killing kinetics of biofilm-eradicating antioxidants
that display grow-back at the MBEC. Mean of at least three independent replicates; error
bars show standard deviations.
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5.3.2 Antibacterial MOA of antioxidants
This study identified membrane damage and disruption of the electron transport chain
following exposure of bacteria to the phenylic antioxidant TBBQ. Similarly, a number
of the antioxidants under investigation here have previously been reported to disrupt
membranes or inhibit the respiratory chain (Reddy et al., 2010; Valacchi et al.,
2001; Zhou et al., 2011; Sabzevari et al., 2004; Kubo et al., 2002; Dumont et al.,
1999; Bhuvaneswaran & Dakshinamurti, 1972; Foss et al., 2013). Therefore, it was
hypothesised that all phenylic antioxidants may have detrimental effects on the bacterial
membrane, and that this effect may contribute to the MOA of the compounds.
At 4x MIC, 10 of 15 antioxidants compromised the integrity of the SH1000 membrane
within 10 minutes, as measured by the BacLightTM assay (Table 5.2). Since this assay
does not reliably detect subtle membrane disruption (e.g. loss of membrane potential),
or perturbation occurring over longer than a 10 minute window, additional assays
were carried out to assess whether the other five antioxidants also mediate membrane
perturbation. All five compounds caused loss of membrane potential within 3 hours at
4x MIC, and some compounds caused reductions in intracellular potassium levels over
this duration and at this concentration (Figure 5.2b and 5.2a). Therefore, the remaining
antioxidants exerted more subtle effects on the membrane, in most instances prompting
depolarisation without leakage of intracellular components.
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Antimicrobial compound % Membrane Integrity (± SE)
No drug 100 ± 0
Vancomycin 100 ± 0
Thymohydroquinone 100 ± 0
Thymoquinone 100 ± 0
Celastrol 100 ± 0
Daptomycin 94.7 ± 5.3
Tetracycline 90.9 ± 9.1
8-Hydroxyquinoline 86.3 ± 3.0
Menadione 80.0 ± 10.7
Idebenone 59.0 ± 4.7
Vitamin K5 hydrochloride 23.0 ± 7.0
Dihdroxychalcone 16.7 ± 5.7
AO 2246 10.8 ± 5.2
Totarol 8.8 ± 1.4
Bakuchiol 7.3 ± 1.1
NDGA 5.2 ± 0.7
Lauryl gallate 4.7 ± 3.7
Nisin 4.6 ± 1.5
Carnosic acid 3.6 ± 1.1
Benzoyl peroxide 2.7 ± 1.4
CTAB 0.5 ± 0.3
5% SDS 0 ± 0
Table 5.2: The BacLightTM assay to determine effects of compounds at 4x MIC on S.
aureus SH1000 membrane integrity. Mean of at least three independent replicates, SE
- standard error.
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Figure 5.2: Effect of antibacterial agents on S. aureus potassium leakage and
membrane potential (4x MIC for 3 hours). Panel (a): release of intracellular potassium
ions; Panel (b): bacterial membrane potential measured by leakage of DiSC(3)5. Filled
bars show comparator agents (mean of at least three independent replicates; error bars
show standard errors).
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To establish whether the antioxidants displayed specificity for the bacterial membrane,
erythrocytes were challenged with all compounds at 4x MIC, and haemoglobin leakage
monitored. Of the 15 antioxidants tested, only six (celastrol, 8-hydroxyquinoline,
menadione, NDGA, thymohydroquinone, and thymoquinone) did not induce haemolysis
(Figure 5.3), suggesting that antioxidant-membrane interactions were bacteria specific.
Of the antioxidants capable of eradicating staphylococcal biofilms, only celastrol and
NDGA were non-haemolytic. Subsequent studies focused on these two antioxidants,
since selectivity for bacterial membranes and the ability to eradicate staphylococcal
biofilms suggested the greatest potential for clinical utility.
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Figure 5.3: Effect of antioxidants and comparator agents at 4x MIC on mammalian
membrane integrity as measured by leakage of haemoglobin from erythrocytes.
Filled bars show comparator agents (mean of at least three independent replicates; error
bars show standard errors).
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5.3.3 Investigating the mechanistic basis for antibiofilm activity of
phenylic antioxidants
Considering that all antioxidants appear to share a similar mechanism of action against
planktonic cells, this study sought to determine why some antioxidants have antibiofilm
activity whilst others do not. Therefore, a representative antioxidant was studied from
each group: 8-hydroxyquinoline, a non-haemolytic antioxidant devoid of antibiofilm
activity, and celastrol, a non-haemolytic antioxidant with the ability to eradicate biofilms.
Initially, experiments were carried out to identify whether lack of activity was due to
a failure of compounds to traverse mature biofilm, as reduced compound penetration
has been implicated in the inability of some antibiotics to eradicate biofilms (Del Pozo
& Patel, 2007). Both antioxidants and the control agent vancomycin proved able to
traverse the biofilm. 8-hydroxyquinoline showed more extensive biofilm penetration
(104.6 ± 2.3%) than vancomycin (56.4 ± 3.8%) or celastrol (44.0 ± 3.8%). Therefore,
failure of compounds to penetrate the biofilm is unlikely to cause the lack of activity of
8-hydroxyquinoline against biofilms.
Instead, differences in antibiofilm activity may be a result of different effects on slow-
growing cells. Biofilms contain bacteria in a variety of metabolic states, including
slow-growing, non-growing and persister cells (Davies, 2003; Kubo et al., 2003).
Biofilm-eradicating antioxidants could exert their antibiofilm effect by retaining activity
against metabolically inactive cells. To examine this, exponential phase and slow-growing
cells were challenged with the biofilm eradicator celastrol at the MBEC (32x MIC). Since
the comparator agent, 8-hydroxyquinoline, had no measurable MBEC, the compound
was used at an equivalent concentration (32x MIC) (Figure 5.4b and 5.4c). Celastrol
did not display enhanced activity against stationary phase or biofilm resuspended cells in
comparison with 8-hydroxyquinoline over a 6 hour period.
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Figure 5.4: Susceptibility of exponential phase, stationary phase or biofilm-
resuspended S. aureus SH1000 cells to celastrol or 8-hydroxyquinoline. Panel (a):
cell viability of untreated cells; Panel (b): viability of cells exposed to celastrol at the
MBEC; Panel (c): viability of cells exposed to 8-hydroxyquinoline at 32x MIC. Mean of
at least three independent replicates; error bars show standard deviations.
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Over extended time-periods (24 hours), antioxidants capable of biofilm eradication
(celastrol and NDGA) were no more active against stationary phase or persister cells than
compounds that are not active against biofilms (Figure 5.5a and Figure 5.5b). Therefore,
biofilm eradication by these antioxidants cannot be attributed to activity against the
slow- or non-growing cells that have previously been implicated in biofilm resistance
to antibiotics (Davies, 2003; Shapiro et al., 2011).
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Figure 5.5: Viability of S. aureus SH1000 slow-growing and persister cells following
exposure to compounds for 24 hours. Panel (a): exponential and stationary phase
cell viability following exposure to biofilm-active agents at the MBEC, or biofilm-
inactive agents at 256 µg/mL. T0 is the culture density before the addition of compounds;
Panel (b): cell viability of ciprofloxacin and ampicillin persisters following exposure to
compounds at 10x MIC. Mean of at least three independent replicates; error bars show
standard deviations.
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Based on the observation that TBBQ triggered extensive hydrolysis of ATP stores, total
bacterial ATP levels were measured following exposure to antioxidants; firstly to test the
hypothesis that ATP depletion is associated with sterilisation of metabolically inactive
cells (Section 4.3.3), and secondly to attempt to distinguish antioxidants with and without
antibiofilm activity. Intracellular and extracellular ATP levels were measured following
exposure of bacterial populations to celastrol and 8-hydroxyquinolone at 4x MIC in
HEPES and glucose buffer (Figure 5.6). Neither compound caused hydrolysis of ATP
pools, suggesting that ATP depletion is not a prerequisite for antioxidant-induced biofilm
eradication. Furthermore, quantification of ATP levels revealed that the MOA of celastrol
and TBBQ are at least partially distinct, despite sharing bacterial membrane-perturbing
activity.
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Figure 5.6: Effects of antioxidants at 4x MIC on total ATP levels in S. aureus. Values
were calculated as a percentage of an untreated control. Mean of at least three independent
replicates; error bars show standard errors.
Since celastrol and NDGA did not have enhanced activity against heterogeneous
populations of cells found within biofilms, they may act by causing physical perturbation
of the biofilm. Alterations in biofilm structural components were quantified in an attempt
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to distinguish biofilm eradicators from non-eradicators. Following 24 hour incubation
with compounds at 256 µg/mL, biofilm eradicators significantly reduced the amount
of adherent material (matrix and cells) in comparison with non-eradicating antioxidants
(Figure 5.7a and 5.7b).
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Figure 5.7: Quantification of matrix material and adherent cells following exposure
of biofilms to compounds at 256 µg/mL for 24 hours. Panel (a): attached matrix; Panel
(b): attached cells. The data labeled T0 shows the quantity of matrix and cells before the
addition of compounds. Data are the means of at least three independent replicates, with
error bars showing standard deviation.
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To investigate whether biofilm dispersion occurs prior to loss of bacterial viability, or is
in fact a consequence of cell death, viable cells and adherent material were quantified
following exposure to NDGA and celastrol for 1 hour. The antioxidants had little
or no effect on total (released and attached cell) viability over this period (Figure
5.8a), while adherent material was significantly reduced within 1 hour (Figure 5.8b and
5.8c). Therefore, short duration experiments revealed that destructuring of the biofilm
occurs before initiation of cell killing, implying that biofilm detachment is not simply a
consequence of cell death. Thus, eradication of staphylococcal biofilms by celastrol and
NDGA involves biofilm disruption, causing release of planktonic cells that are susceptible
to the membrane damaging effects of the compounds.
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Figure 5.8: Cell viability and quantification of adherent material following exposure
of biofilms to compounds at 256 µg/mL for 1 hour. Panel (a): total biofilm cell viability;
Panel (b): attached matrix; Panel (c): attached cells. Data are the means of at least three
independent replicates, with error bars showing standard deviation.
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5.3.4 Synergistic interactions of antioxidants with antibiotics
Previous studies with a subset of the compounds under investigation here identified
antioxidant-mediated potentiation of antibacterial activity. Carnosic acid enhanced
aminoglycoside activity against vancomycin-resistant enterococci (Horiuchi et al., 2007),
dihydroxychalcone acted synergistically with doxycycline, gentamicin and ciprofloxacin
against S. aureus (Tran et al., 2012), and totarol increased carbapenem and β-lactam
activity against S. aureus (Nicholas et al., 1999). To identify potentially useful
synergistic interactions, planktonic cells were exposed to non-haemolytic antioxidants
in combination with licensed antibiotics (Table 5.3). Celastrol and NDGA acted
synergistically with gentamicin (inhibition of bacterial growth at 0.25 and 16 µg/mL
of celastrol and NDGA in combination with 0.03125 or 0.125 µg/mL gentamicin,
respectively), whilst all other combinations had additive effects. Therefore, like some
other antioxidants and membrane-damaging agents, celastrol and NDGA could be used
usefully in combination with existing antibiotics (Horiuchi et al., 2007; Tran et al., 2012;
Nicholas et al., 1999; Hu & Coates, 2013).
Tetracycline Ciprofloxacin Erythromycin Gentamicin Oxacillin
Celastrol 1.00 0.77 0.88 0.33 0.64
NDGA 0.75 0.63 0.75 0.42 0.59
Thymoquinone 0.59 0.75 1.06 0.79 0.75
Thymohydroquinone 0.75 0.88 0.69 1.04 0.88
Menadione 0.69 0.53 0.75 1.01 0.69
8-hydroxyquinoline 0.75 0.75 0.75 0.83 0.77
Table 5.3: Synergism of antioxidants with established antibiotics against planktonic
cultures of S. aureus SH1000. FIC index ≤0.5 is a synergistic interaction, equal to 1 is
an additive interaction and ≥2 is an antagonistic interaction.
Chapter 5. Antioxidants target the cell membrane and eradicate biofilms 125
S. aureus biofilms grown using the CBD were also exposed to combinations of biofilm-
eradicating antioxidants and antibiotics, and assessed for synergistic interactions. As
was identified in experiments with planktonic cultures, celastrol and NDGA only acted
synergistically with gentamicin (Table 5.4). Staphylococcal biofilms were eradicated by
the combination of 1 µg/mL gentamicin with 8 µg/mL celastrol or 0.5 µg/mL gentamicin
and 16 µg/mL NDGA. Therefore, addition of low concentrations of gentamicin to culture
media significantly reduced celastrol and NDGA MBECs (a 4- and 8-fold reduction in
MBEC from 32 and 128 µg/mL respectively).
Tetracycline Ciprofloxacin Erythromycin Gentamicin Oxacillin
Celastrol >0.5 >0.5 >0.5 ≤0.25 >0.5
NDGA >1 >0.5 >1 ≤0.15 >0.5
Table 5.4: Synergism of antioxidants with established antibiotics against S. aureus
SH1000 biofilms. FIC index ≤0.5 is a synergistic interaction, equal to 1 is an additive
interaction and ≥2 is an antagonistic interaction.
5.3.5 Effects of celastrol and NDGA on human LabSkinTM
For a compound to be developed as a topical antibiofilm agent, it should be able to be
applied to the skin without causing damage or irritation. NDGA and celastrol had no
visible adverse effects on human or mouse skin when investigated as high-concentration
topical preparations at 3% (for the treatment of psoriasis) and 5% (for reduction of
inflammation) respectively (Newton et al., 1988; Kim et al., 2009). Furthermore,
cytotoxicity was not identified in rat basophil leukemia cells treated with ≤10 µM
celastrol (∼4.5 µg/mL) (Kim et al., 2009). Exposure to ≤100 µM NDGA (∼30 µg/mL)
was not toxic to bovine fibroblasts, though 1 mM NDGA (∼300 µg/mL) induced
cytotoxicity (Koob et al., 2001). Therefore some toxicity testing has been carried out
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with celastrol and NDGA, but irritation and physical damage to human skin structure has
not been assessed at concentrations that are relevant to their use as antibiofilm agents.
Although antioxidants were not haemolytic (Figure 5.3), further studies were carried out
to determine whether celastrol and NGDA exhibit sufficient selective toxicity to allow
their topical use on human skin. Following a 24 hour exposure of a skin equivalence
system (LabSkinTM) to 10x MIC mupirocin and celastrol, no irritation of skin was
detected by IL-1α release. The limited solubility of NDGA meant that, in order to keep
the solvent load below the level (0.5%) causing damage to LabSkinTM, experiments were
carried out with compound at a concentration equivalent to 4x MIC (S. aureus SH1000).
IL-1α release was below the lowest detectable level for mupirocin, celastrol and NDGA
(0 ± 0% IL-1α release relative to 5% SDS). Hematoxylin and eosin staining of tissue
sections confirmed that 24 hour exposure to the irritant SDS (5%) was severely damaging
to skin, causing shedding of the top layers (stratum corneum and epidermis) and causing
injury to the dermis below (Figure 5.9c). Conversely mupirocin, celastrol and NDGA had
no visible detrimental effects on skin (Figure 5.9d, 5.9e and 5.9f). Therefore, celastrol
and NDGA did not cause irritation, as measured by IL-1α release, nor did they damage
fully differentiated skin at concentrations above those that are able to sterilise bacterial
cultures.
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Figure 5.9: Hematoxylin and eosin stained sections of LabSkinTM exposed to
compounds for 24 hours. Panel (a): untreated control; Panel (b): ethanol (0.2% v/v);
Panel (c) SDS (5% w/v); Panel (d): mupirocin 10x MIC; Panel (e) celastrol 10x MIC;
Panel (f): NDGA 4x MIC. H&E staining and imaging carried out by J Bradley, Evocutis.
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5.3.6 Selection of antioxidant resistant strains
A desirable feature of any potential antibacterial drug is a low propensity to select
resistance. The resistance potential of NDGA and celastrol was evaluated initially by
plating saturated cultures of SH1000 onto agar containing these compounds at 4x MIC.
In neither case were resistant mutants identified (mutation frequency <5.0 x 10−9). This
suggests that the antioxidants have low resistance potentials, and that multiple mutations
may be required to develop resistance to the agents (O’Neill & Chopra, 2004). Therefore,
the extended spectrum MIC method was used to determine whether resistance to these
antioxidants would arise in any of the eight separate lineages that were under continuous
selection over several days (Friedman et al., 2006). Resistance (defined here as a
4-fold increase in MIC) to the control antibiotic daptomycin was identified in all eight
test lineages. The most resistant strain displayed a 16-fold increase in MIC following
40 passages (Figure 5.10). Celastrol resistance was detected in all lineages, and the most
resistant strain, C3, had an MIC of 8 µg/mL (Figure 5.10). It is of note that strains
displaying reduced susceptibility to celastrol had an MIC that was at least 4-fold lower
than the concentration that eradicates staphylococcal biofilms. Resistance to NDGA
could not be selected, and strains exposed to the compound over 40 passages retained
the same MIC throughout the experiment (64 µg/mL). Therefore, NDGA resistance may
not arise readily if the compound were to be used in the clinic. Celastrol resistant strains
are more likely to arise, but reduced susceptibility to celastrol may only be selected by
continuous exposure of bacteria to the compound over extended periods. Furthermore,
this experiment suggests that resistance is unlikely to reach a level that would impact on
antibiofilm therapy.
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Figure 5.10: Selection of daptomycin and celastrol resistant mutants. Experiments
were carried out using eight lineages, and results are representative of replicates.
To investigate how alterations in the celastrol resistant strain (C3) affect susceptibility
to a range of compounds, cross-resistance/susceptibility studies were carried out
with antibiotics, membrane-damaging agents and antioxidants. The MICs of several
antioxidants and ciprofloxacin were reduced 4-fold in comparison with the parental strain
(Table 5.5). This suggests that a number of antioxidants may interact with similar
pathways or components of staphylococci that have been altered in C3 as a response
to celastrol exposure. Alternatively, changes in susceptibility could be due to alterations
in a generalised resistance mechanism, such as an efflux pump (this will be addressed in
the following section).
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MIC (µg/mL)
Compound SH1000 C3
Ampicillin 0.5 0.5
AO2246 4 4
Bakuchiol 4 4
Benzoyl peroxide 64 32
Carnosic acid 32 32
Celastrol 1 8
Dihydroxychalcone 128 128
Chlorhexidine 2 1
Ciprofloxacin 2 0.5
CTAB 2 1
Daptomycin 1 1
Erythromycin 0.5 0.5
Gentamicin 0.5 0.5
8-hydroxyquinoline 4 4
Idebenone 64 64
Lauryl gallate 64 64
Menadione 16 8
NGDA 64 64
Nisin 2 4
TBBQ 8 8
Tetracycline 1 0.5
Thymohydroquinone 16 4
Thymoquinone 16 4
Totarol 4 2
Vancomycin 1 1
Vitamin K5 hydrochloride 32 8
Table 5.5: Susceptibility of the celastrol resistant strain, C3, to antibacterial agents.
Values in green and red denote hypersusceptibilty and resistance to compounds relative
to SH1000.
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5.3.7 Characterisation of the celastrol resistant strain
WGS of strain C3 was used to provide further information about the target of celastrol.
A number of genes and intergenic regions were identified in which there were potential
DNA sequence changes (Table 5.6). It should be noted that the role of each individual
mutation in celastrol resistance has not yet been confirmed, and further work will be
required to do so (see Section 6.2). Broadly the mutations can be grouped into those
that potentially affect the cell envelope, those that may impact on DNA repair, and those
without a definable effect or function. The majority of mutations appear to be located
in genes related to cell envelope function, which may have been anticipated due to the
membrane damaging MOA of celastrol (Section 5.3.2). However, due to time restrictions
it was not possible to investigate the effect of each individual mutation.
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Locus Function
Affected cellular Nucleotide Amino acid
component alteration alteration
SAOUHSC 02866
Hypothetical MmpL
Cell envelope A1889G V630A
efflux pump
SAOUHSC 02866
Hypothetical MmpL
Cell envelope A1679G M560T
efflux pump
SAOUHSC 02866
Hypothetical MmpL
Cell envelope T106C N36D
efflux pump
SAOUHSC 02556
Hypothetical acyl-CoA
Cell membrane Deleted A865 Frame shift; X289dehydrogenase
SAOUHSC 02555∗
Hypothetical acyl-CoA
Cell membrane Deleted T -
dehydrogenase
SAOUHSC 02555∗
Hypothetical acyl-CoA
Cell membrane Deleted T -
dehydrogenase
SAOUHSC 02555∗
Hypothetical acyl-CoA
Cell membrane Deleted C -
dehydrogenase
SAOUHSC 02555∗
Hypothetical acyl-CoA
Cell membrane Deleted A -
dehydrogenase
SAOUHSC 02555∗
Hypothetical acyl-CoA
Cell membrane Deleted A -
dehydrogenase
SAOUHSC 01002 Quinol oxidase AA3 subunit II Cell membrane C349T D117N
Table 5.6: Alterations in the genome of the celastrol resistant strain, C3, identified through WGS. ∗Mutations in intergenic
regions are located upstream of the listed gene.
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Locus Function
Affected cellular Nucleotide Amino acid
component alteration alteration
SAOUHSC 00020
Two-component response
Cell wall A301G T101A
regulator, WalR
SAOUHSC 01287 Glutamine synthetase Cell wall T905C V302A
SAOUHSC 01664 Hypothetical
phosphotransferase
Cell wall T367C K123E
SAOUHSC 01787
Hypothetical lysine-specific
Cell wall G716A P239Lpermease, LysP
SAOUHSC 02798
Hypothetical cell wall
Cell wall Deleted T548 Frame shift;Q183
surface anchor protein
SAOUHSC 01272
DNA mismatch repair
DNA G2005T E669Xprotein, MutS
SAOUHSC 01469 Endonuclease III DNA C383T S128N
SAOUHSC 01403
Cold shock protein
Unknown T74C D25G(transcriptional regulator)
SAOUHSC 01977∗
Hypothetical transcriptional
Unknown A>G -
regulator
SAOUHSC 03022
Hypothetical lipid binding
Unknown C359T P120Lprotein of unknown function
SAOUHSC 01158∗
Hypothetical cell-division
Unknown G>A -
initiation protein
Table 5.6 (continued): Alterations in the genome of the celastrol resistant strain, C3, identified through WGS.
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It was of note that there were significantly more mutations identified in WGS of C3 than in
the TBBQ-resistant strain, for which only four putative mutations were identified (Section
4.3.7). Hypermutators are found in bacterial populations and arise as a consequence of
alterations in the methyl-directed mismatch repair (MMR) system. This DNA repair
pathway identifies and repairs mismatches in newly-synthesised DNA duplexes. In
S. aureus mutations in mutS are associated with accelerated rate of antibiotic resistance
development (O’Neill & Chopra, 2002). Since one of the mutations in C3 was located in
mutS, the mutability of the strain was assessed. Mutation frequencies confirmed that C3
is more mutable than the parental strain SH1000, displaying a 7-fold higher frequency of
mutation to rifampicin (SH1000 mutation frequency of 1.92x10−7 ± ≤ 6.33x10−8, C3
mutation frequency of 1.32x10−6 ±≤ 3.57x10−7). Therefore, the alteration in mutS may
drive the development of further mutations within C3.
5.4 Conclusions
Since there is an urgent need to develop novel antibiofilm agents, it is of some significance
that a number of biofilm-eradicating antioxidants have been identified. Celastrol and
NDGA are the most promising of the antioxidants tested, as they display potent and
specific activity against staphylococci. These antioxidants eradicate biofilms through
disruption of the biofilm structure, causing release of planktonic cells. Subsequent
killing involves perturbation of the bacterial membrane, though the precise nature of this
interaction varies by compound. Celastrol resistance was identified following continuous
selection over several days, whilst NDGA-resistant strains could not be isolated.
Resistant bacteria may evade the effects of celastrol by modifying the architecture of
the cytoplasmic membrane, which is the putative target of celastrol. Both NDGA
and celastrol were applied to skin without measurable detrimental effects. Therefore,
these compounds are attractive candidates for development as topical antistaphylococcal
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biofilm treatments. Since both antioxidants act synergistically with gentamicin, they
could potentially be applied in combination to treat patients with severe skin lesions or
burn wounds.
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General conclusions and future work
6.1 General Conclusions
The antioxidants under investigation here were of interest since they are compounds that
are already used in the cosmetics industry, as food preservatives or in traditional medicines
and have known antibacterial activity (Merrifield & Yang, 1965; Fung et al., 1985; Chaieb
et al., 2011; Martins et al., 2013; Chen et al., 2011; Katsura et al., 2001). Therefore, it
was hoped that this collection of compounds would display useful antibacterial activity
without associated eukaryotic toxicity.
Initial studies focused on the antibacterial activity of the food additive TBHQ. Early
experimentation revealed that TBHQ had little innate antibacterial activity, and that
antimicrobial properties that had been ascribed to the compound were through conversion
to TBBQ under bacterial culture conditions. TBBQ was primarily active against
Gram-positive organisms and eradicated staphylococcal biofilms. This unusual property
was a consequence of TBBQ’s ability to eradicate slow- and non-growing cells. These
sub-populations of cells are recalcitrant to the effects of other antibacterial agents, and
can repopulate the biofilm following removal of antibacterial challenge. Up to 80% of
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bacterial infections are believed to include a biofilm component (National Institute of
Health, 2002), which contributes to recurrent infections and treatment failure. Therefore,
agents with antibiofilm activity are highly sought after.
The MOA of TBBQ was investigated initially by assessing its effects on biosynthetic
pathways using radiolabeled precursors and biosensors that luminesce in response to
particular stresses. TBBQ did not preferentially inhibit any single macromolecular
synthetic pathway or elicit stress responses in the biosensors, which is suggestive of
a compound with membrane-damaging activity (O’Neill & Chopra, 2004). Indeed,
TBBQ was found to have lethal interactions with the cytoplasmic membrane, causing
depolarisation of cells and loss of intracellular components. A low-level TBBQ-resistant
strain was generated under selection, and may have reduced susceptibility due to altered
membrane phospholipid composition. However, staphylococcal liposomes were not
disrupted by TBBQ, suggesting that the antioxidant is unlikely to bind to and disrupt
specific lipids in the membrane. Permeabilisation of the Gram-negative outer membrane
rendered E. coli susceptible to TBBQ, indicating that the cytoplasmic membrane of
Gram-negative bacteria was also susceptible to the antioxidant’s action. Since TBBQ
did not induce haemolysis at concentrations of antioxidant that damaged bacterial
membranes, this suggests that membrane effects were bacteria-specific.
A number of other phenylic antioxidants were screened for antibacterial and antibiofilm
activity. Celastrol and NDGA were identified as potentially useful agents, as they
eradicated surface-attached communities and displayed specific activity against bacteria.
These antioxidants could be distinguished from TBBQ by the mechanism through which
they eradicated biofilms. NDGA and celastrol induced dispersal of the biofilm matrix and
cells in contrast with TBBQ, which killed metabolically active and inactive cells without
significantly destructuring the biofilm. Like TBBQ, celastrol and NDGA disrupted the
cytoplasmic membrane, causing death of planktonic cells, though the exact nature of this
interaction varied for the different antioxidants.
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All three antioxidants acted synergistically with gentamicin against staphylococcal
biofilms. Eradication was achieved with a combination of 0.5-1 µg/mL gentamicin
and 16 µg/mL TBBQ, 16 µg/mL NDGA, or 8 µg/mL celastrol. At concentrations
above those that can eradicate staphylococcal biofilms, antioxidants had no measurable
detrimental effects on a human living skin equivalent. Furthermore, TBBQ, celastrol
and NDGA all potentiated the antibiofilm activity of gentamicin at concentrations that
were tolerated at the skin surface. Amongst other uses, gentamicin is applied as a
topical antimicrobial cream (0.1-1% gentamicin [1-10 mg/mL]) for the sterilisation of
infected wounds (Castellano et al., 2007; Stojadinovic et al., 2008). The combination
of gentamicin and antioxidants could be employed to treat conditions, such as burn
wounds and severe skin lesions, where biofilms are likely to arise (Wolcott et al., 2010).
Combination therapy could significantly reduce the dose and consequent toxic effects of
gentamicin, whilst providing additional antibiofilm activity. Furthermore, an inability
of S. aureus to develop high-level resistance to these antioxidants would allow topical
treatment of infected wounds for prolonged periods.
More generally, the results presented here confirm that compounds with membrane-
damaging effects may be a useful source of antibiofilm agents (Hurdle et al., 2011).
However, it has been shown that effects on the membrane were varied and it may not be
possible to predict which agents will eradicate biofilms based upon the kind of interaction
they have with membranes. For example, NDGA caused rapid permeabilisation of
the membrane, whilst celastrol compromised the membrane potential without inducing
leakage of intracellular ions. Nonetheless, all agents displayed a similar MBEC (4-fold
difference between celastrol, TBBQ and NDGA). Even those compounds that caused
rapid and extensive membrane damage were not necessarily toxic to eukaryotes, and could
be useful as antibacterial agents due to low potential for resistance development.
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6.2 Future work
Although it has been established that TBBQ specifically interacts with components of the
bacterial membrane, the precise nature of this interaction is not yet known. To provide
further insight into the membrane component that TBBQ interacts with, staphylococcal
cell ghosts could be generated, comprising a preserved cell envelope in the absence of
cytoplasmic material (Langemann et al., 2010; Lubitz, 2010). E. coli bacterial ghosts have
been produced previously by controlled expression of phage lysis gene E, which forms
a transmembrane tunnel through which intracellular components are lost (Langemann
et al., 2010). Currently, a chimeric E-L lysis gene that is active in staphylococci is being
developed in combination with methodology to re-seal bacterial ghosts using membrane
vesicles (Lubitz, 2010). Cell ghosts could be impregnated with fluorescent dye, such
as carboxyfluorescein, and exposed to TBBQ. If leakage of dye is not induced, this may
indicate that an energised membrane is required for the interaction. This could distinguish
between agents that disrupt the function of components embedded within the membrane
as opposed to those that simply destructure the membrane.
The contribution of alterations in putative ethanolamine kinase (encoded by
SAOUHSC 01866) to TBBQ susceptibility could be confirmed by generating a deletion
mutant and testing activity of TBBQ against this strain (O’Neill et al., 2006). In Section
4.3.7 it was hypothesised that the TBBQ-resistant strain (B7) had altered phospholipid
production as a consequence of a mutation in ethanolamine kinase. This suggestion could
be investigated by determining and comparing the membrane phospholipid composition
of S. aureus SH1000, B7 and the deletion mutant, in particular quantifying the
phosphatidylethanolamine content (Jones 2008). Similarly, membrane fluidity and fatty
acid content could be analysed to identify physiological changes in the B7 membrane,
which could contribute to the reduction in TBBQ activity (Bayer et al., 2000).
Transcriptional profiling could provide further insight into the target to TBBQ, and
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complement the research presented in this thesis. Antibacterial agents disrupt bacterial
homeostasis, which induces stress responses that relate to the compound’s target.
Additionally, bacteria may upregulate the target itself or target-associated genes in order
to titrate out the compound and avoid inhibitory effects (O’Neill & Chopra, 2004).
Transcriptional profiling would involve extraction of total RNA from untreated planktonic
cultures and those that had been exposed to antioxidants. Following mRNA enrichment
and fragmentation, complementary DNA (cDNA) would be synthesized for amplification
and Next-Generation Sequencing. Reads would be mapped to the reference genome,
and expression levels would be assessed based upon read coverage (Pinto et al., 2011).
Genes displaying >2-fold increase or decrease in expression would be considered to be
differentially regulated, and analysis of expression patterns could provide information
about the target of TBBQ.
Full analysis of the celastrol resistant strain (C3) would complement MOA studies
that have already been carried out with celastrol. WGS has suggested some potential
mutations that could contribute to resistance. However, the sequence of each of these
genes should be determined individually to confirm the presence of a mutation, then
be complemented in C3, as was carried out for the TBBQ-resistant strain. Since a
large number of mutations are present and may have compensatory effects, it would
be beneficial to delete genes of interest individually in a clean host, for example using
site directed mutagenesis (Vickers et al., 2007). Deletion of specific genes causing
increased resistance to celastrol would provide further insight into the cellular target of
the antioxidant.
Finally, in order to progress TBBQ, celastrol and NDGA as clinical candidates, in vivo
experimentation with animal models of infection should be carried out. The compounds
may be most usefully employed as topical agents for use in the treatment of chronic
wounds and surgical site infections, so the experimental design should reflect this situation
(Dai et al., 2011). Ideally these experiments would provide information about efficacy,
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but also further data regarding tolerability. Collectively, these studies could facilitate
development of the antioxidants for human treatments.
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A Primers used in this study.
Oligonucleotide primer Sequence
Tnp out2 5’ GCTTGCATGCCTGCAGGTCGACTC 3’
Tn Fwd 5’ CAGGTATAGGTGTTTTGGGAA 3’
Tn Rev 5’ AAAAAGGATTGATTCTAATGA 3’
01722/3inter Fwd 5’ TTTCATCATTTACACATCCTA 3’
01722/3inter Rev 5’ CAAGCGTAAATGTAACTA 3’
01866 Fwd 5’ ATTAGGGTGGACACTTGATTC 3’
01866 Rev 5’ CCCATGGTTTGTATCGAA 3’
ElitraMCS Fwd 5’ CAGCAGTCTGAGTTATAAAATAG 3’
ElitraMCS Rev 5’ CAGGCAAATTCTGTTTTATCAGAC 3’
01723op XmaI Fwd 5’ TAACCCGGGGGGGATAACGAATTTA 3’
01723op XbaI Rev 5’ AAATCTAGAGATGACACAGATAGTCGATTT 3’
01866 SacI Fwd 5’ AAAGAGCTCATTAGGGTGGACACTTGATTC 3’
01866 XmaI Rev 5’ TAACCCGGGCCCATGGTTTGTATCGAA 3’
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B MICs of TBHQ and TBBQ against a collection of S.
aureus clinical isolates.
Antibiotic MIC (µg/mL)
Strain name susceptibility TBHQ TBBQ
G1 MSSA 8 8
G2 MSSA 8 8
G4 MSSA 8 16
G5 MSSA 16 8
G6 MSSA 8 8
G9 MSSA 16 16
G10 MSSA 16 16
G11 MSSA 8 8
G12 MSSA 8 8
G13 MSSA 8 8
G15 MSSA 16 16
G16 MSSA 8 8
G17 MSSA 16 16
G18 MSSA 16 8
G19 MSSA 16 8
G20 MSSA 8 8
G22 MSSA 16 16
G23 MSSA 16 16
G24 MSSA 8 8
G25 MSSA 16 16
G26 MSSA 16 16
G27 MSSA 16 16
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Antibiotic MIC (µg/mL)
Strain name susceptibility TBHQ TBBQ
G28 MSSA 16 16
G29 MSSA 8 8
G30 MSSA 8 8
G31 MSSA 8 4
G32 MSSA 8 8
G33 MSSA 16 16
G34 MSSA 16 16
G35 MSSA 16 16
Oxford MSSA 8 8
R24 MRSA 8 8
R25 MRSA 8 8
R26 MRSA 16 16
R27 MRSA 16 8
R28 MRSA 8 8
R29 MRSA 8 8
R30 MRSA 16 8
R31 MRSA 16 16
R32 MRSA 16 16
R33 MRSA 16 16
R34 MRSA 16 16
R35 MRSA 16 16
R36 MRSA 16 8
R37 MRSA 16 16
R38 MRSA 16 16
R39 MRSA 8 8
R40 MRSA 16 16
R33 MRSA 16 16
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Antibiotic MIC (µg/mL)
Strain name susceptibility TBHQ TBBQ
12232 MRSA 16 16
12233 MRSA 16 16
W71 MRSA 16 8
W74 MRSA 8 16
W80 MRSA 16 16
W82 MRSA 16 16
W85 MRSA 16 16
W96 MRSA 16 16
W97 MRSA 16 16
W98 MRSA 8 16
W99 MRSA 32 16
EMRSA 15 MRSA 16 16
EMRSA 16 MRSA 16 16
EMRSA17 MRSA 8 8
MW2 MRSA 16 16
VISA 2 VISA 8 8
Mu3 VISA 16 16
New Jersey VISA 16 16
Mu50 VISA 16 16
V99 VISA 8 8
Michigan VISA 16 16
VISA 26 VISA 16 16
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C Addresses of companies
Alfa Aesar, Heysham, UK
AstraZeneca, Wilmington, USA
Avanti Polar Lipids, Birmingham, USA
Bayer, Leverkusen, Germany
Beckman Coulter Genomics, Takeley, UK
Bioline Reagents, London, UK
Bio-Rad, Hemel Hempstead, UK
BMG LABTECH, Ortenberg, Germany
CP Pharmaceuticals, Wrexham, UK
Cubist Pharmaceuticals, Lexington, USA
Destiny Pharma, Brighton, UK
Duchefa Biochemie, Haarlem, Netherlands
EdgeBio, Gaithersburg, USA
Eurofins MWG Operon, Ebersberg, Germany
Evocutis, Wetherby, UK
Fisher Scientific, Loughborough, UK
GE Healthcare, Little Chalfont, UK
Gene Codes Corporation, Ann Arbor, USA
Greiner Bio-One, Stonehouse, UK
Invitrogen, Paisley, UK
LG Life sciences, Seoul, South Korea
Matrix Biologicals, Hull, UK
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Melford, Ipswich, UK
Millipore, Billerica, USA
Molecular Biology Insights Inc., Cascade, USA
MP Biomedicals, Illkirch Cedex, France
Microsynth AG, Balgach, Switzerland
New England Biolabs, Ipswich, USA
Oxoid, Cambridge, UK
Packard Bioscience, Beaconsfield, UK
PerkinElmer, Cambridge, UK
Pfizer, Kalamazoo, USA
Promega, Southampton, UK
Qiagen, Manchester, UK
R&D systems, Abingdon, UK
Sera Laboratories International, Bolney, UK
Sigma-Aldrich, Poole, UK
Sunovion Pharmaceuticals, Marlborough, USA
Theravance, San Francisco, USA
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